

AUTHOR INDEX

VOLUME 36

- Abou-Shala, Nabil, 1553
 Abruzzo, G., 1648
 Ackerman, Bruce H., 1766
 Aerts, Frans, 417
 Affrime, M. B., 1832
 Agger, William A., 1788
 Agrawal, Krishna C., 2370
 Akanio, Joseph C., 255
 Alalusua, S., 1241
 Albritton, William L., 467
 Alcantara, Joel, 2054
 Aldridge, Kenneth E., 851, 854
 Al-Hokail, Abdullah A., 172
 Al Khayat, R., 1519
 Allaman, Jane A., 2037
 Allard, Sylvie, 2085
 Allegra, Carmen, 1935
 Allen, Lois B., 206
 Allendoerfer, R., 217
 Almadany, Rady, 997
 Al-Obeid, S., 77
 Alós, J. I., 1794
 Alpert, Gershon, 2275
 Alpert, Nathaniel M., 2286
 Al-Sibai, M. Badawi, 150
 Amicosante, Gianfranco, 1068
 Amor, E., 1794
 Ancelin, Marie L., 50
 Anders, E.-M., 942
 Anderson, B. D., 2156
 Anderson, J., 1964
 Anderson, M. D., 2552
 Anderson, R., 1236
 Anderson, Ronald, 2729
 Andrada, A. B., 277
 Andremon, A., 2009
 Andremon, Antoine, 502
 Andrews, J., 2360
 Andrews, J. M., 1002, 1928, 2444
 Andries, K., 100
 Andries, Koen, 417, 727
 Andriole, Vincent T., 2681
 Andry, G., 2014
 Angehrn, Peter, 2825
 Antonacci, Barry, 64, 498
 Antony, Kelly K., 115
 Anwar, Hosmin, 890, 1208, 1347
 Aoki, Hiroyuki, 2270
 Aoun, M., 2014
 Aoyama, Hiroshi, 2108
 Appelbaum, Peter C., 856, 1140
 Arai, Sumio, 1322
 Arakawa, Soichi, 188
 Arakawa, Yoshichika, 1460
 Araki, Kimi, 2042
 Araki, Ryouko, 1198
 Araujo, Fausto G., 326, 2454
 Arguedas, Adriano G., 255
 Arika, Tadashi, 2523
 Arima, Yasushi, 2589
 Armstrong, Donald, 808
 Arnett, Gussie, 206
 Arnow, Paul M., 2125
 Arrowood, Michael J., 220
 Arruda, Eurico, 1186
 Artal, A., 2816
 Arthur, Michel, 867, 1514
 Arvin, Ann M., 1991
 Ashida, Noriyuki, 214
 Ashton, Wallace T., 2020
 Asikainen, S., 1241
 Asin, Henk R. G., 1456
 Asselbergs, Fred A. M., 1782
 Atkins, Loretta T., 2346
 Au, Jessie L.-S., 665
 Aubier, M., 2099
 Auge, Annie, 2804
 Auger, François, 2085
 Authors, No, 1584
 Averett, Devron R., 2686
 Aweeka, Francesca T., 1773
 Awni, W. M., 1832
 Ayoub, Rihab, 1404
 Azoulay-Dupuis, Esther, 1412, 2698
 Baba, Masanori, 214, 435, 1432
 Babbar, Sunita, 299
 Babich, John, 2286
 Bacchi, Cyrus J., 2736
 Bäckstrand, B., 2766
 Bacon, Teresa H., 2747
 Bailey, Elaine M., 1109, 1192, 1204, 2709, 2741
 Bains, M., 1057
 Bains, Manjeet, 2566
 Baker, Carolyn N., 717
 Baldwin, D. R., 1171, 1176
 Balkovec, J., 1648, 1964
 Ballesta, Juan P. G., 639
 Balzarini, Jan, 1073
 Bancel, C., 2099
 Bannam, Trudi L., 2548
 Baquero, F., 662
 Baquero, Fernando, 639, 2536
 Baranowski, John, 2778
 Barbhaiya, R. H., 938, 962
 Barbhaiya, Rashmi H., 552, 687, 1181, 1382, 1387, 2075
 Barc, M. C., 1332
 Barclay, M. L., 1951
 Bar-David, Yair, 287
 Bardos, Thomas J., 108
 Baron, Denis, 744
 Barón, M. González, 2816
 Barrett, J. F., 860
 Barrett, M. S., 2049
 Barriere, Steven L., 453, 2233
 Barry, A. L., 137
 Barth, Robert H., 1424
 Bartizal, K., 1648
 Bartlett, M. S., 779
 Barwicz, Joanna, 2310
 Basco, Leonardo K., 209
 Bass, Glenn T., Sr., 2761
 Bastian, Tracey L., 1553
 Bate, B. Jane, 2037
 Batteiger, Byron E., 1144
 Baucher, Jacqueline, 470, 2698
 Bayer, Arnold S., 1665, 1864
 Bazile, S., 2622
 Beach, J. Warren, 672
 Beam, Thomas R., Jr., 2639
 Beauchamp, D., 1504, 2147
 Beauchamp, Denis, 2204
 Bebear, Christiane, 870
 Beckman, Barbara S., 2370
 Bedos, Jean Pierre, 2698
 Begg, E. J., 1951
 Behre, Gerhard, 2139
 Bell, Angus, 2566
 Bellido, F., 1057
 Benedetti, Margherita Strolin, 1958
 Ben-Nathan, David, 2275
 Bennett, P., 1447
 Bennett, W. M., 2556
 Bentorcha, Fairouze, 59
 Berger, Bradley J., 1825
 Berger-Bächi, Brigitte, 25, 566, 1367, 2617
 Bergeron, M. G., 1504
 Bergeron, Michel G., 2204, 2211
 Bergman, L., 2766
 Bergogne-Berezin, E., 2099
 Bergogne-Bérézin, Eugénia, 1412
 Bergogne-Berezin, Eugénie, 669
 Berman, J. D., 1978
 Bernard, Alfred, 1525
 Bernareggi, Alberto, 1744
 Berrocal, A., 2816
 Berry, Alison J., 690
 Berry, Valerie, 1427
 Bertasso, A., 1601, 1779
 Berti, Marisa, 446
 Bertino, Joseph S., Jr., 679
 Bessalle, Roberto, 313
 Bhagavathula, Purushothama R., 2487
 Bhuripanyo, Kiertichai, 158
 Biavasco, Francesca, 331
 Biehle, Jon, 2039
 Billot-Klein, D., 77, 1487
 Binczewski, Brian, 1392
 Biollaz, Jérôme, 1013
 Bisson, Chantal, 2085
 Biswas, Anita N., 92
 Bitonti, Alan J., 2736
 Black, Henry R., 318
 Blacky, Albert R., 2542
 Blanco, Javier, 898
 Blanco, María Teresa, 898
 Blanshard, Christine, 1821
 Blaschke, Terrence F., 1230
 Blaszcak, Larry C., 533
 Blouin, Robert A., 632
 Blumenkopf, Todd A., 934
 Blumenthal, Robert M., 2118
 Bodey, Gerald P., 879
 Bodily, Howard L., 2398
 Boehme, Richard E., 1688
 Boissel, P., 2331
 Bolard, Jacques, 262, 1799, 2518
 Bolger, Michael, 1062
 Bologne, D. P., 982
 Bonnet, M., 1302
 Bonnez, William, 2245
 Boobis, Alan, 1958
 Boonma, Paithoon, 158
 Borchering, Shawn M., 1553
 Borghi, Angelo, 1744
 Borgonovi, Monica, 446, 1744
 Borin, Marie T., 126
 Borner, Klaus, 144, 796
 Borotz, Susan E., 1091
 Borsa Lebas, F., 1519, 2794
 Boslego, J. W., 1682
 Böttiger, D., 1770, 2418
 Boudinot, F. Douglas, 2432
 Bourgaull, Anne-Marie, 343
 Bourlioux, P., 1332
 Bourne, Nigel, 2020
 Bourneix, C., 2009
 Bouten, Anne, 2462
 Bouvet, Anne, 2216
 Bouzard, D., 2622
 Bowler, William A., 2542
 Boyce, John M., 1032
 Boyer, Kenneth, 1040
 Bozza, Mary A., 1151
 Brackman, Marcia A., 115
 Bradford, Patricia A., 394
 Bradley, Suzanne F., 2533
 Branch, R. A., 2670
 Brandimarte, Camillo, 723
 Branger, T., 801
 Branger, Tine, 1456
 Bratoeva, Momka, 2346
 Bravo, Fernando J., 2020
 Bresler, L., 2331
 Bressolle, Françoise, 1404
 Brewer, Thomas G., 1825
 Brier, Gordon L., 318
 Brismar, B., 1997, 2766
 Brivio, Luca, 1499
 Brochu, A., 1504, 2166
 Brochu, N., 2166
 Brodaty, O., 2539
 Brouqui, Philippe, 2799
 Brown, Barbara A., 180, 1987
 Brown, James F., 68
 Brown, Wallace D., 1614
 Brown, William J., 1635
 Bruguerolle, Bernard, 1115
 Brummer, Elmer, 2487
 Brune, K. H., 2670
 Brun-Pascaud, Monique, 470, 2328
 Bryan, Charles S., 2639
 Bryan, Joe P., 949
 Bryskier, A., 1756
 Bugelski, P. J., 982
 Bugg, Timothy D. H., 867
 Bugnon, Denis, 744
 Bunnell, S. T., 2447
 Bure, Anne, 1883
 Burger, Roger, 473
 Burke, Amy, 2392
 Burman, Lars G., 989
 Burnett, D., 1545
 Burnham, Jeffrey C., 2118
 Burns, Jane L., 2280
 Burtin, P., 2493
 Bush, Karen, 1155, 1991
 Byers, Carol, 545
 Caccamo, Francesco, 1567
 Cacciapuoti, Anthony, 64, 498
 Cailon, Jocelyne, 744
 Calandra, Thierry, 1256
 Callahan, Ronald J., 2286
 Callister, Steven M., 1788
 Camarasa, María-José, 1073
 Cameron, Janet M., 202, 733, 1688

- Cammack, Nicholas, 202
 Cammack, Nick, 733
 Campbell, D. A., 938
 Campbell, I., 1619
 Campos, José, 1028
 Candiani, Giampaolo, 446
 Cannon, Deborah, 672, 2423
 Cantón, E., 558
 Canton, Rafael, 2536
 Carbon, Claude, 262, 833,
 907, 1883, 2069, 2216, 2403,
 2462, 2611, 2722
 Cardoso, Marisa, 580
 Carlier, Cecile, 463
 Caroff, Bruno, 2852
 Caron, François, 2611
 Carpentier, Pierre, 378
 Carper, Holliday T., 39, 408,
 2584
 Carroll, M. L., 1971
 Cars, Otto, 1832
 Carson, Dennis A., 2025
 Catchpole, Christopher R.,
 1928
 Catherall, Elaine J., 458
 Cauwenbergh, Geert F. M. J.,
 2661
 Cavaliere, Stephen J., 2039
 Cavanaugh, J., 1147
 Cavenaghi, Luigi, 446, 1744
 Caya, Martine, 2093
 Cercenado, E., 2201, 2526
 Chachaty, E., 2009
 Chacón, I., 2816
 Chambers, Henry F., 656
 Chambers, S. T., 1951
 Chams, Vida, 267
 Chan, C. Y., 2057
 Chanal, Catherine, 1817
 Chance, Michael L., 2228
 Chandy, M., 2468
 Chang, Frank N., 2645
 Chantot, J. F., 1756
 Chantrain, G., 2014
 Chapman, Stanley W., 977
 Chapman, Trevor, 1909
 Chapman, W. L., 1978
 Chappel, Larry R., 2080
 Chartrand, Stephen, 1614
 Chatis, Pamela A., 1589
 Chatterjee, Anadi N., 788
 Chatton, Jean-Yves, 1013
 Chau, Françoise, 997, 2852
 Chaudhuri, Keya, 788
 Chauveau, P., 1519
 Chauvin, Jean Pierre, 833
 Chavalitsheinkoon, Pornpip,
 1644
 Chave, Jean-Philippe, 1013
 Chen, Karen, 1208
 Chen, Thomas J. H., 603
 Cheng, A. F. B., 2057
 Chi, S.-C., 2156
 Chiang, Janie, 1472
 Chin, Nai-Xun, 1310, 1336,
 1418, 1699
 Choi, Woo-Baeg, 672, 2423
 Chong, Yunsop, 195
 Chopra, Ian, 876, 913, 1068
 Chou, Ting-Chao, 808, 1472,
 1559
 Christensson, B. A., 1532
 Christensson, Bengt A., 2512
 Christian, Sylvie, 2310
 Chu, Chung K., 672
 Chu, Daniel T. W., 81
 Chu, S.-Y., 1147, 2447
 Chu, Sou-yie, 2478
 Citron, Diane M., 1158
 Clairoux, N., 1504
 Clark, Dana K., 2280
 Clark, Julie C., 2037
 Clark, Rebecca A., 647
 Clarke, Alison M., 2197
 Cleare, W. J., 607
 Cleary, John D., 977
 Cleeland, Roy, 2286
 Clemons, Karl V., 2656
 Clendennen, T. E., 1682
 Clendennen, T. E., III, 277
 Clermont, Dominique, 59
 Clewell, Don B., 769
 Clink, Hugh M., 172
 Clumeck, Nathan, 2661
 Cluzel, Roger, 1817
 Coates, Jonathan A. V., 202,
 733
 Coene, Marie-Claire, 2602
 Cogollos, R., 1794
 Cohen, B. Eleazar, 2518
 Cohen, Guy M., 1296
 Cohen, Yves, 2104, 2408
 Cole, P. J., 1236
 Coleman, Robert W., 1230
 Collatz, E., 77, 1487
 Collette, P., 1756
 Collignon, A., 1332
 Colonno, Richard J., 1441
 Comstock, R. Dawn, 1695
 Condra, Jon H., 1441
 Condreay, Lynn, 2686
 Connolly, Kevin J., 245, 509
 Connor, James D., 886
 Conti, Cinzia, 95
 Cooley, Timothy P., 1280
 Cooper, M. A., 2444
 Corkill, John E., 1870
 Cornaglia, Giuseppe, 1902
 Cornelissen, J. J., 801
 Correia, John A., 2286
 Corthier, G., 1332, 2009
 Costerton, J. William, 890,
 1208, 1347, 2054
 Coudron, Philip E., 1125
 Courtieu, A. L., 1677
 Courval, Jeanne M., 2392
 Courvalin, Patrice, 463, 502,
 867, 1514, 2005
 Craft, J. Carl, 2478
 Craig, William A., 2577
 Cremieux, Anne-Claude, 2069,
 2216, 2403, 2611
 Crist, Arthur E., Jr., 1635
 Crokaert, F., 46
 Cronqvist, J., 2676
 Crooke, Rosanne M., 527
 Crosa, J. H., 611
 Crump, Carolyn E., 1186
 Crumacker, Clyde S., 1589
 Cuchural, George J., Jr., 540
 Cuenca, Rafaela, 198
 Cummings, Marinella, 1131
 Cundliffe, Eric, 348
 Cynamon, M. H., 1611, 2413
 Czuprynski, Charles J., 68
 Dagan, Ron, 287
 Daifuku, Richard, 2349
 Dalton, M. T., 343
 Dan, M., 677
 Daneau, D., 2014
 Daneels, Guy, 417
 Danenberg, Haim D., 2275
 Darden, Paul, 1614
 Dargis, M., 2147
 Darlison, Sarah J., 2747
 Das, Jyotirmoy, 788
 Daviau, Nathalie, 2085
 Davidson, Ross J., 1136
 Davies, Donald, 1958
 Davis, C. P., 2552
 Davis, Michelle, 2686
 Dayer, Pierre, 1013
 Deaton, R., 1147
 De Brabander, Marc, 417
 de Cespédès, Gilda, 59
 De Clercq, Erik, 435, 1073,
 2628
 de Graaff, J., 2634
 de Graeff, A., 801
 DeJoy, S. Q., 1971
 Dekker, A. W., 801
 De Kruij, A., 1606, 1859
 Delabre, I., 191
 de la Coussaye,
 Jean-Emmanuel, 1404
 de Lalla, Fausto, 1567, 2192
 De Leenheer, A. P., 1606,
 1859
 de Lentdecker, P., 2539
 Del Valle, Robert, 2497
 De Micco, Philippe, 1115
 Denaro, Maurizio, 446
 Denny, William, 1644
 de Paredes, M. L. García,
 2816
 Depitre, C., 1332, 2009
 Depperman, Karl M., 796
 Deraemaeker, R., 2014
 De Raeymaeker, Marc, 417
 Deringer, James R., 626
 De Rosas, Victoria, 180
 Derouin, Francis, 997, 2852
 Deshusses, Jacques, 2506
 Desideri, Nicoletta, 95
 Deslandes, Antoine, 2462
 Desmyter, Jan, 2628
 DeStefano, M. S., 2413
 DeVincenzo, Nicholas, 1424
 Devine, Catherine, 2216, 2403
 Dewindt, B., 100
 De Wit, Stéphane, 2661
 Dillon, William I., 2533
 Dittrich, W., 1119
 Dixon, Russell M., 2075
 Dohin, Elisabeth, 1821
 Doi, Ryuichiro, 1483
 Dolence, E. K., 2166
 Dolence, E. Kurt, 840
 Dolin, Raphael, 1280
 Dombret, M. C., 2099
 Dopff, C., 2331, 2493
 Dor, P., 2014
 Dornsife, Ronna E., 2686
 Doucet-Populaire, Florence,
 502
 Downey, P., 1447
 Drapeau, Chantal, 2085
 Drapeau, Guy, 955
 Drehoel, Margaret A., 1614
 Dreyer, G. B., 982
 Druegon, Henri, 744
 Drusano, George L., 1280
 Dubin, Donald T., 153
 Dubois, C., 2539
 Dukes, George M., 1387
 Dulworth, Jacqueline K., 115
 Dupont, Bertrand, 1805
 DuPont, Herbert L., 87, 2821
 DuPont, Margaret W., 87
 Dureux, J. B., 2331, 2493
 Durkin, M. M., 779
 Dutka-Malen, Sylvie, 2005
 Duval, Jean, 2005
 Duverne, Chantal, 2462
 Dux-Guyot, Anne, 470
 Düzgüneş, Nejat, 2808
 Earnshaw, David L., 2747
 Ebert, Steven C., 2577
 Echeverria, P., 1682
 Echols, Roger M., 993
 Edelstein, Martha A. C.,
 2387, 2559
 Edelstein, Paul H., 2387, 2559
 Edlind, T. D., 779
 Edmonds, Kay, 2747
 Edwards, John E., Jr., 2239
 Edwards, Richard, 223
 Efthymiopoulos, Constantin,
 1958
 Eibl, Hansjörg, 1630
 Eklund, A. E., 2766
 Elabbadi, Nouredine, 50
 Eledjam, Jean-Jacques, 1404
 Eliopoulos, G. M., 2201, 2526
 Eliopoulos, George M., 121,
 1329, 1864
 Ellestad, George, 913
 Ellis, M. Nixon, 934
 Ellis, Michael E., 172
 El-Shaker, Mohammed M.,
 150
 Emini, Emilio A., 1019, 1441
 Engel, Joanne N., 2304
 Entenza, José M., 1256
 Erickson, John, 926
 Erickson, S., 2253
 Ericsson, Charles D., 87, 2821
 Erkkola, Risto, 2652
 Ernst, Peter, 172
 Eron, Joseph J., Jr., 1559
 Erwin, M. E., 2049
 Erwin, Meridith E., 233
 Espinel-Ingroff, Ana, 1805
 Espinosa, E., 2816
 Espinosa, G. E., 277
 Essink, Monika, 2139
 Essiz, M., 2622
 Etienne, I., 2794
 Etter, Laura, 1392
 Etzel, Joseph V., 679
 Eudy, Elizabeth B., 1766
 Ewalenko, P., 2014
 Fabre, David, 1404
 Facklam, Richard, 2176
 Fang, Wei, 1310, 1336, 1418
 Fantin, Bruno, 907
 Farber, Bruce, 2639
 Farinotti, R., 2539
 Farinotti, Robert, 2462
 Fasching, Claudine E., 1166

- Fattorini, Lanfranco, 1068
 Fay, Michel, 470
 Feistauer, S. M., 505
 Feliu, J., 2816
 Fennell, Cynthia L., 712
 Fernández, M. Carmen, 639
 Fernandez-Rodriguez, Amparo, 2536
 Ferrari, Pietro, 1744
 Ferrieri, Patricia, 1215
 Fielding, Robert M., 299
 Figgitt, David, 1644
 Figueiredo, Agnes M. S., 886
 Figueiredo, Hermia T., 1688
 File, Thomas M., 1400
 Fillastre, J. P., 1519, 2794
 Filler, Scott G., 2239
 Finegold, Sydney M., 239, 1658
 Fischler, M., 2539
 Fischman, Alan J., 2286
 Fitzgerald, Thomas J., 598
 Fitzgibbon, Joseph E., 153
 Flaherty, John P., 2125
 Flasher, Diana, 2808
 Fleck, R. Peter, 2542
 Flor, Soledad, 308
 Foleno, Barbara, 860
 Fontana, Roberta, 1902
 Forgue, S. Thomas, 552
 Foss, Robert, 1040
 Fostel, Jennifer, 2778
 Fostel, Jennifer M., 2131
 Foster, Thomas S., 632
 Foulds, George, 603
 Foy, Jilanna, 1935, 1943
 Fraimow, Henry S., 1563
 Frame, George M., 2080
 Franceschini, Nicola, 1068
 Francia, M. Victoria, 1049
 Francoual, S., 77
 Frank, Michael O., 2584
 Franklin, Anders, 2704
 Franzblau, Scott G., 92
 French, G. L., 2057
 Frick, Lloyd W., 2686
 Fridkin, Mati, 313
 Friedland, Ian R., 1596
 Friend, Daniel S., 2808
 Frosolono, Mira, 230
 Frost, R. Wayne, 830
 Frostegard, Cecilia, 1821
 Fu, K. P., 860
 Fu, Yue, 2239
 Fuchs, N., 2316, 2322
 Fuchs, P. C., 137
 Fuhr, U., 942
 Fujii, Akira, 188
 Fujii, K., 387
 Fujii, Noboru, 2589
 Fujii, Nobutaka, 1249
 Fukasawa, Masatomo, 1577
 Fukuda, Hideyuki, 2108, 2562
 Funk, Evelyn, 1596
 Furet, Yves Xavier, 894, 2506
 Furmaga, Kevin, 2125
 Furman, Phillip A., 2423, 2686
 Furtado, Gary, 1032
 Furukawa, Yasuo, 481
 Furuya, Nobuhiko, 1198, 1922
 Fyfe, James A., 2686
 Gallegos, Jesse, 603
 Galtier, Marc, 1404
 Gambertoglio, John G., 1773
 Gan, Vantanya N., 2478
 García, Isabel, 1053
 Gatenbeck, L., 2766
 Gaydos, Charlotte A., 291
 Gazzard, Brian G., 1821
 Gazzard, David, 1821
 Gelber, R. H., 2544
 Gelfusa, Vincenzo, 723
 Genovese, Domenico, 95
 George, David, 2125, 2681
 George, William J., 647
 Georgopapadaku, N. H., 1601, 1779
 Georgopoulos, A., 505
 Georgopoulos, M., 505
 Gerding, Dale N., 2639
 Gerena, Lucia, 1538, 2761
 Gerlach, E. H., 137
 Ghannoum, Mahmoud A., 2239
 Gilbert, Brian E., 1466
 Gilbert, D. N., 2556
 Gilbert, Huguette, 343
 Gilbert, John, 473
 Gill, Maura, 540
 Gilliom, Mercedes, 1062
 Gillon, Valerie, 458
 Gilmore, Michael S., 902
 Ginsburg, Hagai, 1102
 Girard, Dennis, 1671
 Girard, Pierre-Marie, 2328
 Givercman, B., 71
 Glatt, Aaron E., 1131
 Glauser, Michel P., 1013, 1256
 Glazer, Edward A., 368, 2080
 Gleason, Carol R., 552
 Glerum, Jan H., 2458
 Gloff, Carol A., 1472
 Gobernado, M., 558
 Gocke, David J., 153
 Gogu, Sudhir R., 2370
 Goh, Khye Seng, 2841, 2843
 Gohara, Yukiko, 1322
 Goldberg, Burt, 2736
 Goldman, Mark E., 1019
 Goldstein, Beth P., 446
 Goldstein, Ellie J. C., 1158
 Goldstein, F. W., 1677
 Golub, Lorne M., 227
 Gomeni, Roberto, 1404
 Gómez-Garcés, J. L., 1794
 Gómez-García, Antonio C., 898
 Gonzalez, Patricia C., 1163
 Gooding, B. Briggs, 2049
 Gootz, Thomas D., 751, 1671
 Gordon, Gloria, 913
 Gordon, Ronald E., 2497
 Gorla, Alfred, 313
 Goswitz, Joseph J., 1166
 Gotlib, Leah, 1441
 Goto, Sachiko, 17, 573
 Gouin, François, 1115, 2804
 Gourde, P., 1504, 2147
 Gourde, Pierrette, 2204
 Graham, Donald J., 1441
 Graninger, W., 505
 Granneman, G. Richard, 378
 Graves, Donna, 1991
 Gray, Norman M., 1688
 Graybill, J. R., 217
 Graybill, John R., 690, 2790
 Grayson, M. Lindsay, 1864
 Graziano, Frank M., 2075
 Green, Michael, 545
 Greenwood, David, 223
 Griess, Rhonda S., 1296
 Griffith, Marguerite E., 2398
 Grigoriev, G. A., 1619
 Grosset, J., 548
 Grosset, Jacques, 2104, 2408, 2839
 Groves, Eric S., 2349
 Gruda, Ilona, 2310
 Gu, Jian-Wei, 1310, 1336, 1418
 Guan, Liming, 1902
 Guan, Linong, 2118
 Guay, David R. P., 308
 Guerra, Nancy, 545
 Guillen, Jean-Claude, 2804
 Guo, Luke S. S., 299
 Gustafson, John E., 566, 1367
 Gutmann, L., 77, 1487
 Gutmann, Laurent, 2611
 Gutteridge, Winston E., 326
 Guzenda, E., 2418
 Guzman, M. Carmen, 1053
 Haak-Frendscho, Mary, 68
 Haas, Hava, 313
 Haberzettl, Cecilia A., 153
 Hadley, W. Keith, 1163, 2808
 Haeggman, Sara, 989
 Haenftling, Katherine, 2349
 Hajdu, R., 607
 Hak, Lawrence J., 1387
 Hakenbeck, Regine, 783
 Hokusui, Hideo, 2270
 Halim, Magid A., 150
 Hall, James Edwin, 1825
 Hall, M. C., 1057
 Halstenson, C. E., 1832
 Halstenson, Charles E., 126
 Hamelin, Bettina A., 632
 Hames, C. S., 277
 Hamill, R. J., 1785
 Hammer, Scott M., 245, 509, 920
 Hammerschlag, Margaret R., 682, 1573
 Hammond, M., 1648, 1964
 Hamzeh, F. M., 2061, 2473
 Hanboula, Salem Y., 2228
 Hancock, R. E. W., 1057
 Hancock, Robert E. W., 2365, 2566
 Handwerker, Sandra, 1570
 Hanks, D., 2253
 Hanson, Linda H., 477, 486, 2487, 2656
 Hanson, W. L., 1978
 Hara, Keibun, 1483
 Harabe, Eiko T., 1577
 Hardin, Thomas C., 2790
 Harding, Godfrey, 343
 Hardy, D. J., 137
 Hare, R. S., 64, 498, 1447
 Hare, Roberta S., 2222
 Harris, Eugene B., 92
 Harris, Steven C., 603
 Hart, Graham J., 1688
 Hart, T. K., 982
 Hashimoto, Hajime, 2562
 Hata, Katsura, 1894
 Hawkey, Peter M., 1981
 Haworth, S. J., 1532
 Hayakawa, Isao, 1491
 Hayashi, Kyoko, 1890
 Hayashi, Toshimitsu, 1890
 Hayden, Frederick G., 727, 1186
 Hayes, Kathleen A., 2715
 Hazebrucq, Jean, 833
 He, Ping, 769
 Healey, Mark C., 220
 Hector, R. F., 1284
 Heidemann, H. T., 2670
 Heidenreich, Amy C., 283
 Heider, Arvela R., 108
 Heifets, Leonid B., 1695
 Heikkilä, Anne, 2652
 Heim-Duthoy, K. L., 1832
 Heller, Allen H., 993
 Hellinger, Walter C., 1272
 Henry, Nancy K., 56, 1272
 Heritage, John, 1981
 Herman, C. S., 1832
 Hermans, Philippe, 2661
 Hermus, Ad R. M. M., 2785
 Herrmann, J. L., 1081
 Hidaka, T., 387
 Hiddemann, Wolfgang, 2139
 Hikida, Muneo, 481
 Hill, Bertha C., 2176
 Hill, David A., 1575
 Hill, Hal E., 2542
 Hill, S. L., 1545
 Hillier, Valerie F., 172
 Hirai, Keiji, 2108, 2562
 Hirakata, Yoichi, 1198, 1922
 Hiramatsu, Keiichi, 429
 Hirsch, Martin S., 1559
 Hiruma, Ryoichi, 589
 Hisaoka, Masafumi, 1810
 Hjelt, Lena, 2512
 Ho, Dai H., 879
 Hoban, Daryl J., 343, 1136
 Hodel-Christian, Susan L., 2259
 Hodge, R. Anthony Vere, 2747
 Hodges, Teri L., 121
 Hoepelman, Andy I. M., 1456, 2458
 Hoffman, Jacob M., 1019
 Hoffmeister, Karen A., 2542
 Hohl, Peter, 2825, 2835
 Heiby, N., 71
 Hoke, Glenn D., 527
 Holder, Ian Alan, 643
 Hollingshead, Melinda G., 206
 Holy, Antonin, 1837
 Holzknecht, Barbara, 2387
 Hommel, Marcel, 2228
 Honeybourne, D., 1171, 1176
 Honezumi, Ken, 435
 Hooper, David C., 1151
 Hooton, Thomas M., 1144
 Hopkins, Philip, 1097
 Horaus, Thea, 59, 1215
 Horn, Ruth, 2051
 Hosaka, Masaki, 2108
 Hoshino, Kazuki, 1491
 Hoskins, JoAnn, 533
 Hosoe, K., 387
 Hosoya, Mitsuaki, 1432

- Hostettler, John S., 477, 2656
 Hostettler, Karl Y., 2025
 Houston, John, 1909
 Howell, Renee M., 153
 Hoyle, Brian D., 2054
 Hsiung, G. D., 1127
 Hsu, Mei-Chieh, 1276
 Hsu, Pei-Wen, 1276
 Hubbell, James, 1040
 Hubschwerlen, Christian, 2825
 Huffman, John H., 473
 Huggins, Andrea S., 2548
 Hughes, George S., 126
 Hughes-Fulford, M., 2253
 Humbert, G., 1519, 2794
 Hunter, Susan, 2176
 Huovinen, Pentti, 989
 Hürlimann-Dalel, Rocio L., 2617
 Hurn, Sarah, 458
 Hurtado, Cipriano, 898
 Huskinson-Mark, Jayne, 326
 Husson, M. O., 1677
 Hutchison, M., 1532
 Hyman, Charles L., 682
 Hysiop, Newton E., Jr., 647
 Ibrahim, Ashraf S., 2239
 Ibrahim, Safaa S., 2432
 Ikeda, Takao, 214
 Imada, Akira, 1358, 2481
 Imada, Takuma, 573
 Imbimbo, Bruno P., 1296
 Inoue, Eiko, 684
 Inoue, Kazutomo, 1483
 Inoue, Matsuhisa, 883, 2293
 Inoue, Shigeharu, 492
 Inoue, Yoshimasa, 883
 Inukai, Masatoshi, 1024
 Iranmanesh, A., 2544
 Irie, Kenji, 1290
 Irwin, Raymond, 458
 Isaacson, D. M., 860
 Ishida, Kazuo, 1922
 Islam, Khalid, 1374
 Isono, Fujio, 1024
 Ito, Hideo, 1460
 Ito, Keizo, 883
 Ito, Masahiko, 435
 Ito, Tatsuya, 1708
 Itoh, Yuko, 2030
 Iwagaki, Akitaka, 1352
 Iwahi, Tomoyuki, 1358
 Iyobe, Shizuko, 684, 2562
 Jabarit-Aldighieri, N., 2529
 Jacob, L. S., 1263
 Jacobs, Michael R., 856, 1140
 Jacobs, Richard F., 1614
 Jacobson, Mark A., 1773
 Jacques, Mario, 2093
 Jaganathan, V., 938
 Jakics, Eva B., 2562
 Janc, M., 2850
 Jang, In Ho, 195
 Janssen, Cor, 417
 Janssen, P. A. J., 100
 Janssen, Paul A. J., 727
 Jansson, Catarina, 2704
 Jaresko, George S., 2233
 Jehl, F., 2493
 Jehl, François, 1883
 Jenkinson, Helen J., 202, 733
 Jeong, Lak-Shin, 672
 Ji, B., 548
 Ji, Baohong, 2839
 Jimenez, M. T., 558
 Jin, Shao Hong, 1068
 Jobe, Dean A., 1788
 John, Joseph F., Jr., 2346
 John, William J., 632
 Johnson, B. Lamar, Jr., 453, 2233
 Johnson, Caroline C., 2342
 Johnson, D. M., 2049
 Johnson, J., 1002
 Johnson, J. H., 2444
 Johnson, Susan, 2715
 Johnson, Victoria A., 1559
 Johnston, Linda, 1097
 Joly, Véronique, 262, 1799, 2722
 Jones, R. N., 2049
 Jones, Ronald N., 233, 873
 Joone, G., 1236
 Jooné, Gisela K., 2729
 Jousimies-Somer, H., 1241
 Jowett, Amanda J., 733
 Jowett, Michael I., 733
 Joye, Steve M., 2381
 Judson, Franklyn N., 1144
 Juteau, Jean-Marc, 467
 Kaatz, Glenn W., 1109, 1192, 2709
 Kabreria, G., 277
 Kageyama, Seiji, 926
 Kaijser, B., 2847
 Kaiser, Lee, 993
 Kaku, Mitsuo, 1198, 1922
 Kalman, Debra, 453
 Kamidono, Sadao, 188
 Kamimura, Toshiaki, 17
 Kanaani, Jamil, 1102
 Kaplan, Sheldon L., 1703
 Karkas, John D., 2020
 Karle, Isabella L., 1538
 Karle, Jean M., 1538
 Karlowsky, James A., 1136
 Kasholm-Tengve, B., 2766
 Katlama, Christine, 1821
 Kato, Masuhiro, 1290
 Kato, Nobuo, 1460
 Katsu, Kanemasa, 589, 684
 Kauffman, Carol A., 2533
 Kaufhold, Achim, 1215
 Kawahara, Yukinori, 1810
 Kawashima, Kousuke, 481
 Kawashima, Takanori, 1322
 Kayser, Fritz H., 25, 1367, 2617
 Keane, W. F., 1832
 Keck, C. W., 1764
 Kees, E. S., 277, 1682
 Kelloway, J. H., 1832
 Kelloway, Judy S., 126
 Kempf, Dale J., 926
 Kenny, Michael T., 115
 Kerestédjian, Jean-Jacques, 1244
 Kernodle, Douglas S., 440
 Kerwar, S. S., 1971
 Khan, Bashir A., 150
 Khoosal, Manikant, 1596
 Kibsey, Patricia C., 343
 Kiehlbauch, Julia A., 717
 Kihlström, E., 2766
 Kim, C. Kurtis, 1935
 Kim, Michael H., 626
 Kim, Young Jin, 195
 Kimura, Makoto, 2774
 Kinsman, Oonagh, 1909
 Kinzig, M., 1997
 Kisicki, James C., 1296
 Kita, Yasuo, 2481
 Kitagawa, Takayasu, 1219
 Kitzis, Marie-Dominique, 2611
 Kivistö, Kari T., 489
 Klare, I., 77
 Klare, Ingo, 783
 Klatzmman, David, 267
 Klein, Robert S., 1935
 Klemens, S. P., 1611, 2413
 Klich, M., 1756
 Klostermann, Heidrun, 1230
 Klotz, Stephen A., 132
 Klugman, Keith P., 1596
 Knapp, Joan S., 1639
 Knupp, Catherine A., 552, 1181, 1382, 1387, 2075
 Ko, T. C., 2057
 Kobashi, Yoshihiro, 2774
 Kobayashi, George S., 1805
 Kobayashi, Shinobu, 1352
 Kociba, Gary J., 2715
 Kodama, Kentaro, 1024
 Koeppe, Peter, 144, 796
 Kohlbrenner, William E., 81
 Kohler, C. A., 1971
 Kohlhepp, S. J., 2556
 Kohnen, P. W., 2556
 Kohzuki, Tsuneo, 1290, 1577
 Kojima, Kana, 1715
 Kondo, Masahiro, 1358
 Kong, Xiang-Bin, 808, 1472
 Konishi, Masaharu, 757
 Kontinen, Yrjö T., 227
 Koornhof, H. J., 1236
 Kornhauser, D. M., 2473
 Korvick, Joyce A., 620, 2639
 Kosunen, Timo U., 163
 Koszalka, George W., 353
 Kotera, Yasuo, 883
 Kovarik, John M., 2458
 Koyanagi, Yoshio, 1249
 Krajden, M., 1619
 Kramer, Barnett S., 1062
 Kropp, H., 607
 Krupa, D., 1648
 Ksionski, G., 1978
 Kuhlencord, Armin, 1630
 Kuistila, Maud, 989
 Kullberg, Bart-Jan, 1225
 Kulmala, Henrik K., 115
 Kunimoto, Setsuko, 492
 Kunz, Samuel, 2693
 Kuo, Cho-Chou, 1478
 Kurihara, Atsushi, 1810
 Kusmiesz, Helen T., 2478
 Kuwahara, S. K., 2473
 Kuwano, Koichi, 1322
 Kuwao, Sadahito, 481
 Kyle, Dennis E., 2761
 Labia, Roger, 1817
 Labrousse, Valérie, 2843
 Lacave, Charlotte, 1316
 Lacroix, C., 548
 Lacroix, Jean-Michel, 740
 Ladd, Elizabeth A., 920
 LaForge, Robert G., 1032
 Lafredo, Stephen C., 860
 Lagrange, P. H., 1081
 Lai, C. W., 2057
 Lalonde, Richard L., 1553
 Lam, Y. F. Francis, 2790
 Lambe, Catherine U., 353
 Lambert, D. M., 982
 Lambert, Dominique, 1115
 Lambert, John S., 1280
 Lambert, P. A., 71
 Lamberth, Linda B., 1703
 Lamothe, François, 343
 Lamp, Kenneth C., 1109, 1192, 2709, 2741
 Landini, Paolo, 446
 Lanéelle, Gilbert, 1316
 Lang, R., 973
 Lang, Stanley A., Jr., 808
 Larder, Brendan A., 2664
 Larson, Tom A., 2334
 Larrey, Paul A., 2778
 Lasseter, K. C., 830
 Lavallée, Jocelyne, 2051
 Lavoie, M. C., 2166
 Leary, J. J., 982
 LeBel, Marc, 2085
 LeBlanc, Barbara, 879
 LeBlanc, Donald J., 712
 Le Bras, Jacques, 209
 Lebrun, Annie, 2093
 Leclercq, Roland, 2005
 Le Conte, Philippe, 744
 Lecso-Bornet, Marilyn, 669
 LeDuc, Barbara W., 1553
 Lee, Hsi-Ming, 227
 Lee, Kyungwon, 195
 Lee, Linda, 712
 Leffers, Nilima Pai, 704
 Le Gallou, Florence, 744
 Leggett, J. E., 2556
 Legrand, Philippe, 2518
 Lehnert, Erich K., 495
 Le Jeune, Ludo, 2602
 Lejko-Zupanc, T., 2850
 Lemeland, Jean-François, 2611
 Lemozy, J., 1677
 Lenert, Leslie A., 1230
 Leonhardt, Judy A., 1837
 Léophonte, Paul, 833
 Lepage, Jean-Yves, 744
 Leroy, A., 2794
 Lertora, Juan J. L., 647
 Lettieri, J. T., 830
 Lettieri, John T., 993
 Leung, J. W. C., 2057
 Levesque, Roger C., 467
 Levin, Myron J., 2037
 Levin, Samuel, 1040
 Levison, Matthew E., 2342
 Levitz, Robert E., 1575
 Levy, Stuart B., 695
 Lewis, Eric W., 115
 Lewis, Ian J., 1981
 Lewis, L. D., 2061, 2473
 Li, Karl I., 545
 Li, Shixiong, 206
 Li, Su-Ling, 1770
 Liberator, P., 1964
 Liebman, Howard A., 1280
 Lietman, P. S., 2061, 2473
 Ligtvoet, Eric, 1456

- Lin, Teri, 2454
 Lindblad, Anders, 2512
 Lindholm-Levy, Pamela J., 1695
 Ling, Kah-Hing John, 108
 Liotta, Dennis C., 672, 2423, 2432, 2686
 Liu, Yu-Ying, 2286
 Livermore, David M., 1870, 2046
 Livni, E., 2286
 Ljungberg, B., 1437
 Ljungberg, Bengt, 2512
 Ljungdahl-Ståhle, E., 2418
 Lloyd, Robert M., 2423
 Lobe, David C., 934
 Lobo, Juan M. García, 1049
 Lockhart, Brian Paul, 1750
 Lode, Hartmut, 144, 796
 Loebenberg, David, 64, 217, 498
 Lohia, Anuradha, 788
 Lokiec, F., 2331
 Lokiec, François, 2804
 Loo, Vivian G., 1133
 Lopardo, Horacio A., 230
 Lounis, Nacer, 2839
 Loving, A. L., 1545
 Low, Donald E., 343
 Löwdin, Elisabeth, 1852
 Lubera, Sylviane, 669
 Lubowski, Teresa J., 651, 2758
 Lucaín, Christine, 894
 Ludlam, Hugo, 1097
 Lumish, Robert, 2639
 Lupidi, Remo, 331
 Lurie, Jon, 1230
 Lustig, Shlomo, 2275
- Macdonald, Timothy L., 495
 MacGowan, Alasdair, 463
 Machida, Haruhiko, 214
 Mack, Doug, 1040
 Maclean, Ian W., 467
 Maddon, Paul J., 267
 Madu, Assumpta, 32
 Madu, Christian N., 32
 Maeda, Hiroshi, 188
 Mahr, G., 942
 Majumdar, Sabita, 788
 Majumdar, Sadhana, 2808
 Malanoski, Gregory J., 1329
 Malinvern, Raffaele, 1256
 Malmberg, A. S., 2766
 Malmberg, Anna-Stina, 2512
 Malone, John D., 1062
 Malouin, F., 1504, 2147, 2166, 2569
 Mandell, Carol P., 2381
 Mandell, Gerald L., 39, 408, 2584
 Manfrin, Vinicio, 2192
 Maniera, Titus, 1630
 Mann, P., 1447
 Manning, Carolina, 2432
 Maple, P. A. H., 2346
 Marceau, François, 955
 Marcker, Victor, 2245
 Marichal, Patrick, 2602
 Mario, N., 2009
 Markowitz, Sheldon M., 1125
 Markus, A., 1756
- Marlin, Steven D., 1186
 Marone, Piero, 1567
 Maroushek, Nancy, 68
 Marquis, A. J., 217
 Marshall, Steven H., 1843
 Marthas, Marta L., 2381
 Martin, Barbara Anne, 751
 Martin, Claude, 1115, 2804
 Martin, R. Russell, 552
 Martin, Rodger K., 2761
 Martinez-Beltran, Jesus, 2536
 Martino, Pietro, 723
 Martinsen, Bernt, 1738
 Maserati, Renato, 1567
 Mason, Edward O., Jr., 1703
 Massias, L., 2539
 Masters, Helen B., 2037
 Masuda, Koji, 1460
 Masuda, Masao, 1249
 Masuda, Nobuhisa, 1847
 Mathes, Lawrence E., 2715
 Mathewson, John J., 87, 2821
 Mathis, Rodney, 672, 2423
 Mathisson, Kevin, 32
 Matlow, Anne G., 1133
 Matsubara, Kenichi, 2042
 Matsubara, Shuzo, 1715
 Matsubayashi, Kyuichi, 966
 Matsuda, Akira, 435
 Matsumoto, Akiyoshi, 1249
 Matsumoto, Keizo, 1352
 Matsumoto, Masahiko, 1715
 Matsumoto, Satoru, 17
 Matsumoto, Tetsuya, 1198, 1922
 Matsumura, Haruki, 1577
 Matsuno, S., 762
 Matsushima, Toshiharu, 2774
 Matsuyama, Shinichi, 1432
 Mattern, William, 1387
 Mattheuws, D., 1606
 Matthews, T. J., 982
 Mattie, Herman, 2375, 2439
 Matzke, Gary R., 308
 May, Phyllis, 2342
 Mayer, Roger M., 2228
 Mayers, Martin, 32
 Maziere, Bernard, 2216, 2611
 Mc Koy, Judith, 2497
 McCaffrey, C., 1601
 McCann, Peter P., 2736
 McClure, Harold M., 2432
 McCormack, Robert J., 1296
 McCormack, William, 1131
 McDanal, C. E., 982
 McDermott, Laura, 540
 McDonald, Peter J., 10
 McDougal, Linda K., 2176
 McFadden, D. C., 1964
 McFarland, James W., 368, 372
 McGowan, Ellen K., 2381
 McGrath, Betty J., 2741
 McGrath, Jacqueline M., 920
 McGrath, M. S., 2253
 McGuirk, Paul R., 751, 1671
 McKee, J. A., 2166
 McKee, Julia A., 840
 McLaughlin, James, 463
 McLaughlin, J. C., 137
 McLeod, Gavin X., 920
 McLeod, Rima, 1040
 McMahon, F. Gilbert, 308
- McMillan, Angela, 672, 2423
 McNicholas, Paul, 913
 Mead, Jan R., 1837
 Medeiros, Antone A., 1032
 Medina, D. J., 1127
 Meek, T. D., 982
 Mellors, J. W., 1127
 Mentec, Hervé, 1883
 Mentzing, L. O., 2766
 Menzel, Fred, Jr., 64
 Menzel, Frederick, Jr., 498
 Merle-Melet, M., 2331
 Merluzzi, Vincent J., 1186
 Merrill, Debra P., 1559
 Mertens, Jacqueline C. C., 1456
 Mertes, P. M., 2493
 Metcalf, B. W., 982
 Meulemans, A., 295
 Meunier, F., 2014
 Meurer, Laura C., 2020
 Meyer, Christian, 71
 Meyers, Fred J., 2349
 Meyran, M., 1677
 Micozzi, Alessandra, 723
 Mierzwa, R., 1447
 Mierzwa, Ronald, 2222
 Migaki, Thomas T., 2080
 Mignon, F., 1519
 Miick, Cathleen, 656
 Mildvan, Donna, 1570
 Milhous, Wilbur K., 1538, 2761
 Millar, Michael Ronald, 185
 Miller, G. H., 64, 498, 1447
 Miller, George H., 2222
 Miller, M. J., 2166
 Miller, Marvin J., 840
 Miller, Michael H., 32
 Miller, Wayne H., 2686
 Minitier, Peggy, 2681
 Minkler, Paul, 1392
 Minnick, A. A., Jr., 2166
 Minnick, Albert A., 840
 Miranda, Abraham G., 1325
 Mitsuhashi, Susumu, 684, 2185, 2293
 Mitsuya, H., 2156
 Mitsuya, Hiroaki, 926
 Mitsuyama, Jun-Ichi, 2030
 Mitsuyama, Masao, 361
 Miwa, Hideaki, 1219
 Miyake, Akio, 1358
 Miyashiro, Deborah, 1991
 Miyazaki, Shuichi, 573
 Mizen, Linda, 458, 1427
 Mizojiri, K., 762
 Mizukane, Ryusuke, 1922
 Moellering, R. C., Jr., 2201, 2526
 Moellering, Robert C., Jr., 121
 Moeremans, Marc, 417
 Molinas, Catherine, 867, 1514
 Molitoris, Eric, 239
 Monosov, M., 2316
 Monsigny, Michel, 2228
 Monteil, H., 2493
 Montero, J. M., 2816
 Montgomery, Debra A., 2131, 2778
 Moore, Carol Wood, 2497
 Moosmann, Yves, 1256
- Morán, Francisco J., 898
 Moreau, N., 2622
 Morel, C., 1677
 Moreno, A., 662
 Morgan, M. E., 2156
 Mori, Shuichi, 435
 Morita, Naokata, 1890
 Morris, Janis L. B., 1837
 Morrison, Paul J., 378
 Morse, Gene, 1280
 Morse, Gene D., 2245
 Moscon, Bret, 473
 Moss, Eugene L., Jr., 64, 498
 Motley, Milwood, 1639
 Motomiya, Masakichi, 6
 Movahhed, Hassan, 552
 Muchmore, Elizabeth, 808
 Muder, Robert R., 620, 2639
 Muffat-Joly, Martine, 2216, 2403
 Müller, Christine, 144
 Müller, Johannes, 1805
 Muller-Serieys, C., 2099
 Munafó, Alain, 1013
 Munakata, Kei-Ichi, 1580
 Munayyer, H., 1447
 Murakami, K., 2156
 Murakami, Tsutomu, 1249
 Muratani, Tetsuro, 2293
 Murciano, G., 2099
 Murray, Barbara E., 230, 273, 1325, 1720, 2259, 2265, 2355
 Murray, L., 2544
 Musher, D. M., 1785
 Mutton, Ian M., 202
 Myhr, Egil, 1738
- Nafziger, Anne N., 679
 Nagahata, Takemitsu, 2042
 Naganawa, Hiroshi, 492
 Nagano, Hiroyuki, 1715
 Naganuma, Hideo, 1810
 Nagaraj, R., 2468
 Nagashima, Minoru, 2589
 Nagatake, Tsuyoshi, 1352
 Naiman, Noreen A., 1825
 Nakae, Taiji, 1791
 Nakahama, Chikara, 167
 Nakamura, Junichi, 2774
 Nakamura, Kiyoto, 435
 Nakamura, Mariko, 492
 Nakano, Hirofumi, 2589
 Nakashima, Hideki, 1249
 Nakashima, M., 762
 Nakata, Katsuhisa, 188
 Nakayama, Hiroaki, 1626
 Nassos, Patricia, 2808
 Nassos, Patricia S., 1163
 Nathan, Henry C., 2736
 Naumovski, Louie, 1991
 Neely, Alice N., 643
 Nègre, Éric, 2228
 Neider, Katharina, 796
 Nelis, H. J., 1606, 1859
 Nelson, Donald J., 353, 2686
 Nentwig, Birgit, 2139
 Neu, Harold C., 1310, 1336, 1418, 1699
 Neuvonen, Pertti J., 489, 1086
 Newcomb, Deborah M., 368, 372
 Neyfakh, Alexander A., 484
 Ng, Eva Y., 1151

- Nguyen, Hieu T., 879
 Nicas, T. I., 2166
 Nicholls-Vasquez, Ines, 2821
 Nicolin, Roberto, 1567, 2192
 Nielsen, Eva Möller, 401
 Nightingale, Charles, 651
 Nightingale, Charles H., 1575, 2758
 Niki, Yoshihito, 167
 Nikolich, Mikeljon P., 1005
 Nilsson-Ehle, I., 1437, 1532, 2676
 Nilsson-Ehle, Ingrid, 2512
 Nishida, Minoru, 573
 Nishikawa, Takashi, 1219
 Nishiki, Katsuyuki, 481
 Nishino, Takeshi, 1708, 1894, 2595
 Nishizawa, Kazuaki, 481
 Noe, A. J., 830
 Noguchi, Hiroshi, 1290
 Nolan, Rathel L., 977
 Nollstadt, K., 1648
 Nomoto, Kikuo, 361
 Nomoto, Koji, 361
 Norbeck, Daniel W., 926
 Nord, C. E., 1997, 2766
 Nord, Carl-Eric, 144
 Nordmann, Patrice, 1244
 Norman, Dean C., 1665
 Norrby, S. R., 1532, 2676
 Norris, Christine, 64, 498
 Nothnagel, Robert F., 1091
 Nouda, Hiroshi, 1577
 Novak, E., 1764
 Novick, Richard P., 626
 Numazaki, Yoshio, 435
 Nunberg, Jack H., 1019
 Nyhart, Eldon H., Jr., 318
 Nyström, P. O., 2766

 Obara, Takumi, 435
 Öberg, B., 1770, 2418
 Öberg, Bo, 339
 Oblon, David J., 1062
 O'Brien, Julie A., 1019
 Ochi, Hiroshi, 1290
 Odds, Frank C., 1727, 2602
 Odenholt-Tornqvist, Inga, 1852
 O'Doherty, Elizabeth, 2661
 Oduola, Ayoade M. J., 2761
 Oguma, T., 762
 Oguma, Takayoshi, 1219
 O'Halloran, James J., 1424
 O'Hara, Caroline, 1785
 Ohashi, Masami, 883
 Ohno, Tsuneya, 492
 Ohta, Michio, 1460
 Ohya, Satoshi, 1847
 Oishi, Kazunori, 1352
 Ojala-Karlsson, Pirjo, 489
 Okabayashi, Yoshito, 1219
 Okamoto, Seiki, 2030
 Okazaki, Osamu, 2270
 Okonogi, Kenji, 1358
 Okuda, Takao, 1577
 Oldfield, Edward C., III, 2542
 Oliva, Brunello, 876, 913
 Olson, John, 2245
 Olson, Julie A., 372, 2080, 2338
 Olsson-Liljequist, B., 2766

 Onishi, J., 607
 Onyi, Grace O., 180, 1987
 Opal, Steven M., 1032
 Oppegard, Hanne, 1738
 Opsahl, John A., 308
 Öqvist, B., 1532, 2676
 Ordóñez, A., 2816
 Orefici, Graziella, 1068
 O'Reilly, Terry, 2693
 Oronsky, A. L., 1971
 Orr, David C., 1688
 Orsi, Nicola, 95
 Osada, Yasuaki, 1491
 Osheroff, Neil, 751
 Oshitani, Hitoshi, 435
 Ossi, Michael J., 1614
 Ostrander, Michael, 808
 O'Sullivan, John F., 2729
 O'Sullivan, N., 1002
 Otsuki, Masako, 1708, 1894, 2595
 Ott, Christopher L., 1296
 Otter, Brian A., 1935
 Outman, William R., 1575

 Pace, J., 1601
 Padmos, M. Andrew, 172
 Paff, Melanie, 2686
 Page, Malcolm, 2825
 Painter, George, 2423
 Painter, George R., 2686
 Pajukanta, R., 1241
 Palzkill, Tim, 1991
 Paradis, Dominique, 2085
 Parent de Curzon, O., 1519
 Parker, Richard, 1329
 Parmegiani, Raulo, 64, 498
 Parr, T. R., Jr., 1504, 2166
 Pascual, Alvaro, 1053
 Patel, Marlynn, 1991
 Patterson, Thomas F., 2681
 Patton, Dorothy L., 1478
 Pauwels, Rudi, 2628
 Pavičić, M. J. A. M. P., 2634
 Paxton, L. M., 1764
 Peacock, James E., Jr., 620
 Pearson, Bridget A., 202, 733
 Pearson, Richard D., 495
 Pechère, Jean-Claude, 894, 2506
 Peck, Annette, 672, 2423
 Pecking, Michèle, 2804
 Pedersen, Gordon, 473
 Pedersen, Niels C., 2381
 Peggins, James, 1825
 Peltola, Heikki, 1086
 Pemán, J., 558
 Penn, Charles R., 202, 733, 1688
 Perea, Evelio J., 1053
 Perez, R., 1677
 Perez-Diaz, Jose C., 2536
 Pérez-Giraldo, Ciro, 898
 Perez-Perez, María-Jesús, 1073
 Pérez-Rivilla, A., 1794
 Perkins, B. A., 1785
 Perkins, Robert M., 2747
 Pernet, Andre G., 378
 Perronne, Christian, 2104, 2408
 Petavy, A. F., 191
 Peterson, Lance R., 1166

 Petitclerc, Eric, 955
 Petitpretz, Patrick, 833
 Petrikos, G. L., 1447
 Petteway, S. R., Jr., 982
 Pfaller, M. A., 137
 Pfaller, Michael A., 1805
 Pfeffer, Morris, 1382, 1387
 Pfefferkorn, E. R., 1091
 Pfeiffer, S., 505
 Phan, M., 2014
 Picard, M., 1504, 2569
 Picazo, Juan J., 2536
 Pickering, Larry K., 1720
 Pickett, W. C., 1971
 Piddock, L. J. V., 1057
 Piddock, Laura J. V., 819
 Pierre, Josiane, 669
 Pike, Jane, 185
 Pillai, V. N. R., 2468
 Pinelli, G., 2493
 Piriz, Segundo, 198
 Pitsakis, Peter, 2342
 Pittarelli, L., 1964
 Pittman, K. A., 938, 962
 Pittman, Kenneth A., 552, 687, 1181, 1382, 1387
 Plank, Carol, 2245
 Plattner, Jacob J., 926
 Pleterski-Rigler, D., 2850
 Pocidallo, Jean-Jacques, 470, 997, 1412, 2104, 2216, 2328, 2408, 2698, 2852
 Podbielski, Andreas, 1215
 Poell, Robert J. M., 1225
 Poignet, J. L., 1519
 Polas, Phyllis J., 2715
 Polsky, Bruce, 808
 Portet, Cécile, 1115
 Portmore, Amy C., 2245
 Potel, Gilles, 744
 Potter-Bynoe, Gail, 1032
 Poupard, Marie-Christine, 1817
 Powles, M. A., 1964
 Poyart-Salmeron, Claire, 463
 Pramanik, Ajay, 2497
 Preat, Veronique, 1525
 Preston, David A., 533
 Price, F. C., 277
 Principi, Nicola, 1499
 Projan, Steven J., 626
 Prokocimer, Philippe, 2852
 Prokocimer, Phillippe, 2454
 Prosser, Barbara L., 2286
 Prus, Karen L., 283
 Pruul, Hendrik, 10
 Pulliam, L., 2253
 Punyagupta, Sompon, 158

 Qadri, S. M. Hussain, 150
 Quale, John M., 1424
 Quassem, C., 677
 Queener, S. F., 779
 Quémar, Annaik, 1316
 Quentin-Noury, C., 1677
 Quinn, John P., 1991
 Quinn, Thomas C., 291
 Quintero, Julio C., 1019
 Quintiliani, Richard, 651, 2758
 Qumei, Khaldoon K., 1573

 Raasch, Ralph, 1773
 Rabadan, Pablo M., 1272
 Ragni, Jacques, 2804
 Ralph, Ray, 1644

 Ramamurthy, Nungavaram, 227
 Ramón, M. S., 558
 Ramos, Marcelo C., 1864
 Ramos, Ross A., 2381
 Ramphal, Reuben, 1062
 Ranaldi, Giulia, 1374
 Rand, Kenneth H., 1062
 Raoult, D., 2529
 Raoult, Didier, 2799
 Ras, G. J., 1236
 Rasmussen, Beth A., 1155
 Rasmussen, Kathleen R., 220
 Rastogi, Nalin, 2841, 2843
 Rather, P. N., 1447
 Rather, Philip N., 2222
 Rathod, Pradipsinh K., 704
 Rautelin, Hilpi, 163
 Raynaud, G., 191
 Raza, Jocelyne, 744
 Reeves, Michael, 2176
 Rege, Arvind B., 647
 Reichman, Richard C., 2245
 Reig, M., 662
 Reig, Milagro, 639
 Reinert, C., 71
 Remington, Jack S., 326, 2454
 Renaudin, Helene, 870
 Renkonen, Olli-Veikko, 163, 1086, 2652
 Resetar, Andrea, 353
 Reverdy, M. E., 1677
 Reves, Randall R., 1720
 Reyman, Diane, 2628
 Rezvani, Y., 1677
 Rice, John R., 372, 2338
 Rice, Louis B., 1843
 Richman, Douglas D., 2025
 Ricketts, Anthony P., 368, 372, 2080, 2338
 Riess, G., 2360
 Rigoli, Roberto, 1567, 2192
 Rinaldi, Enrico, 2192
 Rinaldi, M. G., 217
 Rinaldi, Michael G., 603, 690, 1805, 2790
 Ripamonti, Franca, 446
 Roberts, M. C., 611
 Robinson, Kristin A., 2533
 Robinson, Megan J., 751
 Roblin, Patricia M., 682, 1573
 Robson, Hugh G., 2051
 Roche, Annie-Claude, 2228
 Rodloff, Arne C., 783
 Rodriguez, Ana, 1028
 Rodriguez, Carlos A., 616
 Rogge, Mark C., 993
 Roland, Michel, 1525
 Rolston, Kenneth V. I., 879
 Romero, Eneida A., 2518
 Ronald, Allan R., 467
 Ronco, Esthel, 1244
 Rood, Julian I., 2548
 Roscoe, Diane L., 2197
 Rosebaum, M., 1677
 Rosenberg, E., 2316, 2322
 Rosenthal, M. E., 860
 Rotmensch, H. H., 677
 Rotschafer, John C., 2334
 Rouse, Mark S., 56, 1272
 Rouse, Philippa L., 733
 Rousseau, N., 1504, 2147
 Rouveix, Bernard, 997

- Rozenberg-Araska, M., 801
 Rozenberg-Araska, Maja, 2458
 Rubaglio, Etelvina A., 230
 Ruberg, Stephen J., 115
 Rubin, Robert H., 2286
 Rubinstein, E., 973
 Rueppel, W. J., 277
 Ruffing, Thomas L., 1019
 Rush, Dawn, 32
 Rybak, Michael J., 1109,
 1192, 1204, 2709, 2741
 Ryffel, Cristina, 25, 2617
- Saarela, M., 1241
 Saari, Herkko, 227
 Saathoff, Nina, 796
 Sabatelli, F. J., 1447
 Sabra, R., 2670
 Saenger, S., 1682
 Sahm, Daniel F., 902
 Saint-Julien, Line, 262, 2722
 Saissi, Gilbert, 1404
 Saito, H., 387
 Saito, Isao, 481
 Sakai, Osamu, 2270
 Sakata, Shinji, 214
 Sakaue, Morito, 492
 Saldivar, Ayda, 81
 Saleh-Mghir, Azzam, 1883,
 2216, 2403, 2611
 Salstrom, Sara-Jane, 1400
 Salyers, Abigail A., 1005
 Samathanam, Glory, 32
 Sambuy, Yula, 1374
 Samuelson, John C., 2392
 Sanchez, Martha L., 873
 Sande, Eric, 2693
 Sande, Merle A., 2693
 Sanders, Christine C., 394,
 1877
 Sanders, Cynthia A., 1163
 San-Felix, Ana, 1073
 Sarafian, Samuel K., 1639
 Sarciron, M. E., 191
 Sardana, Vinod V., 1441
 Sarkis-Karam, Dolla, 669
 Sassella, Daniela, 1958
 Sastre, Bernard, 1115
 Sato, K., 387
 Sato, Kenichi, 1491
 Satoh, Ken, 6
 Satoh, Masaru, 1580
 Satta, Giuseppe, 1902
 Saulnier, P., 2009
 Saunders, J., 1236
 Sautter, Robert L., 1635
 Savage, J. E., 1236
 Scardaci, Giovanna, 1068
 Scarpellini, Paolo, 1567, 2192
 Schaberg, Dennis R., 2533
 Schaller, K., 1284
 Schaub, R. E., 1971
 Schedel, Ingolf, 2139
 Scheffel, J. M., 1677
 Scheld, W. Michael, 949
 Schenfeld, Louis, 2639
 Schinazi, Raymond F., 108,
 672, 2423, 2432, 2686
 Schiro, Denise D., 854
 Schlabach, Abner J., 1441
 Schleif, William A., 1019
 Schlievert, Patrick M., 626
 Schlundt, Jørgen, 401
- Schmatz, D., 1648
 Schmatz, D. M., 1964
 Schmid, George, 1639
 Schneider, Sheila A., 2037
 Schols, Dominique, 2628
 Schrempf, H., 1119
 Schuster, F. L., 1263
 Schwartz, R., 1648
 Schwarz, Stefan, 580
 Scotti, Roberto, 446
 See, Darryl M., 425
 Seibert, G., 1756
 Seidlin, Mindell, 1280
 Sekh, Beata Razab, 2375
 Sekh, Beate A. Razab, 2439
 Self, Timothy H., 1553
 Seman, Michel, 2722
 Sengupta, Tapas K., 788
 Sennello, L. T., 2447
 Seo, Susan M., 1192
 Seoane, Asunción, 1049
 Seppälä, Kari, 163
 Serra, Pietro, 723
 Seuba, Teresa, 1028
 Severin, Anatoly, 886
 Shadomy, Smith, 1805
 Shah, V. R., 938
 Shalit, Itamar, 313
 Shamblen, E. C., 830
 Shands, Joseph W., Jr., 1062
 Shannon, William M., 206
 Shapiro, Bruce E., 126
 Sharkey, Patricia K., 2790
 Shasha, B., 973
 Shaw, K. J., 1447
 Shaw, Karen J., 2222
 Shaw, M. M., 779
 Shen, Linus L., 2131, 2778
 Sherertz, Robert J., 1062
 Sherman, Philip, 1133
 Shiba, Kohya, 1219, 2270
 Shigeta, Shiro, 214, 435, 1432
 Shiki, Shikiko, 1358
 Shimada, Jingoro, 1219, 2270
 Shiman, Ross, 1140
 Shimizu, Kihachiro, 757
 Shimokawa, Osamu, 1626
 Shintani, Shozo, 966
 Shirasaka, Takuma, 926
 Shively, Jesse E., 368
 Shlaes, David M., 1392
 Shoemaker, Jo Ellen E., 527
 Shoemaker, Nadja B., 1005
 Shoji, Satoru, 6
 Shonekan, Dokun, 1570
 Shuto, Satoshi, 435
 Shyu, W. C., 938, 962
 Shyu, Wen Chyi, 687
 Sidwell, Robert W., 473, 1837
 Siegl, Peter K. S., 1019
 Signs, Steven A., 1400
 Simard, Marie, 2204
 Singer, Allen W., 299
 Singer, Susan B., 1991
 Singh, Kavindra V., 230,
 1325, 1720
 Singlas, E., 1519
 Singlas, Eric, 1821
 Sips, Peter A., 2458
 Sirot, D. L., 1677
 Sirot, Danielle, 1817
 Sirot, Jacques, 1817
 Sitaram, N., 2468
- Siu, P., 2544
 Sjöberg, L., 2766
 Sjoerdsma, Albert, 2736
 Sjögren, E., 2847
 Skatrud, Paul L., 533
 Skau, T., 2766
 Sköld, Ola, 2704
 Slaney, Leslie, 467
 Slusher, J. T., 2473
 Smee, Donald F., 1837
 Smit, Jan M., 2458
 Smith, Anthony M., 1019
 Smith, David E., 616
 Smith, Deborah A., 632
 Smith, J. W., 779
 Smith, John A., 343
 Smith, Monica C., 273, 2265
 Smith, Robert L., 132
 Smithers, Jacquelyn A., 115
 Snoeks, J., 100
 Snyderman, David R., 540
 Sobel, A., 1519
 Soler, P., 2099
 Sommadossi, Jean-Pierre,
 2423
 Sommereijns, Bernadette,
 2661
 Sonders, R. C., 2447
 Sonoda, Fuminari, 1352
 Sookpranee, Mondej, 158
 Sörgel, F., 942, 1997
 Soriano, Francisco, 223
 Sorsa, Timo, 227
 Sørum, H., 611
 Soussy, C. J., 1677
 Spangler, Sheila K., 856, 1140
 Spector, Thomas, 353, 934
 Spence, David G., 172
 Sperber, Steven J., 153
 Spruance, Spotswood L., 1144
 St. Clair, Marty, 2423
 St. Peter, John V., 126
 Stähle, L., 1770, 2418
 Stähle, Lars, 339
 Staib, A. H., 942
 Stamm, Walter E., 1144
 Stanberry, Lawrence R., 2020
 Stasi, Patrizia, 1499
 Steckelberg, James M., 56,
 1272
 Steele, Paul, 1935, 1943
 Stein, Maria Luisa, 95
 Stevens, David A., 477, 486,
 2487, 2656
 Stewart, Brian W., 132
 Stockley, R. A., 1545
 Stokbroekx, R., 100
 Storer, Richard, 202
 Strandvik, Birgitta, 2512
 Strap, Janice L., 890, 1208,
 1347
 Strässle, Anni, 566, 1367
 Stratton, Charles W., 440
 Strauss, H. William, 2286
 Strle, F., 2850
 Stuhmiller, Louise M., 2025
 Stutman, Harris R., 255
 Su, W. J., 1332
 Su, Yan A., 769
 Sullivan, Gail W., 39, 408,
 2584
 Sumita, Yoshihiro, 1577
 Summanen, Paula, 1658
- Sunagawa, Makoto, 1577
 Sundar, Latha, 2645
 Sundelof, J. G., 607
 Suomalainen, Kimmo, 227
 Susaengrat, Watanachai, 158
 Suzuki, Eiko, 429
 Suzuki, Hitoshi, 1432
 Swan, S. K., 2556
 Sweeney, Kevin, 651, 2758
 Sweep, C. G. J. (Fred), 2785
 Swenson, Cheryl L., 2715
 Swenson, Jana M., 2176
 Szczec, George M., 934
- Taburet, A. M., 1519
 Taburet, Anne-Marie, 1821
 Tachizawa, Haruo, 966
 Takahashi, Yoshikazu, 492
 Takahata, Masahiro, 2030
 Takeuchi, Hideo, 1580
 Takeuchi, Tomio, 492
 Tallan, Barbara M., 56
 Tally, F. P., 2766
 Tan, James S., 1400
 Tanaka, Mayumi, 1491, 2595
 Tanaka, Shigenori, 1460
 Tanio, Tomoharu, 1577
 Tasset, Chantal, 1525
 Tatara, Osamu, 167
 Tateda, Kazuhiro, 1198, 1922
 Täuber, Martin G., 2693
 Tawara, Shuichi, 17
 Taylor, Charlene, 2245
 Taylor, G. W., 1236
 Taylor, Shirley, 2342
 Teal, M. A., 1832
 Tellier, R., 1619
 Tenney, James, 552
 Tenover, Fred C., 712, 2176
 Tereshima, Masazumi, 1290
 Terpenning, Margaret S., 2533
 Teutsch, G., 1756
 Tharpe, William N., 172
 Then, Rudolf, 2825
 Thom, Edna, 2286
 Thompson, Gary A., 115
 Thomson, Kenneth S., 1877
 Thornber, D., 2128, 2360
 Thornber, Dawn, 2197
 Tidwell, Richard R., 1825
 Tilles, Jeremiah G., 425
 Tillman, Jill, 1703
 Tobe, Takayoshi, 1483
 Tobia, A. J., 860
 Todd, Neil, 1981
 Tokiwa, Hiroshi, 1810
 Tokue, Yutaka, 6
 Tolchinsky, S., 2316, 2322
 Tolman, Richard L., 2020
 Tomao, Paola, 95
 Tomasz, Alexander, 886
 Tomioka, H., 387
 Tomizawa, Hiroshi, 2108
 Tommasi, Paola, 1499
 Tomono, Kazunori, 1198
 Tong, William P., 1472
 Tordo, Noel, 1750
 Torley, L. W., 1971
 Torres, H., 2529
 Toscano, John P., 2334
 Totsuka, Kyoichi, 757
 Toulouse, André, 955
 Toyer, Barbara, 206

- Trainor, C., 1648
 Tramarin, Andrea, 2192
 Trieu-Cuot, Patrick, 463, 502
 Troetel, William M., 1296
 Troke, Peter F., 1805
 Trouvin, Jean-Hugues, 2462
 Truffot-Pernot, C., 548
 Truffot-Pernot, Chantal, 2104, 2408, 2839
 Trujillo, Gloria, 1028
 Tsang, M., 2544
 Tsiang, Henri, 1750
 Tubbs, H. J., 1764
 Tullus, Kjell, 989
 Tully, Joseph G., 870
 Tunevall, G., 2766
 Turcotte, André, 2211
 Turner, L. F., 1764
 Turrell, Corrine, 2349
 Tuttle, Joel V., 2686

 Uematsu, T., 762
 Uezumi, Ikuko, 1290
 Uitto, Veli-Jukka, 227
 Umez, Keiichi, 188
 Unger, Clemens, 1630

 Vaara, Martti, 826
 Väärälä, Marita, 1086
 Vadillo, Santiago, 198
 Vainio, Unto, 163
 Valentine, Fred T., 1280
 Valle, Jorge, 198
 Vallee, Eric, 2698
 Vallée, Éric, 1412
 Vallée, François, 2085
 Vallois, Jean-Marie, 1883, 2216, 2403, 2611
 van Barneveld, Peter W. C., 1456
 Vance-Bryan, Kyle, 2334
 Vandamme, Anne-Mieke, 2628
 van den Bosch, Henk, 2025
 Vanden Bossche, Hugo, 2602
 Vandenbranden, J., 1606, 1859
 Van der Auwera, P., 521, 1302, 2014
 van der Horst, Charles, 1773
 Van der Linden, M. P., 46
 van der Meer, Jos W. M., 1, 2785
 Van de Velde, Vera, 2661
 Van Eemeren, K., 100
 van Furth, Ralph, 1225, 2375
 van Heijenoort, J., 77, 1487
 Vanmiddlesworth, F., 1648
 van Niekerk, E., 1236
 Vannier, Ann M., 1766
 van Ogtrop, Marc L., 2375, 2439
 Van Rensburg, Constance E. J., 2729
 Van Rompay, Koen K. A., 2381
 van Someren, Petri, 1782

 van Strijen, Elisabeth, 2375, 2439
 Van't Wout, Jan W., 1225
 van Wijk, Gijbert M. T., 2025
 van Winkelhoff, A. J., 2634
 Varaldo, Pietro E., 331
 Varga, L. L., 2447
 Vargas, Ofelia M., 255
 Vargas, Ramon, 308
 Varner, Laura M., 854
 Varon, M., 2316, 2322
 Vaz Pato, Maria Vitoria, 886
 Veber, Benoit, 2698
 Vékey, Karoly, 1744
 Velazquez, Sonsoles, 1073
 Venditti, Mario, 723
 Venitz, J., 938
 Venuti, Elaine, 1563
 Verdonck, L. F., 801
 Verhaeghe, B., 1606
 Verhoeft, J., 801
 Verhoeft, Jan, 2458
 Vial, Henri J., 50
 Victor, Gary, 1032
 Vidal, Pedro, 1472
 Vidal, Pedro M., 808
 Viganò, Alessandra, 1499
 Vilde, Jean-Louis, 2104
 Vildé, Jean-Louis, 2408
 Villa, Anna Dalla, 1499
 Villemot, J. P., 2493
 Vincent, Sophie, 1392
 Viner, K. Claire, 733
 Viron, B., 1519
 Visser, Maarten R., 1456
 Vogels, Maria T. E., 1, 2785
 von Graevenitz, Alexander, 2835
 Vuorio, Riitta, 826

 Wacharotayankun, Rochaporn, 1460
 Wachsmuth, I. Kaye, 717
 Wagener, Marilyn M., 2639
 Wagle, N., 2552
 Wagner, Jutta, 783
 Wahren, B., 2418
 Waits, V. B., 1978
 Wakebe, Hirokazu, 2185
 Walbaum, S., 191
 Wald, Ellen R., 545
 Walker, Clay B., 740
 Walker-Cador, Janice Y., 647
 Wallace, Jack E., 603, 2790
 Wallace, Richard J., III, 180
 Wallace, Richard J., Jr., 180, 1987
 Walsh, Christopher T., 867, 1514
 Walsh, Thomas J., 1805
 Walters, Ruth N., 819
 Walzer, Peter D., 1935, 1943
 Wang, Laurene H., 299
 Wang, Lotte, 687
 Wang, Sha-ke, 1478

 Wanger, Audrey R., 1325
 Warbasse, Lawrence H., 1204
 Warnock, David W., 1805
 Warren, M. M., 2552
 Warren, Reed P., 473
 Watanabe, Akira, 6
 Watanabe, Kyoichi A., 808
 Watanabe, Masato, 684
 Watanabe, Nao-Aki, 589
 Wegener, Henrik C., 580
 Weidler, Donald J., 552
 Weigl, Debra, 81
 Weinbaum, David, 2639
 Weinberg, Adriana, 2037
 Weinstein, John N., 926
 Weiss, Peter J., 2542
 Welker, Horst A., 632
 Welsh, Laura E., 291
 Wennersten, C. B., 2201, 2526
 Wennersten, Christine, 121
 Wenzel, Richard P., 873
 Werbovetz, Karl A., 495
 Werner, M., 2847
 Westenborghs, Robert, 2661
 Westphal, Jean-Frédéric, 2462
 Wexler, Hannah M., 239, 1658
 Wheeler, Rebecca R., 620
 White, Michael, 1935, 1943
 Wichström, Reidun, 1738
 Wideburg, Norman, 81
 Wiedemann, Bernd, 1915
 Wientjes, M. Guillaume, 665
 Wignall, F. S., 277, 1682
 Wilairat, Prapon, 1644
 Wilber, R. B., 938, 962
 Wilkinson, Brian J., 566
 Willard, Keith E., 1166
 Willebrords, R., 100
 Wilson, D. S., 2447
 Wilson, Jeanne, 2423
 Wilson, Lawrence J., 2686
 Wilson, R., 1236
 Wilson, Samuel Z., 1466
 Wilson, Walter R., 56, 1272
 Wise, R., 1002, 1171, 1176, 1928, 2360, 2444
 Wise, Richard, 2197
 Wissner, A., 1971
 Withers, Shawn, 1040
 Witte, Wolfgang, 783
 Witvrouw, Myriam, 2628
 Wolfgang, Jill A., 1441
 Wolfson, John S., 1151
 Wolny, James D., 318
 Wong, Edward S., 1125
 Wong, M. O., 1832
 Woodnutt, Gary, 1427
 Woodworth, James R., 318
 Wörmann, Bernhard, 2139
 Wren, Cathie G., 2037
 Wretling, B., 2766
 Wright, Gerard D., 867, 1514
 Wu, C. Y. Ernie, 533
 Wurster, J. A., 2686
 Wyde, Philip R., 1466

 Yajko, David, 2808
 Yajko, David M., 1163
 Yamaguchi, Hideyo, 2523
 Yamaguchi, Keizo, 573, 1198, 1922
 Yamamoto, Naohiko, 2628
 Yamamoto, Naoki, 1249
 Yamamoto, S., 762
 Yamamoto, Sadao, 757, 1219
 Yamamura, Ken-Ichi, 2042
 Yamane, T., 387
 Yamashita, K., 387
 Yamashita, Yoshinori, 2589
 Yamazaki, Toshiyuki, 1358, 2481
 Yang, Youjun, 1155
 Yarlett, Nigel, 2736
 Yarosh-Tomaine, Taisa, 64, 498
 Yasuda, Takashi, 2030
 Yasue, Tokutaro, 2108
 Yates, R. R., 217
 Yatsu, J., 1764
 Yeaman, Michael R., 1665
 Yen, Patrick, 262, 1799, 2722
 Yeola, Suresh, 672
 Yetman, Robert, 1614
 Yokokura, Teruo, 361
 Yokoo, Mamoru, 2523
 Yokota, Takeshi, 429, 1715
 Yoneyama, Hiroshi, 1791
 Yoshida, Osamu, 1580
 Yoshida, T., 762
 Yoshihara, Eisaku, 1791
 Yoshikai, Yasunobu, 361
 Yoshimura, Yohko, 1219
 Yoshioka, Mariko, 966
 Young, John, 2349
 Young, Michele, 2365
 Young, Michele L., 2566
 Young, Robert D., 704
 Yourassowsky, E., 46
 Yu, Victor L., 620, 2639
 Yuen, Geoffrey J., 1280

 Zaccardelli, David, 1387
 Zaidi, Akbar A., 1639
 Zak, Oto, 2693
 Žakelj, J., 2850
 Zambias, R., 1964
 Zamora, P., 2816
 Zanol, Margherita, 1744
 Zarlenga, Lana J., 902
 Zemcov, S. Janet V., 2197
 Zerilli, Luigi F., 1744
 Zervos, Marcus J., 1032
 Zhanel, George G., 1136
 Zhong, Min, 470
 Zhu, Qing-Yu, 808
 Zighelboim-Daum, Sonia, 121
 Zimmerman, Thomas P., 283
 Zollinger-Iten, Jacqueline, 2835
 Zorza, Grégoire, 1821
 Zuabi, T., 677
 Zühlendorf, Michael T., 1915
 Zygmunt, Deborah J., 440

SUBJECT INDEX

VOLUME 36

- aac(6')-Ic*
S. marcescens
 aminoglycoside resistance, 1447
 characterization of, 1447
- aac(3)-Vb*
S. marcescens
 cloning and sequence analysis, 2222
- Acanthamoeba polyphaga*
 magainins
 amoeba and cyst stages, effects on, 1256
- Acridines
 antiparasitic agents, 1644
P. falciparum, 1644
T. lewisi, 1644
- Actinobacillus actinomycetemcomitans*
 azithromycin
 comparative evaluation, 1241
 erythromycin
 comparative evaluation, 1241
 in vitro susceptibilities
 antibiotic combinations, 2634
- Active efflux mechanisms
 minireview, 695
- Acyclovir
 combinations
 herpes simplex virus, 934
 inactivators of herpes simplex virus
 ribonucleotide reductase, 934
 herpes simplex virus
 type 1, 2037
 type 2, 2037
 pharmacokinetics
 distribution over blood-brain barrier, 339
 rats, 339
- Aeromonas salmonicida*
 oxytetracycline
 temperature-dependent activity, 1738
 4-quinolones
 temperature-dependent activity, 1738
- Agar dilution
B. fragilis group
 antimicrobial susceptibilities, 195
 foot rot
 antimicrobial susceptibilities, 198
- AM-1155
 in vitro and in vivo activities
 comparative evaluation, 2108
- Amikacin
 cefepime
 pharmacokinetic interaction, lack of, 1382
 combinations
 aztreonam, 2741
 cefepime, 2741
 ceftazidime, 2741, 2808
 clarithromycin and ciprofloxacin, 1567
 clindamycin, 2014
 comparative evaluation, 2808
 febrile neutropenic patients with cancer, 2808
M. avium-M. intracellulare complex, 1567
 major head and neck surgery in cancer patients, prophylaxis, 2014
P. aeruginosa, 2741
 piperacillin, 2808
- E. coli*
 postantibiotic sub-MIC effects, 1852
- P. aeruginosa*
 postantibiotic sub-MIC effects, 1852
 pharmacokinetics
 cefepime, lack of interaction with, 1382
R. equi, 1244
 resistance in a neonatal unit, 1596
- Amino acids
Enterococcus resistance to vancomycin
 effects on expression, 902
- 9-Aminoacridines
Leishmania spp.
 cytotoxicity for promastigotes, 495
- Aminoglycosides
 computer-assisted dosing, 1230
E. cloacae
 factors affecting in vivo activity, 744
E. faecium resistance
 β -lactamase-producing strain, 1125
 endocarditis
 factors affecting in vivo activity, 744
Enterococcus resistance
 ampicillin, continuous intravenous
 versus intermittent therapy, 1263
 modifying enzymes
 β -lactamase-harboring isolates, 2536
S. marcescens
 factors affecting in vivo activity, 744
S. marcescens resistance
aac(6')-Ic, characterization of, 1447
aac(3)-Vb, cloning and sequence analysis, 2222
 synergy
 endocarditis, 2403
 optimal dosing regimen, 2403
 penicillin, 2403
S. adjacens, 2403
 transfected prokaryotic and eukaryotic cells
 increased susceptibility, 1782
- Amoxicillin
 bronchitis
 5-day course, 1456
 acute exacerbations of, 1456
 comparative evaluation, 1456
 combinations
 BRL 42715, 1140
 clavulanate, 1140, 1785
 clavulanic acid, 1794
 gram-negative organisms, 1140
H. pylori, metronidazole resistant, 163
K. rhinoscleromatis, 1785
 metronidazole and bismuth subcitrate, 163
 salmonellae, ampicillin resistant, 1794
 comparative evaluation
 erythromycin, minocycline, ampicillin, cefixime, metronidazole, and bismuth subcitrate, 185
 gram-negative organisms, 1140
H. pylori
 slowly growing, 185
 high-performance liquid chromatography
 bovine plasma, determination in, 1859
 potency determination, 1272
 tandem solid-phase extraction method, 1859
 pharmacokinetics
 enzyme-linked immunosorbent assay, use to assess, 1545
 penetration into lung secretions, 1545
 pneumonia
- community acquired, 833
 comparative evaluation, 833
 efficacy and safety, 833
- Amphotericin B
 aggregation state
 toxicity, effect on, 2310
C. albicans
 endothelial cells, interaction with, modulation of, 2239
 cholesterol dispersion
 leishmaniasis, visceral, 1978
 colloidal dispersion
 deoxycholate suspension, comparative evaluation, 486, 2656
 distribution in tissue, relationship to safety, 299
 murine cryptococcosis, 2656
 pharmacokinetics, relationship to safety, 299
 deoxycholate suspension
 colloidal dispersion, comparative evaluation, 486, 2656
 effect on neutrophil function, 39
 murine cryptococcosis, 2656
 derivatives
 MS-8209, activity against systemic mycoses, 2722
 flucytosine
 nephrotoxicity, effects on, 2670
 human mononuclear cells
 interleukin-1 expression, pharmacologic modulation, 977
 immunoglobulin G
C. albicans infection in burned mice, 643
 lipid complex
 effect on neutrophil function, 39
 liposomal
C. neoformans, 1466
 pulmonary and systemic infections, 1466
 nephrotoxicity
 different formulations, comparative evaluation, 1525
 flucytosine, acute and chronic effects of, 2670
 neutrophils, activation of
 modulation by pentoxifylline, 408
 phospholipid type
 influence on renal cell toxicity and fungicidal activity, 262
 phospholipid/amphotericin B ratio
 influence on renal cell toxicity and fungicidal activity, 262
 toxicity
 aggregation and solvent, effects on, 2518
 effect of aggregation state on, 2310
 infusion rates, effect of, 172, 2573
 letter to the editor, 2573
 ventricular dysrhythmias
 1-hour infusions in patients with preserved renal function, 2542
- Ampicillin
B. fragilis group, 2051
 combinations
B. fragilis group, 2051
E. faecium, vancomycin and ampicillin resistant, 1563
 endocarditis, 1864
Enterococcus spp., penicillin resistant,

- 1864
gentamicin, 1864
major head and neck surgery in cancer patients, prophylaxis, 2014
pharmacokinetics, 2233
sulbactam, 2014, 2051, 2233
vancomycin and gentamicin, 1563
comparative evaluation
erythromycin, minocycline, amoxicillin, cefixime, metronidazole, and bismuth subcitrate, 185
endocarditis
continuous intravenous versus intermittent therapy, 1263
Enterococcus resistance
emergence and nosocomial transmission, 1032
Enterococcus spp.
aminoglycoside resistant, 1263
Enterococcus spp., highly vancomycin resistant
vancomycin, absence of synergy, 2201
Enterococcus susceptibility
gentamicin resistance, high level, and beta-hemolysis, influence on, 2526
H. pylori, 1133
slowly growing, 185
high-performance liquid chromatography improved determination, 1606
tandem solid-phase extraction method, 1606
L. monocytogenes
comparative evaluation, 2375
hydrocortisone-treated mice, 2375
N. meningitidis susceptibility
discrimination between moderately and fully susceptible isolates, 1028
pharmacokinetics
2085P, after oral administration of, 1002
liver transplant patients, 2125
prophylaxis
liver transplant patients, 2125
Anaerobic organisms
antimicrobial susceptibilities, 198
CI-960
comparative evaluation, 1158
CI-990
comparative evaluation, 1158
ciprofloxacin
comparative evaluation, 1158
foot rot, ovine
antimicrobial susceptibilities, 198
ofloxacin
comparative evaluation, 1158
sparfloxacin, 239
comparative evaluation, 1158
temafloxacin, 239
comparative evaluation, 1158
WIN 57273, 239
comparative evaluation, 1158
Angiotensin II
cefonicid
effect on clearance in rat kidneys, 616
Animal models
synergy, in vivo
minireview, 907
Antacids
DR-3355
pharmacokinetics, effect on, 2270
lomefloxacin
effect of antacid on, 1219
pharmacokinetics
DR-3355, effect on, 2270
Antibodies
P. aeruginosa
monoclonal, antilagellar, in combination with antibiotics, 1290
sparfloxacin, combination with, 1352
Anticancer agents
acridines
possible antiparasitic agents, 1644
Anticoccidial agents
in vivo expression of in vitro activity, 2338
Antifolate agents
P. carinii
rat model, 1935
pneumonia
P. carinii, 1935
Antifungal agents
C. albicans
turbidimetric method, 898
Candida spp.
susceptibility testing, 1727
L-646,991, 1648
L-671,329, 1648
L-687,781, 1648
susceptibility testing
Candida spp., 1727
endpoint determination system, 1619
tetrahydroechinocandin B, 1648
toxicity
in vitro models, 1799
minireview, 1799
Antileishmanial agents
drug targeting
polymers internalized by macrophages, 2228
Antimycobacterial agents
susceptibility testing
stability in, 2398
Antipyrine
pharmacokinetics
rifampin, 2- and 4-day regimens, effect of, 1553
Antiviral agents
cytomegalovirus
novel method for evaluation, 206
ginkgetin
herpes simplex virus, 1890
mechanism of action, 1890
hepatitis B virus
inhibition of replication, 2042
mouse model, novel transgenic, 2042
herpesvirus resistance
minireview, 1589
human immunodeficiency virus
protease inhibitors, 982
P. carinii
rat model, 1935
pneumonia
P. carinii, 1935
retroviruses
minireview, 509
aphA-7
kanamycin resistance
C. jejuni, 712
characterization of plasmid, 712
1- β -D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil
combinations
anticancer nucleosides, 214
anti-human immunodeficiency virus agents, 214
azidothymidine, 214
human immunodeficiency virus, 214
Aspergillosis
pulmonary
MS-8209, 2722
saperconazole
comparative evaluation, 2681
oral and intravenous, 2681
Aspergillus fumigatus
saperconazole
comparative evaluation, 2681
oral and intravenous, 2681
Aspergillus niger
topoisomerases
targets for discovery of antifungal agents, 2778
Autolysis
S. aureus
methicillin resistant, 566
methicillin susceptible, 566
3'-Azido-3'-deoxythymidine
cellular transport
comparative evaluation, 808
2',3'-dideoxyinosine
pharmacokinetic interaction, lack of, 665
high-pressure liquid chromatography-radioimmunoassay
intracellular concentrations, measurement of, 2473
human immunodeficiency virus
comparative evaluation, 808
human immunodeficiency virus resistance
suppression by mutation conferring resistance to reverse transcriptase inhibitors, 2664
pharmacokinetics
comparative evaluation, 808
S. typhimurium
intracellular activity, 1081
simian immunodeficiency virus
rhesus macaques, 2381
3'-Azido-3'-dideoxythymidine
feline leukemia virus
pre- and postexposure chemoprophylaxis, 2715
3'-Azidothymidine
simian immunodeficiency virus
long-term tolerance and efficacy, 1770
Azithromycin
A. actinomycetemcomitans
comparative evaluation, 1241
AIDS patients
tolerability, pharmacokinetics, and effect on zidovudine disposition, 1013
bronchitis
3-day course, 1456
acute exacerbations of, 1456
comparative evaluation, 1456
C. pneumoniae, 291, 1573
C. trachomatis, 291
elementary body formation, block of, 2304
combinations
clarithromycin, 1611
comparative evaluation, 1611
rifampin, 2693
staphylococcal osteomyelitis, 2693
comparative evaluation
erythromycin, clarithromycin, and roxithromycin, 180

- H. influenzae*
lung infection, 1412
- H. pylori*, 1133
- inhibitory activity in presence of human serum, 10
- intraleukocytic accumulation
in vitro and in vivo, 1302
- M. avium*
comparative evaluation, 1611
- M. chelonae*, 180
- M. chelonae*-like organisms, 180
- M. fortuitum*, 180
- osteomyelitis
comparative evaluation, 2693
concentration in bone and efficacy, relationship between, 2693
- staphylococcal, 2693
- pharmacokinetics
AIDS patients, 1013
lung, 1412
uptake by phagocytes, 1412
- serum protein binding, 10
- synergy
pyrimethamine, 997
sulfadiazine, 997
toxoplasmosis, 997
- T. gondii*, 997
- tolerability
AIDS patients, 1013
toxoplasmosis, 997
- U.S. FDA approval, 1584
- zidovudine
effect on disposition, 1013
- Azoles
C. glabrata resistance
characterization of isolate, 2602
- combinations
C. albicans, 1284
nikkomycins, 1284
- pharmacokinetics
effect of cyclodextrin, 477
- synergy
C. albicans, 1284
nikkomycins, 1284
- Aztreonam
combinations
amikacin, 2741
P. aeruginosa, 2741
- salmonellae
ampicillin resistant, 1794
- B669
lysophospholipids
mediators of antimicrobial activity, 2729
- Bacillus subtilis*
multidrug efflux transporter Bmr
homolog of *Staphylococcus* NorA, 484
- Bacitracin
renovascular effects, 955
- Bacteremia
daptomycin, 1109
erythromycin, 1198
- Klebsiella* spp.
combination versus monotherapy, 2639
- P. aeruginosa*
erythromycin, 1198
rifampin- β -lactam-aminoglycoside therapy, 620
- vancomycin, 1109
- Bacteroides fragilis*
antimicrobial susceptibilities, in vitro
agar dilution method, 195
- β -lactamases
CcrA, biochemical characterization, 1155
- Bacteroides fragilis* group
cefotaxime
correlation of in vitro testing with clinical outcome, 540
in vitro susceptibilities, 2051
susceptibility patterns
Canada, 343
- Bacteroides* spp.
tetracycline resistance
ribosome protection gene, 1005
- Bacteroides vulgatus*
clindamycin resistance, ribosomal
inducible expression, 639
- BCH-189
human immunodeficiency virus type 1
activities of the four optical isomers, 672
inhibition of replication, 202
- Benzimidazoles
P. carinii
antimicrotubule activity, 779
- Benzoxazinorifamycins
KRM-1648
M. avium complex, 387
- Benzylamines
butenafine
interdigital tinea pedis, reduction of
relapse rate, 2523
- β -Lactamase inhibitors
sulfones
CO₂ and pH, effect on inhibition, 1870
- β -Lactamases
B. fragilis
CcrA, biochemical characterization, 1155
- Capnocytophaga* spp.
characterization, 2197
- CAZ-2
nucleotide sequence, 1817
- CAZ-6
nucleotide sequence, 1817
- CAZ-7
nucleotide sequence, 1817
- ceftazidime resistance
outbreak in cancer patients, 1991
- E1077
affinity for, 589
susceptibility to hydrolysis, 589
- E. coli*
epidemiology, 989
relation to antimicrobial therapy, 989
- E. corrodens*
partial Tn3 transposon, 740
- E. faecalis*
incorporation into a transposon derived from staphylococci, 1843
- E. faecalis*, gentamicin resistant
intrahospital spread, 230
- E. faecium*
aminoglycoside resistant, 1125
- Enterobacter* spp.
epidemiology, 989
relation to antimicrobial therapy, 989
- Enterobacteriaceae*
three-dimensional versus double-disk
tests, 1877
- Enterococcus* spp.
minireview, 2355
- Staphylococcus* spp., comparison, 273
- extended spectrum
aminoglycoside-modifying enzymes in
isolates harboring, 2536
- H. ducreyi*, 467
plasmid content, correlation with anti-
microbial susceptibility, 1639
- Klebsiella* spp.
epidemiology, 989
relation to antimicrobial therapy, 989
- LJC 10,627
stability of, 1418
- M. fortuitum*, 1068
- P. aeruginosa*
activity in sputum samples from cystic
fibrosis patients, 71
imipenem resistant, 2046
impermeability, association with, 2046
- ROB-1
H. ducreyi, 467
- S. aureus*
characterization, 440
WIN 57273, inhibitory activity, 894
- S. aureus* repressor gene
homology with enterococci, 2265
sequence analysis, 2265
- Staphylococcus* spp.
Enterococcus spp., comparison, 273
- sulfones
CO₂ and pH, effect on inhibition, 1870
- TEM-12
transposition of gene encoding, 1981
- Y. enterocolitica*
ampC-ampR nucleotide sequence, 1049
- β -Lactams
combinations
E. coli, 2166
siderophores, 2166
- continuous infusion
minireview, 2577
- E1040
P. aeruginosa, imipenem resistant, 684
- E. coli*
effect of inoculum size on bacteriolytic
activity, 223
siderophore conjugates, mechanism of
action, 2166
- Enterobacteriaceae* resistance, 1677
- H. influenzae*
peptidoglycan metabolism, effect on, 2147
- H. influenzae* resistance
molecular basis, 1504
non- β -lactamase mediated, 1504
- M. fortuitum* resistance
 β -lactamases, 1068
penicillin-binding proteins, 1068
- Methylobacterium* spp.
susceptibility testing, 1635
- pharmacokinetics
continuous infusion, 2577
minireview, 2577
- RU44790
in vitro activity, 1756
- V. cholerae*
interaction, novel features of, 788
- V. cholerae* resistance, 788
- Biflavones
ginkgetin
herpes simplex virus, 1890

- mechanism of action, 1890
Bilophila wadsworthia
 susceptibility testing
 triphenyltetrazolium chloride, end-point determination, 1658
- Bioavailability
 cefixime
 nifedipine, effect on, 2462
 ceftazidime
 patients with pneumonia, 1404
 ciprofloxacin
 aluminum hydroxide, effect on, 830
 calcium carbonate, effect on, 830
 cystic fibrosis patients, 2512
 clarithromycin
 oral administration in humans, 1147
 epithelial cells
 intestinal transport of antimicrobial agents, use as a model for, 1374
 rifampin
 letter to the editor, 2066
 murine tuberculosis, 2066
- Biofilms
 mechanisms of bacterial resistance
 minireview, 1347
P. aeruginosa
 piperacillin, barrier to diffusion, 2054
- Biologics
 U.S. FDA approvals, 1584
- Bismuth subcitrate
 combinations
H. pylori, metronidazole resistant, 163
 metronidazole and amoxicillin, 163
 comparative evaluation
 erythromycin, minocycline, ampicillin, amoxicillin, cefixime, and metronidazole, 185
H. pylori
 slowly growing, 185
- Blastomyces dermatitidis*
 itraconazole-macrophages
 synergy, 2487
- [S-methyl-³H]bleomycin A₂
S. cerevisiae
 lesions and preferential initial localization on cell walls, 2497
- Borrelia burgdorferi*
 cefaclor
 comparative evaluation, 1788
 cefadroxil
 comparative evaluation, 1788
 cefixime
 comparative evaluation, 1788
 ceftriaxone
 comparative evaluation, 1788
 cefuroxime
 comparative evaluation, 1788
 cephalixin
 comparative evaluation, 1788
- BRL 42715
 combinations
 amoxicillin, 1140
 cefazolin, 1427
E. coli, 1427
 gram-negative organisms, 1140
 piperacillin, 1427
S. marcescens, 1427
 pharmacokinetics
 rats, 1427
- Broctam
 pharmacokinetics
 2085P, after oral administration of, 1002
- 7-Bromo-N-(2-imidazolidinylidene)-1H-indazol-6-amine
 anticoccidial activity, 368, 372
E. tenella
 chickens, 368, 372
- Bronchitis
 amoxicillin
 5-day course, 1456
 comparative evaluation, 1456
 azithromycin
 3-day course, 1456
 comparative evaluation, 1456
- Bropiramine
 cytomegalovirus
 severe combined immunodeficient mice, 1837
- Brucella melitensis*
 ciprofloxacin, 150, 973
 co-trimoxazole, 973
 doxycycline, 973
 ofloxacin, 973
 pefloxacin, 973
 rifampin, 973
 streptomycin, 973
- Brucellosis
 ciprofloxacin, 973
 co-trimoxazole, 973
 doxycycline, 973
 ofloxacin, 973
 pefloxacin, 973
 rifampin, 973
 streptomycin, 973
- Butenafine
 tinea pedis, interdigital
 relapse rate reduction, 2523
- Campylobacter butzleri*
 susceptibilities, in vitro, 717
- Campylobacter coli*
 antimicrobial susceptibility
 10-year follow-up report, 2847
- Campylobacter cryaerophila*
 susceptibilities, in vitro, 717
- Campylobacter jejuni*
 antimicrobial susceptibility
 10-year follow-up report, 2847
- R plasmids
 aphA-7 kanamycin resistance determinant, 712
 characterization, 712
- Campylobacter* spp.
 aerotolerant
 antimicrobial susceptibilities, in vitro, 717
- Candida albicans*
 adherence
 arginine-glycine-aspartic acid containing, effect of, 132
 amphotericin B
 endothelial cells, interaction with, modulation of, 2239
 antifungal agents
 turbidimetric method, 898
 chitin biosynthesis, 1909
 nikkomycin Z, inhibition by, 1909
 cilofungin
 rabbits, 56
 fluconazole, 64
 endothelial cells, interaction with, modulation of, 2239
 fluconazole-interleukin-1, 1225
 hydrogen peroxide
 increased sensitivity after growth with sub-MIC concentrations of clotrimazole, 1626
 immunoglobulin G-amphotericin B
 burned mice, 643
 ketoconazole, 64
 L-646,991, 1648
 L-671,329, 1648
 L-687,781, 1648
 MS-8209, 2722
 naftifene, 1779
 nikkomycin Z
 chitin biosynthesis, inhibition of, 1909
 nikkomycin-azole combinations
 synergistic activity, 1284
 SCH 39304, 64
 SCH 42427, 498
 SDZ 87-469, 1779
 squalene epoxidase inhibitors, 1779
 terbinafine, 1779
 tetrahydroechinocandin B, 1648
 tolclate, 1779
 tolnaftate, 1779
 topoisomerase I
 drug discovery, target for, 2131
 topoisomerases
 targets for discovery of antifungal agents, 2778
- Candida glabrata*
 azole resistant
 characterization of, 2602
- Candida* spp.
 susceptibility testing
 relative growth measurement, 1727
- Candidiasis
 cilofungin
 rabbits, 56
 fluconazole-interleukin-1, 1225
 MS-8209, 2722
 nikkomycin-azole combinations
 synergistic activity, 1284
- Capnocytophaga* spp.
 antimicrobial susceptibilities, 2197
 β -lactamases
 characterization, 2197
- Carbapenems
 L-627
 in vitro activity, 1928
P. aeruginosa, 1928
 LJC 10,627
 β -lactamase stability, 1418
 comparative evaluation, 1418
 gram-negative organisms, 1418
 gram-positive organisms, 1418
 renal dehydropeptidase-I stability, 481
 panipenem-betamipron
 pharmacokinetics, prediction from animal data, 1810
- Carboxypeptidase
Enterococcus spp., activity in vancomycin inducible, 77
- Cefaclor
B. burgdorferi
 comparative evaluation, 1788
 comparative evaluation
 cefdinir, 46
H. influenzae
 kill and growth rates, 46
 molecular basis of efficacy, 2569
S. pneumoniae
 kill and growth rates, 46

- Cefadroxil**
B. burgdorferi
 comparative evaluation, 1788
 skin infections
 children, 1614
S. aureus, 1614
S. pyogenes, 1614
- Cefazolin**
 combinations
 BRL 42715, 1427
E. coli, 1427
S. marcescens, 1427
 pharmacokinetics
 rats, 1427
- Cefdinir**
 comparative evaluation
 cefaclor, 46
H. influenzae
 kill and growth rates, 46
S. pneumoniae
 kill and growth rates, 46
- Cefepime**
 amikacin
 pharmacokinetic interaction, lack of, 1382
 bactericidal activity, 453
 combinations
 amikacin, 2741
P. aeruginosa, 2741
E. coli
 comparative evaluation, 2439
 in vitro and in vivo, 2439
 pharmacokinetics
 age and gender, effects of, 1181
 amikacin, lack of interaction with, 1382
 patients on continuous ambulatory peritoneal dialysis, 1387
 serum and blister fluid, 453
 single and multiple intravenous administrations, 552
 subjects with renal impairment, 2676
- Cefetamet pivoxil**
 syphilis
 rabbits, 598
T. pallidum, 598
- Cefixime**
B. burgdorferi
 comparative evaluation, 1788
 bioavailability
 nifedipine, effect on, 2462
C. difficile
 correlation of presence in feces, 2009
 comparative evaluation
 erythromycin, minocycline, ampicillin, amoxicillin, metronidazole, and bismuth subcitrate, 185
H. pylori, 1133
 slowly growing, 185
 pharmacokinetics
 bioavailability, effect of nifedipine on, 2462
- Cefmenoxime**
 combinations
K. pneumoniae, 167
 romurtide, synergy, 167
 pharmacokinetics
 concentrations in sera and peritoneal tissues, 1483
 patients undergoing gastrointestinal surgery, 1483
- Cefminox**
E. coli
 effect of inoculum size on bacteriolytic activity, 223
- Cefonicid**
 clearance in rat kidneys
 angiotensin II-induced alterations in renal flow, 616
- Cefoperazone**
 bactericidal activity, 453
 cancer patients, bacterial isolates from comparative evaluation, 879
 pharmacokinetics
 serum and blister fluid, 453
 tissue penetration model, 295
- Cefoperazone-sulbactam**
 disk diffusion tests
 new disk, development of, 394
- Cefotaxime**
E. coli
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
Enterobacteriaceae resistance, 1677
 pharmacokinetics
 liver transplant patients, 2125
 prophylaxis
 liver transplant patients, 2125
S. pneumoniae resistance, high level characterization of isolate, 886
 salmonellae
 ampicillin resistant, 1794
- Cefotetan**
B. fragilis group, 2051
 pharmacokinetics
 patients undergoing colorectal surgery, 1115
 serum and blister fluid, 2233
 single dose, 1115
- Cefoxitin**
B. fragilis group, 2051
 correlation of in vitro testing with clinical outcome, 540
 pharmacokinetics
 serum and blister fluid, 2233
- Cefpirome**
 bactericidal activity, serum
 comparative evaluation, 2085
 pharmacokinetics
 comparative evaluation, 2085
- Cefpodoxime**
K. rhinoscleromatis, 1785
- Cefpodoxime proxetil**
C. difficile
 correlation of presence in feces, 2009
N. gonorrhoeae
 urethritis, 1764
 pharmacokinetics, 796
 effect of antacid and H₂-receptor antagonist on absorption, 796
 healthy volunteers, 126
 patients with impaired renal function, 126
 penetration into lung parenchyma and epithelial lining fluid, 2099
 urethritis, 1764
- Cefprozil**
 absolute bioavailability
 beagles, 687
 bioavailability
 antacid, effect of, 962
 excretion in human breast milk, 938
 intestinal flora, effect on, 144
 pharmacokinetics, 938
 antacid, effect of, 962
 beagles, 687
 multiple dosing, 144
- Ceftazidime**
 bactericidal activity, 453
 bactericidal activity, serum
 comparative evaluation, 2085
 bioavailability
 patients with pneumonia, 1404
 cancer patients, bacterial isolates from comparative evaluation, 879
 combinations
 amikacin, 2741, 2808
 chloramphenicol-doxycycline-co-trimoxazole, comparative evaluation, 158
 comparative evaluation, 2808
 co-trimoxazole, 158
 febrile neutropenic patients with cancer, 2808
 melioidosis, severe, 158
P. aeruginosa, 2741
E. coli
 comparative evaluation, 2439
 in vitro and in vivo, 2439
E. coli resistance
 β -lactamase, extended spectrum, 1991
 cancer patients, 1991
 febrile neutropenic patients
 vancomycin, not necessary for initial treatment, 1062
K. pneumoniae resistance
 β -lactamase, extended spectrum, 1991
 cancer patients, 1991
P. aeruginosa, 1580
P. mirabilis, 1580
 pharmacokinetics
 comparative evaluation, 2085
 patients with pneumonia, 1404
 serum and blister fluid, 453
 resistance, outbreak of
 β -lactamase, extended spectrum, 1991
 urinary tract infections, 1580
- Ceftizoxime**
B. fragilis group, 2051
 pharmacokinetics
 serum and blister fluid, 2233
- Ceftriaxone**
B. burgdorferi
 comparative evaluation, 1788
 bactericidal activity, serum
 comparative evaluation, 2085
C. difficile
 emergence, influence on, 2850
 comparative evaluation
 imipenem, ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole, 949
 meningitis, 949
N. gonorrhoeae resistance, 1682
 pharmacokinetics
 1,000 mg intravenously, 2804
 comparative evaluation, 2085
 diclofenac, effects on, 2331
 prophylaxis in thoracic surgery, 2804
 tissue penetration, 2804
 transudative and exudative pleural effusion, penetration, 2774
S. enteritidis, 949
S. pneumoniae resistance, high level characterization of isolate, 886
 salmonellae
 ampicillin resistant, 1794

- Cefuroxime
B. burgdorferi
 comparative evaluation, 1788
 combinations
 comparative evaluation, 801
 febrile neutropenic patients, 801
 gentamicin, 801
K. rhinoscleromatis, 1785
- Cefuroxime axetil
 skin infections
 children, 1614
S. aureus, 1614
S. pyogenes, 1614
- Cephalexin
B. burgdorferi
 comparative evaluation, 1788
K. rhinoscleromatis, 1785
S. aureus biofilm cells
 interaction in a chemostat system, 890
- Cephalosporins
Y. enterocolitica
ampC-ampR nucleotide sequence, 1049
- Cephalosporins
 DQ-2556
 in vitro and in vivo activities, 2595
 mode of action, 2595
 pharmacokinetics, 966
 E1077
 β -lactamases, susceptibility to hydrolysis by, 589
 comparative evaluation, 589
 in vitro activity, 589
 in vitro and in vivo activities, 1894
 Ro 09-1227
Enterobacteriaceae, 233
 RU 29246
 comparative evaluation, 2360
 in vitro activity, 2360
 S-1006
 in vitro activity, 1336
 susceptibility to hydrolysis, 1336
 SCE-2787
 comparative evaluation, 1358
 in vitro and in vivo activities, 1358
- Cephalothin
 combinations
 comparative evaluation, 801
 febrile neutropenic patients, 801
 gentamicin, 801
- Cephem antibiotics
 serum protein binding
 effect on therapeutic efficacy, 17
- Cephems
P. aeruginosa resistance
 meropenem and quinolone cross-resistance, 1847
 outer membrane protein overproduction, association with, 1847
- Cervical infections
 doxycycline
 comparative evaluation, 1144
 ofloxacin
 comparative evaluation, 1144
- Checkerboard titration technique
A. actinomycetemcomitans
 susceptibility to antibiotic combinations, 2634
- Chlamydia pneumoniae*
 azithromycin, 291, 1573
 ciprofloxacin
 comparative evaluation, 682
 clarithromycin, 1573
 doxycycline, 1573
 erythromycin, 291, 1573
 fleroxacin
 comparative evaluation, 682
 ofloxacin
 comparative evaluation, 682
 L-ofloxacin, 1573
 sparfloxacin
 comparative evaluation, 682
 temafloxacin
 comparative evaluation, 682
 tetracycline, 291
- Chlamydia trachomatis*
 azithromycin, 291
 elementary body formation, block of, 2304
 doxycycline
 cervical infection, 1144
 comparative evaluation, 1144
 erythromycin, 291
 nonoxynol 9
 infected HeLa 229 cells, 1478
 infected primary monkey cervical epithelial cells, 1478
 ofloxacin
 cervical infection, 1144
 comparative evaluation, 1144
 quinolones
 comparative evaluation, 188
 sparfloxacin
 comparative evaluation, 188
 in vivo and in vitro activity, 188
 tetracyclines, 291
 comparative evaluation, 188
- Chloramphenicol
 combinations
 ceftazidime-co-trimoxazole, comparative evaluation, 158
 doxycycline-co-trimoxazole, 158
 melioidosis, severe, 158
K. rhinoscleromatis, 1785
 salmonellae
 ampicillin resistant, 1794
- Chloramphenicol acetyltransferases
C. butyricum
 sequence analysis, comparative, 2548
- Chloroquine
 combinations
 chlorpromazine, 209
P. falciparum, 209
 prochlorperazine, 209
P. falciparum resistance
 fluoxetine hydrochloride, enhancement of susceptibility, 2761
- Chlorpromazine
 combinations
 chloroquine, 209
P. falciparum, 209
- CI-960
 anaerobic bacteria
 comparative evaluation, 1158
 endocarditis, 1192
Legionella spp., 2049
S. aureus
 ciprofloxacin susceptible and resistant, 1192
 endocarditis, 1192
Staphylococcus spp.
 comparative evaluation, 851
- CI-990
 anaerobic bacteria
 comparative evaluation, 1158
- Cilastatin
 combinations
 comparative evaluation, 2766
 effect of biliary obstruction on hepatic excretion, 2057
 imipenem, 2057, 2766
 intra-abdominal infections, 2766
 pharmacokinetics, 2057
- Cilofungin
C. albicans
 rabbits, 56
 candidiasis
 rabbits, 56
- Cinchona alkaloids
P. falciparum
 stereochemical evaluation, 1538
- Cinnamic acid
 malaria-infected cells
 permeability, effect on, 1102
P. falciparum, 1102
- Ciprofloxacin
 anaerobic bacteria
 comparative evaluation, 1158
B. melitensis, 150, 973
 bactericidal activity, serum
 comparative evaluation, 2085
 bioavailability
 aluminum hydroxide, effect on, 830
 calcium carbonate, effect on, 830
 cystic fibrosis patients, 2512
 brucellosis, 973
C. burnetii, 2529
C. pneumoniae, 682
 cancer patients, bacterial isolates from
 comparative evaluation, 879
 combinations
 clarithromycin and amikacin, 1567
M. avium-M. intracellulare complex, 1567
 comparative evaluation
 ofloxacin, fleroxacin, temafloxacin, sparfloxacin, 682
E. coli
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
 SOS-response and cell-division mutants, 819
Enterococcus resistance
 increasing occurrence of, 2533
H. pylori, 1133
K. rhinoscleromatis, 1785
L. monocytogenes
 comparative evaluation, 2375
 hydrocortisone-treated mice, 2375
M. avium-M. intracellulare complex
 human peripheral blood monocyte/macrophages, 2816
 liposome encapsulated, 2816
 methicillin-resistant *S. aureus* resistance
gyrA mutations, analysis of, 1166
 penetration into ascitic fluid
 single 750-mg dose, 677
 penetration into blister fluid
 fleroxacin, comparative evaluation, 651
 pharmacokinetics
 bioavailability in cystic fibrosis patients, 2512
 comparative evaluation, 2085
 infants and small children, 1086
 single 750-mg dose, 677
 single intravenous and oral doses, 993
R. conorii, 2529

- R. equi*, 1244
R. rickettsii, 2529
salmonellae
 ampicillin resistant, 1794
 CL 184,005
 sepsis, bacterial
 animal models, evaluation in, 1971
 Clarithromycin
 bioavailability
 oral administration in humans, 1147
C. pneumoniae, 1573
 combinations
 ciprofloxacin and amikacin, 1567
 gentamicin, 1695
M. avium, 1695
M. avium complex, 2413
M. avium-M. intracellulare complex, 1567
 pyrimethamine, 2454
 rifabutin, 2413
 sulfadiazine, 2454
T. gondii, 2454
 comparative evaluation
 erythromycin, azithromycin, and roxithromycin, 180
M. avium complex
 beige mice, 2413
 comparative evaluation, 1163
 human macrophages, 2104
 J774 cells and alveolar macrophages, 1163
M. avium resistance
 selection of mutants by monotherapy, 2839
M. chelonae, 180
M. chelonae-like organisms, 180
M. fortuitum, 180
M. kansasii
 in vitro susceptibility, 2039
M. paratuberculosis
 comparative evaluation, 2843
 ethambutol, enhancement of activity, 2843
 metabolites
 pharmacokinetics, 2478
Mycobacterium spp.
 pH, effect on MICs, 2841
 slowly growing, nontuberculous, 1987
 pharmacokinetics
 infants and children, 2478
 metabolite, 14-(*R*) hydroxylated, 2478
 oral administration in humans, 1147
 single ascending oral doses, 2447
 synergy
 minocycline, 2852
T. gondii, 2852
T. gondii, 2454
 U.S. FDA approval, 1584
 Clavulanate
 combinations
 amoxicillin, 1140, 1785
 gram-negative organisms, 1140
K. rhinoscleromatis, 1785
 pharmacokinetics, 2233
 ticarcillin, 2233
 Clavulanic acid
 combinations
 amoxicillin, 1794
 letter to the editor, 2352
S. aureus endocarditis, 458
salmonellae, ampicillin resistant, 1794
 susceptibility tests, error rates, 137
 ticarcillin, 137, 458, 2352
 zone size criteria, 2352
 Clindamycin
B. fragilis group, 2051
B. vulgatus resistance, ribosomal
 inducible expression, 639
 combinations
 amikacin, 2014
 major head and neck surgery in cancer
 patients, prophylaxis, 2014
 gram-negative organisms, 1140
P. aeruginosa
 proinflammatory interactions, inhibition of, 1236
T. gondii
 infected human fibroblasts, 1091
 resistant mutant, selection of, 1091
 Clofazimine
 B669
 lysophospholipids, mediators of anti-
 microbial activity, 2729
 lysophospholipids
 mediators of antimicrobial activity, 2729
Clostridium butyricum
 chloramphenicol acetyltransferase
 sequence analysis, comparative, 2548
Clostridium difficile
 cefixime
 correlation of presence in feces, 2009
 cefpodoxime proxetil
 correlation of presence in feces, 2009
 ceftriaxone
 emergence, influence on, 2850
 diarrhea
 teicoplanin, oral, 2192
 vancomycin, oral, 2192
 teicoplanin
 comparative evaluation, 2192
 oral, 2192
 toxin production
 effects of antibiotics, 1332
 vancomycin
 comparative evaluation, 2192
 oral, 2192
 Clotrimazole
C. albicans
 sub-MIC concentrations, increased
 sensitivity to hydrogen peroxide
 after growth in, 1626
Coccidioides immitis
 meningitis
 RR 42427, 217
 SCH 39304, 217
 SS 42426, 217
 Coccidiosis
 CP-72,588, 2080
 Collagenase
 tetracyclines
 relevance of specificity to anti-inflam-
 matory potential, 227
Corynebacterium spp.
 CDC group II
 antimicrobial susceptibilities, 1325
 penicillin, vancomycin, and gentami-
 cin susceptibility, 1325
 penicillin-gentamicin synergy, 1325
 vancomycin-gentamicin, 1325
 Co-trimoxazole
B. melitensis, 973
 brucellosis, 973
 combinations
 ceftazidime, 158
 chloramphenicol-doxycycline, 158
 melioidosis, severe, 158
salmonellae
 ampicillin resistant, 1794
Coxiella burnetii
 ciprofloxacin, 2529
 ofloxacin, 2529
 PD 127,391, 2529
 PD 131,628, 2529
 pefloxacin, 2529
 Cocksackievirus
 WIN 54954
 mice, 425
 CP-72,588
 coccidiosis, 2080
Eimeria spp., 2080
 pharmacokinetics, 2080
 CP-74,667
 pharmacokinetics
 laboratory animals, 1671
 Cryptococcosis
 amphotericin B
 colloidal dispersion, 2656
 deoxycholate suspension, 2656
 MS-8209, 2722
Cryptococcus neoformans
 amphotericin B
 colloidal dispersion, 2656
 deoxycholate suspension, 2656
 liposomal, aerosolized, 1466
 meningitis
 RR 42427, 217
 SCH 39304, 217
 SS 42426, 217
 MS-8209, 2722
Cryptococcus spp.
 meningitis
 fluconazole, 690
 Cryptosporidiosis
 dehydroepiandrosterone
 immunosuppressed rats, 220
Cryptosporidium parvum
 dehydroepiandrosterone
 immunosuppressed rats, 220
 Cyclodextrin
 azole, oral
 effect on pharmacokinetics, 477
 Cytochromes
 P450IA2
 quinolones, inhibitory potency of, 942
 Cytokines
 minireview, 1
 nonspecific resistance to infection, 1
 Cytomegalovirus
 antiviral agents
 novel method for evaluation, 206
 broprimine, 1837
 ganciclovir, 1837
 (S)-1-[3-Hydroxy-2-(phosphonyl-
 methoxy)propyl]cytosine, 1837
 interferon
 recombinant alpha, 1837
 Daptomycin
 bacteremia, 1109
 combinations
E. faecium, glycopeptide resistant,
 2611
 endocarditis, 2611
 gentamicin, 2611
E. faecium
 glycopeptide resistant, 2611
 endocarditis, 1109, 2611

- comparative evaluation, 1854
 enterococci, penicillin resistant, 1864
Enterococcus sp., 318
Enterococcus spp.
 comparative evaluation, 1864
 endocarditis, 1864
 penicillin resistant, 1864
 gram-positive organisms
 blood isolates, 1570
 comparative evaluation, 1570
 pharmacokinetics
 healthy volunteers, 318
 intravenous drug abusers, 1109
S. aureus, 318
S. aureus early killing
 in vitro pharmacodynamic model, investigation by, 2334
 serum bactericidal activity
 concentration, pH, and growth phase, effects on, 2709
- Decaplanin
 gram-positive organisms, 873
- Dehydroepiandrosterone
C. parvum
 immunosuppressed rats, 220
 cryptosporidiosis
 immunosuppressed rats, 220
 endotoxin toxicity
 protection from in mice, 2275
 tumor necrosis factor
 reduction of production of in mice, 2275
- 2'-Deoxy-3'-thiacytidine
 human immunodeficiency virus
 inhibition of replication, 202
- (-)-2'-Deoxy-3'-thiacytidine
 human immunodeficiency virus
 inhibition of replication, 733
 type 1, 733
 type 2, 733
- (-)-2'-Deoxy-3'-thiacytidine 5'-triphosphate
 human immunodeficiency virus
 DNA polymerases alpha, beta, and gamma, 1688
 reverse transcriptase inhibition, 1688
- 3'-Deoxythymidine
 lipid prodrug
 human immunodeficiency virus,
 greatly enhanced inhibition, 2025
- 3'-Deoxythymidine diphosphate dimyristoylglycerol
 human immunodeficiency virus type 1
 greatly enhanced inhibition, 2025
- dhfrIX*
 trimethoprim resistance
 spread among human and porcine
 pathogens, 2704
- Diarrhea
 bacterial
 ofloxacin, three versus five days of
 therapy, 87
C. difficile associated
 teicoplanin, oral, 2192
 vancomycin, oral, 2192
 ofloxacin
 three versus five days of therapy, 87
 teicoplanin
 comparative evaluation, 2192
 oral, 2192
 vancomycin
 comparative evaluation, 2192
 oral, 2192
- Diclofenac
 ceftriaxone
 pharmacokinetics, effects on, 2331
- 4',6-Dicyanoflavan
 rhinovirus
 mechanism of action, 95
- Didanosine
 human immunodeficiency virus type 1
 ganciclovir antagonism, 1127
 human immunodeficiency virus type 1
 resistance
 replication endpoint concentration assay, 920
 pharmacokinetics
 influence of hemodialysis, 1519
 patients with normal and impaired renal function, 1519
 ranitidine, interaction with, 2075
 U.S. FDA approval, 1584
- 2',3'-Dideoxy-3'-thiacytidine
 human immunodeficiency virus type 1
 activities of the four optical isomers, 672
- 2',3'-Dideoxycytidine
 combinations
 human immunodeficiency virus type 1,
 1559
 zidovudine, 1559
 human immunodeficiency virus type 1
pol gene mutations, decreased susceptibility, 153
 mitochondrial function
 impairment of, 2061
 Molt-4 cells, 2061
 Molt-4 cells
 impaired mitochondrial function, 2061
 ultrastructural changes, 2061
 ultrastructural changes
 Molt-4 cells, 2061
- 2',3'-Dideoxy-5-fluoro-3'-thiacytidine
 metabolism
 racemic, 2432
 rhesus monkeys, 2432
 pharmacokinetics
 racemic, 2432
 rhesus monkeys, 2432
- 2',3'-Dideoxyinosine
 3'-azido-3'-deoxythymidine
 pharmacokinetic interaction, lack of,
 665
 bioavailability
 maximal tolerated dose, impact on
 determination, 1280
- 3,5-Dihydroxy-4-ethyl-*trans*-stilbene
 in vitro activity
 guanosine-3',5'-bis-pyrophosphate,
 role in, 2645
 mechanism of action, 2645
- Dimethyl prostaglandin A₁
 herpes simplex virus
 replication, effect on, 2253
 human immunodeficiency virus type 1
 replication, effect on, 2253
- 6-Dimethylaminopurine arabinoside
 pharmacokinetics and metabolism, 353
- Disk diffusion tests
 cefoperazone-sulbactam
 new disk, development of, 394
- DNA gyrase
 fluoroquinolones
 inhibition of, relationship among antibacterial activity and intracellular accumulation, 2622
- Doxycycline
B. melitensis, 973
 brucellosis, 973
C. pneumoniae, 1573
C. trachomatis
 cervical infection, 1144
 comparative evaluation, 1144
 combinations
 ceftazidime-co-trimoxazole, comparative evaluation, 158
 chloramphenicol-co-trimoxazole, 158
 melioidosis severe, 158
H. pylori, 1133
 DQ-2556
 in vitro and in vivo activities, 2595
 mode of action, 2595
 pharmacokinetics
 rats, rabbits, dogs, and monkeys, 966
- DR-3355
 pharmacokinetics
 antacids, effect of, 2270
 ferrous sulfate, effect of, 2270
 ranitidine, effect of, 2270
- DU-6859
 antimicrobial activity
 comparative evaluation, 1491
 inoculum size, media, pH, serum, and
 urine
 effects on activity, 1491
- E1040
P. aeruginosa, 1580
 imipenem resistant, 684
P. mirabilis, 1580
 urinary tract infections, 1580
- E1077
 β -lactamase
 affinity for, 589
 susceptibility to hydrolysis by, 589
 comparative evaluation
 ceftipime, ceftazidime, cefuzonam,
 cefoperazone, and cefotaxime,
 589
 in vitro and in vivo activities
 comparative evaluation, 1894
P. aeruginosa
 morphological changes, 1894
S. aureus
 morphological changes, 1894
- E4695
Legionella spp., 2049
- Echinococcus multilocularis*
 isoprinisone
 effect of multiple doses on metacystodes, 191
- Ehrlichia chaffeensis*
 in vitro antibiotic susceptibilities, 2799
- Ehrlichiosis
E. chaffeensis
 in vitro antibiotic susceptibilities, 2799
- Eikenella corrodens*
 β -lactamase, 740
 streptomycin resistance gene, 740
- Eimeria* spp.
 CP-72,588, 2080
- Eimeria tenella*
 7-bromo-*N*-(2-imidazolidinylidene)-1*H*-
 indazol-6-amine, 368, 372
- Emetine
E. histolytica resistance mutants
 channel blockers, susceptibility to,
 2392

- susceptibilities, in vitro, 2392
- Endocarditis**
- aminoglycosides
- factors affecting in vivo activity, 744
- ampicillin
- continuous intravenous versus intermittent therapy, 1263
- Corynebacterium* CDC group I1
- penicillin, vancomycin, and gentamicin susceptibility, 1325
- penicillin-gentamicin synergy, 1325
- vancomycin-gentamicin, 1325
- E. faecalis*
- teicoplanin, comparative evaluation, 1276
- vancomycin, comparative evaluation, 1276
- E. faecium*, glycopeptide resistant
- daptomycin, 2611
- daptomycin-gentamicin, 2611
- teicoplanin, high versus low dose, 2611
- Enterococcus** spp.
- ampicillin-gentamicin, 1864
- daptomycin, 1864
- penicillin resistant, 1864
- vancomycin, 1864
- gram positive
- daptomycin, 1109
- vancomycin, 1109
- penicillin-tobramycin
- optimal tobramycin dosing regimen, 2403
- synergy, 2403
- pharmacokinetic and pharmacodynamic requirements
- minireview, 2069
- S. aureus*
- CI-960, 1192
- ciprofloxacin susceptible and resistant, 1192
- ticarcillin-clavulanic acid, 458
- streptococcal
- teicoplanin, 723
- teicoplanin
- 4-week treatment, 723
- streptococcal, 723
- temafloxacin
- S. adjacens*, 2216
- ticarcillin-clavulanic acid, 458
- Endotoxin**
- neutropenic patients
- anti-endotoxin core antibodies, 2139
- correlation with clinical outcome, 2139
- Enoxacin**
- E. coli*
- SOS-response and cell-division mutants, 819
- P. aeruginosa* resistance
- mechanism of resistance, 1057
- pleiotropic, posttherapy mutant, 1057
- U.S. FDA approval, 1584
- Entamoeba histolytica*
- emetine-resistant mutants
- channel blockers, susceptibility to, 2392
- susceptibilities, in vitro, 2392
- Enterobacter cloacae**
- aminoglycosides
- factors affecting in vivo activity, 744
- Enterobacter** spp.
- β -lactamases
- epidemiology, 989
- relation to antimicrobial therapy, 989
- Enterobacteriaceae**
- β -lactam resistance, 1677
- β -lactamases
- three-dimensional versus double-disk tests, 1877
- cefotaxime resistance, 1677
- OPC-17116
- assay conditions, effect on activity, 1310
- comparative evaluation, 1310
- Ro 23-9424
- cancer patients, isolates from, 879
- Ro 40-6890
- intestinal species, 2835
- ticarcillin
- susceptibility tests, error rates, 137
- ticarcillin-clavulanic acid
- susceptibility tests, error rates, 137
- Enterococcus faecalis**
- β -lactamase
- incorporation into a transposon derived from staphylococci, 1843
- gentamicin resistance
- comparison of regions encoding, isolates from diverse geographic locations, 2259
- structural gene, identical to those for *E. faecium* and *S. agalactiae*, 1215
- gentamicin resistant, β -lactamase producing
- intrahospital spread, 230
- kanamycin resistance plasmid
- conjugal transfer to *E. coli*, 502
- penicillin
- effect of exposure on antimicrobial susceptibility, 121
- teicoplanin
- comparative evaluation, 1276
- Tn5281
- comparison in isolates from diverse geographic locations, 2259
- vancomycin
- comparative evaluation, 1276
- Enterococcus faecium**
- aminoglycoside resistant
- β -lactamase-producing strain, 1125
- gentamicin resistance
- structural gene, identical to those of *E. faecalis* and *S. agalactiae*, 1215
- glycopeptide resistant
- daptomycin, 2611
- daptomycin-gentamicin, 2611
- teicoplanin, high versus low dose, 2611
- penicillin resistance
- mechanisms of, 783
- vancomycin and ampicillin resistant
- vancomycin-ampicillin-gentamicin, 1563
- vancomycin resistant
- VanY, characterization of, 1514
- Enterococcus gallinarum**
- vancomycin resistance
- vanC, species specificity, 2005
- vancomycin resistant, 1392
- penicillin-binding protein 6, possible role, 1392
- Enterococcus** spp.
- aminoglycoside resistant
- ampicillin, continuous intravenous
- versus intermittent therapy, 1263
- ampicillin resistant
- emergence and nosocomial transmission, 1032
- ampicillin susceptibility
- gentamicin resistance, high level, and beta-hemolysis, influence on, 2526
- β -lactamase-encoding fragments
- comparison with those from *Staphylococcus* spp., 273
- β -lactamases
- minireview, 2355
- ciprofloxacin resistance
- increasing occurrence of, 2533
- daptomycin, 318
- gentamicin resistant
- ramoplanin, 2342
- penicillin G resistant
- ramoplanin, 2342
- penicillin resistant
- ampicillin-gentamicin, 1864
- daptomycin, 1864
- vancomycin, 1864
- ramoplanin
- antibiotic-resistant isolates, 2342
- tetracycline resistant
- occurrence of structures with homology to Tn916, 59
- vancomycin resistance
- effects of amino acids on expression, 902
- vancomycin resistant
- carboxypeptidase activity, inducible, 77
- D-lactate, incorporation into peptidoglycan precursors, 867
- peptidoglycan precursors, analysis of, 1487
- ramoplanin, 2342
- vancomycin resistant, highly
- ampicillin-vancomycin, absence of synergy, 2201
- vancomycin susceptibility
- gentamicin resistance, high level, and beta-hemolysis, influence on, 2526
- Enterovirus**
- pirodavir, 100
- R 61837, 100
- Enzyme-linked immunosorbent assays**
- human immunodeficiency virus
- inhibitors of gp120-CD4 binding, detection of, 267
- Erythromycin**
- A. actinomycetemcomitans*
- comparative evaluation, 1241
- bacteremia, 1198
- C. pneumoniae*, 291, 1573
- C. trachomatis*, 291
- comparative evaluation
- azithromycin, clarithromycin, roxithromycin, 180
- minocycline, ampicillin, amoxicillin, cefixime, metronidazole, and bismuth subcitrate, 185
- H. pylori*, 1133
- slowly growing, 185
- host defense systems, 1922
- impetigo
- comparison with mupirocin, 287
- erythromycin-resistant *S. aureus*, 287
- inhibitory activity in presence of human serum, 10
- M. avium* complex

- comparative evaluation, 1163
J774 cells and alveolar macrophages, 1163
M. chelonae, 180
M. chelonae-like organisms, 180
M. fortuitum, 180
P. aeruginosa, 1198
proinflammatory interactions, inhibition of, 1236
virulence effect on, 1922
R. equi, 1244
serum protein binding, 10
Escherichia coli
amikacin
 postantibiotic sub-MIC effects, 1852
 β -lactam hypersusceptible siderophores, antibacterial activity, 840
 β -lactam-siderophore conjugates mechanism of action, 2166
 β -lactamases
 epidemiology, 989
 relation to antimicrobial therapy, 989
 BRL-42715-cefazolin, 1427
 BRL-42715-piperacillin, 1427
 cefepime
 comparative evaluation, 2439
 in vitro and in vivo, 2439
 cefminox
 effect of inoculum size on bacteriolytic activity, 223
 cefotaxime
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
 ceftazidime
 comparative evaluation, 2439
 in vitro and in vivo, 2439
 ceftazidime resistance
 β -lactamase, extended spectrum, 1991
 cancer patients, 1991
 ciprofloxacin
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
 colonization ability
 norfloxacin, use to study, 401
 gentamicin
 postantibiotic effect, effect of human cerebrospinal fluid, 1136
 imipenem
 diffusion through outer membrane, correlation with activity, 1902
 kanamycin resistance plasmid
 conjugal transfer from *E. coli*, 502
 lpxA2
 antibiotic supersusceptibility, 826
 meropenem
 diffusion through outer membrane, correlation with activity, 1902
 nonspecific immunostimulation
 prevention of infection, 361
 outer membrane mutants
 tosufloxacin, 2030
 tosufloxacin uptake, 2030
 postantibiotic effect
 macromolecular biosynthesis, analysis of, 2118
 quinolones, 2118
 quinolone accumulation
 fluorometric assay, 1601
 quinolone resistance loci
 genetics and regulation, 1151
 nfxB, *nfxC*, and *cfxB*, 1151
 quinolones
 SOS-response and cell-division mutants, 819
 sparfloxacin
 renal infection in mice, 505
 tosufloxacin
 outer membrane mutants, 2030
 uptake, 2030
 trimethoprim resistant
 identification of new gene, 1720
Ethambutol
 clarithromycin
 M. paratuberculosis, enhancement of activity, 2843
 combinations
 M. avium complex, 2408
 RU-40 555, 2408
 sparfloxacin, 2408
 M. avium complex, 2408
Ethanolate
 P. falciparum
 use of incorporation into phospholipids to measure activity, 50
Ethionamide
 Mycobacterium spp.
 mechanism of action, 1316
 mycolic acid synthesis inhibition, 1316
5-Ethyl-1- β -D-ribofuranosylimidazole-4-carboxamide
 myxoviruses, 435
 orthoviruses, 435
[¹⁴C]FCE 22891
 pharmacokinetics
 healthy volunteers, 1958
Feline leukemia virus
 3'-azido-3'-dideoxythymidine
 pre- and postexposure chemoprophylaxis, 2715
Ferrous sulfate
 DR-3355
 pharmacokinetics, effect on, 2270
 pharmacokinetics
 DR-3355, effect on, 2270
Flavanoids
 4',6-dicyanoflavan
 mechanism of action, 95
 rhinovirus, 95
Fleroxacin
 C. pneumoniae, 682
 cancer patients, bacterial isolates from
 comparative evaluation, 879
 comparative evaluation
 ciprofloxacin, ofloxacin, temafloxacin, sparfloxacin, 682
 E. coli
 SOS-response and cell-division mutants, 819
 L. pneumophila
 pneumonia in guinea pigs, 2387
 Legionella spp., 2387
 penetration into blister fluid
 ciprofloxacin, comparative evaluation, 651
 pharmacokinetics
 aqueous and vitreous humors, 32
 guinea pigs, 2387
 patients with liver cirrhosis, 632
 positron emission tomography, 2286
 rabbits with *E. coli* infections, 2286
 sucralfate, effect of, 2758
Fluconazole
 C. albicans, 64
 endothelial cells, interaction with, modulation of, 2239
 combinations
 C. albicans, 1225
 candidiasis, 1225
 interleukin-1, human, 1225
 comparative evaluation
 SCH 39304 and ketoconazole, 64
 gas chromatography
 electron capture detection, 647
 high-performance liquid chromatography
 concentrations in plasma, serum, and cerebrospinal fluid, 603
 mixed-phase column, 603
 meningitis
 cryptococcal, 690
 patients with AIDS, 690
 susceptibility testing
 standardization, 1805
 systemic fungal infections, 64
Flucytosine
 amphotericin B nephrotoxicity
 acute and chronic effects on, 2670
3'-Fluoro-3'-deoxythymidine
 cellular transport
 comparative evaluation, 808
 human immunodeficiency virus
 comparative evaluation, 808
 pharmacokinetics
 comparative evaluation, 808
 penetration into brains, muscle tissue, and veins of monkeys, 2418
 relation to antiviral action, 2418
2'-Fluoro-5-ethyl-1- β -D-arabinofuranosyluracil
 pharmacokinetics
 mice and rats, 1472
 preclinical pharmacology, 1472
cis-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
 (-) and (+) enantiomers
 anabolic profiles, 2686
 cytotoxicities, 2686
 hepatitis B virus, 2686
 hepatitis B virus
 (-) and (+) enantiomers, 2686
 human immunodeficiency virus
 racemates and enantiomers, 2423
Fluorometric assay
 quinolone accumulation
 E. coli, 1601
 P. aeruginosa, 1601
 S. aureus, 1601
5-Fluoroorotate
 malaria, 704
 P. falciparum
 molecular targets, 704
Fluoroquinolones
 antibacterial activity
 DNA gyrase inhibition and intracellular accumulation, relationship among, 2622
 B. subtilis resistance
 multidrug efflux transporter Bmr, 484
 CI-960
 ciprofloxacin-susceptible and -resistant
 S. aureus, 1192
 comparative evaluation, 851
 Legionella spp., 2049
 Staphylococcus spp., 851
 DNA gyrase

- inhibition, relationship among antibacterial activity and intracellular accumulation, 2622
- DU-6859
antimicrobial activity, 1491
inoculum size, media, pH, serum, and urine, effects on activity, 1491
- E4695
Legionella spp., 2049
- intracellular accumulation
DNA gyrase inhibition and antibacterial activity, relationship among, 2622
- OPC-17116
comparative evaluation, 1310
Enterobacteriaceae, 1310
in vitro activity, 1310
- P. aeruginosa* supersusceptibility
OprH overexpression, 2365
- P. carinii*
mice, 470
- PD127,391
gram-positive cocci, 1329
- pneumonia
mice, 470
- Q-35
in vitro activity, comparative evaluation, 1708
photostability and biological activity after UV irradiation, 1715
- S. sonnei*, 2346
- T-3761
in vitro activity, 2293
- topoisomerase II
effects on catalytic activities, 751
influence of C-8 fluorine group, 751
- WIN 57273
comparative evaluation, 851
Staphylococcus spp., 851
- 3'-Fluorothymidine
simian immunodeficiency virus
long-term tolerance and efficacy, 1770
- Fluoxetine hydrochloride
P. falciparum
chloroquine resistant, enhancement of susceptibility, 2761
- Foot rot
anaerobic bacteria
antimicrobial susceptibilities, 198
- Foscarnet
combinations
pharmacokinetics, 1773
zidovudine, 1773
pharmacokinetics
AIDS patients, 1821
twice-daily administration, 1821
- Foscarnet sodium
U.S. FDA approval, 1584
- Fungi
amphotericin B
colloidal dispersion, 486
deoxycholate suspension, 486
- Fusidic acid
M. leprae
intracellular and extracellular, 92
- Ganciclovir
antagonism
didanosine anti-human immunodeficiency virus activity, 1127
zidovudine anti-human immunodeficiency virus activity, 1127
- cytomegalovirus
severe combined immunodeficient mice, 1837
- Gas chromatography
electron capture detection
fluconazole, 647
- Gentamicin
combinations
ampicillin, 1864
cefuroxime, 801
cephalothin, 801
clarithromycin, 1695
comparative evaluation, 801
E. faecium, vancomycin and ampicillin resistant, 1563
endocarditis, 1864
Enterococcus spp., penicillin resistant, 1864
febrile neutropenic patients, 801
K. pneumoniae, 1883
M. avium, 1695
piperacillin, 1883
piperacillin-tazobactam, 1883
tazobactam, 1883
vancomycin and ampicillin, 1563
- Corynebacterium* CDC group II, 1325
endocarditis, 1325
synergy with penicillin, 1325
- E. coli*
postantibiotic effect, effect of human cerebrospinal fluid, 1136
- E. faecalis* resistance
 β -lactamase-producing strain, intra-hospital spread, 230
regions encoding, isolates from diverse geographic locations, 2259
endocarditis, 1325
- Enterococcus* resistance
ramoplanin, 2342
K. pneumoniae, 1883
M. avium, 1695
- P. aeruginosa* resistance
OprH, role in, 2566
- pharmacokinetics
patients with end-stage renal disease, 1832
patients with pleural effusions and hypoalbuminemia, 679
tobramycin, comparative evaluation, 679
- piperacillin
disposition, effect on, 1832
- resistance
E. faecium, *E. faecalis*, *S. agalactiae*, same structural gene, 1215
resistance, adaptive
dynamic in vitro model, 1951
salmonellae
ampicillin resistant, 1794
toxicity
polyaspartic acid, protection from, duration, 2556
- Ginkgetin
herpes simplex virus
mechanism of action, 1890
- Glycerol monolaurate
S. aureus, 626
- toxic shock syndrome toxin 1, 626
- Glycopeptides
decaplanin
gram-positive organisms, 873
- Gram-negative organisms
amikacin resistance
neonatal unit, 1596
amoxicillin, 1140
amoxicillin-BRL 42715, 1140
amoxicillin-clavulanate, 1140
clindamycin, 1140
fluoroquinolones
comparative evaluation, 1708
Q-35, 1708
LJC 10,627
comparative evaluation, 1418
Q-35
comparative evaluation, 1708
sparfloxacin
comparative evaluation, 558
temafloxacin, 1140
Tn21-specific structures, 1915
- Gram-positive organisms
daptomycin
comparative evaluation, 1570
decaplanin, 873
fluoroquinolones
comparative evaluation, 1708
Q-35, 1708
LJC 10,627
comparative evaluation, 1418
MDL 62208, 331
MDL 62211, 331
MDL 62873, 331
OPC-17116
comparative evaluation, 2185
PD127,391
comparative evaluation, 1329, 1570
Q-35
comparative evaluation, 1708
ramoplanin
comparative evaluation, 1570
RP 59500
pharmacodynamic interaction, 2211
sparfloxacin
comparative evaluation, 558
teicoplanin
comparative evaluation, 1570
vancomycin
comparative evaluation, 1570
- Guanosine-3',5'-bis-pyrophosphate
3,5-dihydroxy-4-ethyl-*trans*-stilbene activity
role in mediating, 2645
- gyrA*
S. aureus, methicillin resistant
analysis of mutations associated with ciprofloxacin resistance, 1166
- Haemophilus ducreyi*
 β -lactamase
ROB-1, 467
 β -lactamase plasmid contents
antimicrobial susceptibility, correlation with, 1639
- Haemophilus influenzae*
azithromycin
lung infection, 1412
 β -lactam resistance
molecular basis, 1504
non- β -lactamase mediated, 1504
 β -lactams
peptidoglycan metabolism, effect on, 2147
cefaclor
kill and growth rates, 46

- molecular basis of efficacy, 2569
 cefdinir
 kill and growth rates, 46
 rifampin
 prophylaxis for contacts of infected patients, 545
 Ro 23-9424
 cancer patients, isolates from, 879
 6-Halo-dideoxypurine nucleosides
 central nervous system uptake, 2156
 pharmacokinetics, 2156
 central nervous system uptake, 2156
 Head and neck surgery
 cancer patients
 clindamycin-amikacin, 2014
 sulbactam-ampicillin, 2014
Helicobacter pylori
 ampicillin, 1133
 azithromycin, 1133
 cefixime, 1133
 ciprofloxacin, 1133
 doxycycline, 1133
 erythromycin, 1133
 metronidazole, 1133
 metronidazole resistance
 metronidazole-amoxicillin-bismuth subcitrate, 163
 role in infection, 163
 omeprazole, 1133
 slowly growing
 antimicrobial agents, activity of, 185
 tinidazole, 1133
 Hemodialysis
 vancomycin
 serum, removal from by high-flux hemodialysis membranes, 1424
 Hepatitis B virus
 antiviral agents
 inhibition of replication, 2042
 mouse model, novel transgenic, 2042
 cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
 (-) and (+) enantiomers, 2686
 mouse model, novel transgenic
 inhibition of replication, 2042
 Hepatitis virus
 2'-fluoro-5-ethyl-1- β -D-arabinofuranosyluracil
 pharmacokinetics, 1472
 Herpes simplex virus
 acyclovir, 2037
 dimethyl prostaglandin A₁
 replication, effect on, 2253
 ginkgetin
 mechanism of action, 1890
 L-653,180
 experimental genital herpes, 2020
 penciclovir, 2037
 ribonucleotide reductase inactivators
 acyclovir, in vivo potentiation, 934
 hematological profiles, 934
 Herpes simplex virus type 1
 acyclovir, 2037
 penciclovir, 2037
 mechanism of action, 2747
 MRC-5 cells, 2747
 Herpes simplex virus type 2
 acyclovir, 2037
 penciclovir, 2037
 mechanism of action, 2747
 MRC-5 cells, 2747
 Herpesviruses
 minireview
 resistance, 1589
 resistance
 minireview, 1589
 Hexadecylphosphocholine
L. donovani, 1630
L. infantum, 1630
 leishmaniasis
 visceral, 1630
 High-performance liquid chromatography
 amoxicillin
 bovine plasma, determination in, 1859
 potency determination, 1272
 tandem solid-phase extraction method, 1859
 fluconazole
 concentrations in plasma, serum, and cerebrospinal fluid, 603
 mixed-phase column, 603
 radioimmunoassay
 combined procedure for measuring intracellular zidovudine, 2473
 tandem solid-phase extraction method
 ampicillin, improved determination, 1606
 Human immunodeficiency virus
 (-)-2'-deoxy-3'-thiacytidine 5' triphosphate
 DNA polymerase alpha, beta, and gamma, 1688
 reverse transcriptase inhibition, 1688
 reverse transcriptase inhibition
 (-)-2'-deoxy-3'-thiacytidine 5' triphosphate, 1688
 Human immunodeficiency virus type 1
 1- β -D-arabinofuranosyl-5-(2-bromovinyl)uracil
 anticancer nucleosides, 214
 anti-human immunodeficiency virus agents, 214
 3'-azido-3'-deoxythymidine
 comparative evaluation, 808
 3'-azido-3'-deoxythymidine resistance
 suppression by mutation conferring resistance to reverse transcriptase inhibitors, 2664
 2'-deoxy-3'-thiacytidine
 enantiomers, 202
 inhibition of virus replication, 202
 (-)-2'-deoxy-3'-thiacytidine
 inhibition of replication, 733
 3'-deoxythymidine diphosphate dimyristoylglycerol
 greatly enhanced inhibition, 2025
 didanosine
 antagonism by ganciclovir, 1127
 didanosine resistance
 replication endpoint concentration assay, 920
 2',3'-dideoxy-3'-thiacytidine (BCH-189)
 activities of the four optical isomers, 672
 2',3'-dideoxycytidine
pol gene mutations, decreased susceptibility, 153
 dimethyl prostaglandin A₁
 replication, effect on, 2253
 3'-fluoro-3'-deoxythymidine
 comparative evaluation, 808
 cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
 racemates and enantiomers, 2423
 ganciclovir
 antagonism of zidovudine and didanosine, 1127
 inhibitors
 gp120-CD4 binding, 267
 screening assay, 267
 L-696,229, 1019
 inhibition of reverse transcriptase, 1019
 5-mercapto-substituted poly- and oligonucleotides
 mechanisms of action, 108
 structure-activity relationships, 108
 polyethers
 inhibition of replication, 492
 [Tyr-5,12, Lys-7]polyphemusin II (T22), 1249
 protease inhibitors, 982
 protease inhibitors, C₂ symmetry based
 inhibition of replication, 926
 purine nucleosides, TSAO derivatives
 potent and selective inhibitors, 1073
 pyrimidine nucleosides, TSAO derivatives
 potent and selective inhibitors, 1073
 reverse transcriptase
 nonnucleoside inhibitors, residues that contribute to the activity of, 1441
 Ro5-3335
 cell type-specific activity, 2628
 zidovudine
 antagonism by ganciclovir, 1127
 zidovudine-2',3'-dideoxycytidine
 synergy, 1559
 zidovudine resistance
 replication endpoint concentration assay, 920
 Human immunodeficiency virus type 2
 (-)-2'-deoxy-3'-thiacytidine
 inhibition of replication, 733
 (R)-9-[4-Hydroxy-2-(hydroxymethyl)butyl]guanine
 pharmacokinetics
 distribution over blood-brain barrier, 339
 rats, 339
 (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
 cytomegalovirus
 severe combined immunodeficient mice, 1837
 Hydroxynaphthoquinones
 566C80
T. gondii cysts, 326
 ICI 213,689
 pharmacokinetics
 healthy subjects, 2794
 renal impairment, patients with, 2794
 young and elderly healthy men, 1437
 Imipenem
B. fragilis group, 2051
 bactericidal activity, serum
 comparative evaluation, 2085
 combinations
 cilastatin, 801, 2057, 2766
 comparative evaluation, 801, 2766
 effect of biliary obstruction on hepatic excretion, 2057
 febrile neutropenic patients, 801
 intra-abdominal infections, 2766
 pharmacokinetics, 2057

- comparative evaluation
ceftriaxone, ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole, 949
- E. coli*
diffusion through outer membrane, correlation with activity, 1902
- meningitis, 949
- P. aeruginosa* resistance
 β -lactamase and impermeability, association of, 2046
- E1040, 684
- protein D2, nucleotide sequence, 1791
- pharmacokinetics
comparative evaluation, 2085
- serum and skin window fluid of healthy adults, 1400
- transplacental passage, 2652
- R. equi*, 1244
- S. enteritidis*, 949
- Immunoglobulin G
amphotericin B
C. albicans infection in burned mice, 643
- Immunomodulators
minireview, 1
- nonspecific resistance to infection, 1
- Impetigo
erythromycin-resistant *S. aureus*
erythromycin and mupirocin, comparative evaluation, 287
- Influenza virus
pulse oximetry
measurement of antiviral activity in mice, 473
- ribavirin
pulse oximetry, 473
- Interferon
alpha
cytomegalovirus, 1837
- cytomegalovirus
severe combined immunodeficient mice, 1837
- Interleukin-1
amphotericin B-stimulated human mononuclear cells
expression, pharmacologic modulation of, 977
- combinations
C. albicans, 1225
- candidiasis, 1225
- fluconazole, 1225
- minireview, 1
- nonspecific resistance to infection, 1
- resistance to bacterial infection
glucocorticosteroids, not mediated by, 2785
- Interleukin-6
combinations
interleukin- α , 68
- L. monocytogenes*, 68
- tumor necrosis factor alpha, 68
- L. monocytogenes*
mice, 68
- minireview, 1
- nonspecific resistance to infection, 1
- Interleukin- α
combinations
interleukin-6, 68
- L. monocytogenes*, 68
- Intra-abdominal infections
imipenem-cilastatin
comparative evaluation, 2766
- piperacillin-tazobactam
comparative evaluation, 2766
- Iontophoresis
antimicrobial effect
chloroquine-containing medium, 2552
- Isepamicin
pharmacokinetics
patients with end-stage renal disease, 1832
- piperacillin
disposition, effect on, 1832
- ISIS 1082
toxicology, in vitro, 527
- Isoniazid
M. tuberculosis
pyrazinamide-rifampin, comparative evaluation, 548
- pyrazinamide-rifampin
antagonism, 548
- Isoiprinosine
E. multilocularis
effect of multiple doses on metacystodes, 191
- Isothiazoloquinolones
topoisomerase II
DNA breakage, 81
- Itraconazole
synergy
B. dermatitidis, 2487
- macrophages, 2487
- Kanamycin
C. jejuni resistance
aphA-7 resistance determinant, plasmids carrying, 712
- E. faecalis* resistance plasmid
conjugal transfer to *E. coli*, 502
- KB-5246
S. aureus, accumulation in
carbonyl cyanide *m*-chlorophenylhydrazone, lack of effect on, 883
- Ketamine
rabies virus
transcription, inhibition of, 1750
- Ketoconazole
C. albicans, 64
comparative evaluation
SCH 39304 and fluconazole, 64
- systemic fungal infections, 64
- Klebsiella oxytoca*
 β -lactamase
transposition of gene encoding, 1981
- Klebsiella pneumoniae*
ceftazidime resistance
 β -lactamase, extended spectrum, 1991
- cancer patients, 1991
- cephem antibiotics
effect of serum protein binding on efficacy, 17
- gentamicin, 1883
- piperacillin, 1883
- piperacillin-gentamicin, 1883
- piperacillin-tazobactam, 1883
- piperacillin-tazobactam-gentamicin, 1883
- romurtide-cefmenoxime
synergy, 167
- tazobactam, 1883
- tazobactam-gentamicin, 1883
- Klebsiella rhinoscleromatis*
amoxicillin-clavulanate, 1785
- cefepodoxime, 1785
- cefuroxime, 1785
- cephalexin, 1785
- chloramphenicol, 1785
- ciprofloxacin, 1785
- streptomycin, 1785
- tetracycline, 1785
- trimethoprim-sulfamethoxazole, 1785
- Klebsiella* spp.
bacteremia
combination versus monotherapy, 2639
- β -lactamases
epidemiology, 989
- relation to antimicrobial therapy, 989
- KRM-1648
M. avium complex
mice, 387
- L-627
in vitro activity
comparative evaluation, 1928
- P. aeruginosa*
comparative evaluation, 1928
- L-646,991
antifungal activity, 1648
- 1,3- β -D-glucan synthesis inhibition, 1648
- L-653,180
herpes simplex virus
experimental genital herpes, 2020
- L-671,329
antifungal activity, 1648
- 1,3- β -D-glucan synthesis inhibition, 1648
- pharmacokinetics
rhesus monkeys and DBA/2 mice, 607
- L-687,781
antifungal activity, 1648
- 1,3- β -D-glucan synthesis inhibition, 1648
- L-693,989
P. carinii
rats, 1964
- L-696,229
human immunodeficiency virus type 1, 1019
- inhibition of reverse transcriptase, 1019
- Lactobacillus casei*
YIT 9018
protection against infection induced by 5-fluorouracil, 361
- Legionella pneumophila*
floxacin, 2387
- pneumonia
floxacin, 2387
- Ro 23-9424, 2559
- Legionella* spp.
CI-960, 2049
- E4695, 2049
- floxacin
in vitro activity, 2387
- fluoroquinolones
CI-960, 2049
- E4695, 2049
- Ro 23-9424, 2559
- Leishmania donovani*
drug targeting
polymers internalized by macrophages, 2228
- hexadecylphosphocholine, 1630
- leishmaniasis
hexadecylphosphocholine, 1630
- Leishmania infantum*
hexadecylphosphocholine, 1630
- leishmaniasis

- hexadecylphosphocholine, 1630
- Leishmania* spp.
topoisomerase II inhibitors
cytotoxicity for promastigotes, 495
- Leishmaniasis
amphotericin B
cholesterol dispersion, 1978
hexadecylphosphocholine, 1630
L. donovani
hexadecylphosphocholine, 1630
L. infantum
hexadecylphosphocholine, 1630
visceral
hexadecylphosphocholine, 1630
- Letters to the editor
amphotericin B
toxicity, effect of infusion rates, 2573
- Mediterranean spotted fever
trimethoprim-sulfamethoxazole, 1342
- rifampin
bioavailability in murine tuberculosis, 2066
- S. aureus*
methicillin resistance, detection by
polymerase chain reaction, 1585
- ticarcillin-clavulanic acid
dosing ratio, 1585
interpretive criteria, new, 1343
S. aureus endocarditis, 1585
zone size criteria, 2352
- trimethoprim-sulfamethoxazole
Mediterranean spotted fever, 1342
- Levofloxacin
antibacterial activities, in vitro and in vivo
comparative evaluation, 860
- Lincosamides
Peptostreptococcus spp.
inducible and constitutive phenotypes, 662
- Lipopeptides
L-693,989
P. carinii, 1964
- Listeria monocytogenes*
ampicillin
comparative evaluation, 2375
hydrocortisone-treated mice, 2375
- ciprofloxacin
comparative evaluation, 2375
hydrocortisone-treated mice, 2375
- interleukin-6, 68
interleukin-6-interleukin- α , 68
interleukin-6-tumor necrosis factor α , 68
- tetracycline resistance
genetic basis, 463
- LJC 10,627
 β -lactamase stability, 1418
gram-negative organisms
comparative evaluation, 1418
gram-positive organisms
comparative evaluation, 1418
renal dehydropeptidase-I stability
imipenem, comparative evaluation, 481
- Lomefloxacin
pharmacokinetics
absorption, effect of antacid on, 1219
sputum penetration, 2458
steady state, 2458
transudative and exudative pleural effusion, penetration, 2774
- Loperamide
combinations
traveler's diarrhea, T426
trimethoprim-sulfamethoxazole, 2821
- Loracarbef
bactericidal titers and killing rates
patients receiving 200 versus 400 mg, 521
U.S. FDA approval, 1584
- lpxA2*
E. coli
antibiotic supersusceptibility, 826
- Lysophospholipids
B669
mediators of antimicrobial activity, 2729
clofazimine
mediators of antimicrobial activity, 2729
- Macrolides
inhibitory activity in presence of human serum, 10
M. genitalum, 870
M. pneumoniae, 870, 1322
MC-352
in vitro activity, comparative evaluation, 1699
Peptostreptococcus resistance
inducible and constitutive phenotypes, 662
S. lividans resistance
MGT enzyme, 348
serum protein binding, 10
- Macrophages
synergy
B. dermatitidis, 2487
itraconazole, 2487
- Magainins
A. polyphaga
ameba and cyst stages, effects on, 1256
positive-charge chain extension
augmentation of activity, 313
- Malaria
5-fluoroorotate
molecular targets, 704
infected cells
cinnamic acid, effect on permeability, 1102
- MC-352
in vitro activity
comparative evaluation, 1699
- MDL 62208
comparative evaluation
MDL 62211, MDL 62873, teicoplanin, and vancomycin, 331
gram-positive organisms, 331
- MDL 62211
comparative evaluation
MDL 62208, MDL 62873, teicoplanin, and vancomycin, 331
gram-positive organisms, 331
- MDL 62,873
antimicrobial activity, 446
comparative evaluation
MDL 62208, MDL 62211, teicoplanin, and vancomycin, 331
gram-positive organisms, 331
S. aureus, 446
S. pneumoniae, 446
S. pyogenes, 446
- MDL 73811
T. brucei rhodesiense
S-adenosylmethionine decarboxylase inhibitor, 2736
- mecA*
methicillin-resistant staphylococci
distribution, 429
- Mediterranean spotted fever
trimethoprim-sulfamethoxazole
letter to the editor, 1342
- Melioidosis
ceftazidime-co-trimoxazole, 158
chloramphenicol-doxycycline-co-trimoxazole, 158
- Meningitis
ceftriaxone
comparative evaluation, 949
- coccidioid
RR 42427, 217
SCH 39304, 217
SS 42426, 217
- cryptococcal
fluconazole, 690
RR 42427, 217
SCH 39304, 217
SS 42426, 217
- imipenem
comparative evaluation, 949
- S. enteritidis*
ceftriaxone, 949
imipenem, 949
- Meropenem
E. coli
diffusion through outer membrane, correlation with activity, 1902
- metabolites
pharmacokinetics, 1437, 2794
- P. aeruginosa* resistance
cephem and quinolone cross-resistance, 1847
outer membrane protein overproduction, association with, 1847
- pharmacokinetics
healthy subjects, 2794
renal impairment, patients with, 2794
renal impairment, subjects with, 1532
young and elderly healthy men, 1437
- renal dehydropeptidase I
 β -methyl substitution, effect on stability, 1577
stability to, 1577
- Methicillin
S. aureus resistance
chromosomal factors, mapping and characterization of, 1367
mecA, *mecR1-mecI*, and *femA-femB*, 2617
- Staphylococcus* resistance
mecA distribution, 429
mecA transcription, correlation with, 25
- 6-Methoxypurine arabinoside
transport into human erythrocytes, 283
- 2'-O-valerate prodrug
transport into human erythrocytes, 283
- 6'-(R)-6'-C-Methylneplanocin A
myxoviruses, 435
orthoviruses, 435
- Methylobacterium* spp.
susceptibility testing, 1635
 β -lactams, 1635

- Metronidazole**
B. fragilis group, 2051
 combinations
 amoxicillin and bismuth subcitrate, 163
 H. pylori, metronidazole resistant, 163
 comparative evaluation
 erythromycin, minocycline, ampicillin, amoxicillin, cefixime, and bismuth subcitrate, 185
H. pylori, 1133
 slowly growing, 185
H. pylori resistance, 163
 amoxicillin-metronidazole-bismuth subcitrate, 163
- Minireviews**
 active efflux mechanisms, 695
 antifungal agents
 toxicity, in vitro models for, 1799
 antimicrobial resistance
 active efflux mechanisms, 695
 antiviral agents
 retroviruses, 509
 β -lactamases
 enterococci, 2355
 β -lactams
 continuous infusion, 2577
 pharmacokinetics by continuous infusion, 2577
 biofilms, aging
 mechanism of resistance to antimicrobial therapy, 1347
 endocarditis
 pharmacokinetic and pharmacodynamic requirements, 2069
 herpesviruses
 resistance, 1589
 immunomodulators
 nonspecific resistance to infection, 1
 pulmonary disposition of antimicrobial agents
 clinical relevance and in vivo observations, 1176
 methodological considerations, 1171
 retrovirus
 reverse transcriptase inhibition, 245
 therapy, 245
 synergism, in vivo
 animal models, contribution of, 907
 toxicity
 antifungal agents, in vitro models for, 1799
- Minocycline**
 comparative evaluation
 erythromycin, ampicillin, amoxicillin, cefixime, metronidazole, and bismuth subcitrate, 185
H. pylori
 slowly growing, 185
M. avium complex
 human macrophages, 2104
R. equi, 1244
 synergy
 clarithromycin, 2852
 T. gondii, 2852
- Monoclonal antibodies**
 antilipopolysaccharide
 MAB-T88, phase I study, 2349
 MAB-T88
 phase I study, 2349
 MS-8209
 C. albicans, 2722
 C. neoformans, 2722
- mycoses, experimental systemic, 2722
 toxicity
 renal tubular cells, 2722
- Mupirocin**
 comparative evaluation
 erythromycin, 287
 impetigo
 erythromycin-resistant *S. aureus*, 287
- Mureidomycins**
Pseudomonas spp., 1024
 imipenem resistant, 1024
 ofloxacin resistant, 1024
- Mycobacterium avium***
 azithromycin
 combinations, 1611
 comparative evaluation, 1611
 azithromycin-clarithromycin
 comparative evaluation, 1611
 clarithromycin resistance
 selection of mutants by monotherapy, 2839
 gentamicin, 1695
 gentamicin-clarithromycin, 1695
- Mycobacterium avium* complex**
 clarithromycin
 beige mice, 2413
 comparative evaluation, 1163
 human macrophages, 2104
 J774 cells and alveolar macrophages, 1163
 clarithromycin-rifabutin
 beige mice, 2413
 erythromycin
 comparative evaluation, 1163
 J774 cells and alveolar macrophages, 1163
 ethambutol, 2408
 ethambutol-RU-40 555, 2408
 KRM-1648
 mice, 387
 minocycline
 human macrophages, 2104
 RU-40 555, 2408
 sparfloxacin, 2408
 sparfloxacin-ethambutol-RU-40 555, 2408
 sparfloxacin-ethambutol, 2408
 WIN-57273
 human macrophages, 2104
- Mycobacterium avium-M. intracellulare* complex**
 bacteremia
 clarithromycin-ciprofloxacin-amikacin, 1567
 ciprofloxacin
 clarithromycin-ciprofloxacin-amikacin, 1567
 human peripheral blood monocyte/macrophages, 2816
 liposome encapsulated, 2816
 streptomycin
 human peripheral blood monocyte/macrophages, 2816
 liposome encapsulated, 2816
- Mycobacterium chelonae***
 azithromycin, 180
 clarithromycin, 180
 erythromycin, 180
 roxithromycin, 180
- Mycobacterium fortuitum***
 azithromycin, 180
 β -lactam resistance
 β -lactamases, 1068
- penicillin-binding proteins, 1068
 clarithromycin, 180
 erythromycin, 180
 roxithromycin, 180
- Mycobacterium kansasii***
 clarithromycin
 in vitro susceptibility, 2039
- Mycobacterium leprae***
 fusidic acid, 92
 quinolones
 comparative evaluation, 2544
- Mycobacterium paratuberculosis***
 clarithromycin
 comparative evaluation, 2843
 ethambutol, enhancement of activity, 2843
- Mycobacterium* spp.**
 clarithromycin, 1987
 pH, effect on MICs, 2841
 ethionamide
 mechanism of action, 1316
 mycolic acid synthesis inhibition, 1316
 slowly growing, nontuberculous
 clarithromycin, 1987
- Mycobacterium tuberculosis***
 isoniazid
 antagonism with pyrazinamide-rifampin, 548
 pyrazinamide-rifampin
 antagonism with isoniazid, 548
- Mycoplasma genitalum***
 susceptibilities, in vitro, 870
- Mycoplasma pneumoniae***
 macrolides, 1322
 quinolones, 1322
 susceptibilities, in vitro, 870
 tetracyclines, 1322
- Myocarditis**
 coxsackievirus
 WIN 54954, 425
 WIN 54954, 425
- Myxococcus xanthus***
 antibiotic TA
 expression of genes required for production, 2322
 genes involved in production, mutation and mapping of, 2316
- Myxovirus**
 5-ethyl-1- β -D-ribofuranosylimidazole-4-carboxamide, 435
 6'-(R)-6'-C-methylnepianocin A, 435
 ribavirin, 435
- Myxoviruses**
 protease inhibitors
 effects on replication, 1432
- Naftifene**
C. albicans
 squalene epoxidase inhibition, 1799
- Nalidixic acid**
E. coli
 SOS-response and cell-division mutants, 819
 salmonellae
 ampicillin resistant, 1794
- Naphthoquinones**
 topoisomerase II
 DNA cleavage, induction of, 2589
- Neisseria gonorrhoeae***
 antibiotic susceptibilities
 isolates from the Philippines, 277
 antibiotic susceptibility survey, 1682

- cefpodoxime proxetil, 1764
 ceftriaxone resistance, 1682
 temafloxacin
 comparative evaluation, 1131
 urethritis
 cefepodoxime proxetil, 1764
Neisseria meningitidis
 ampicillin susceptible
 discrimination between moderately
 and fully susceptible isolates,
 1028
 penicillin susceptible
 discrimination between moderately
 and fully susceptible isolates,
 1028
 Nephrotoxicity
 amphotericin B
 different formulations, comparative
 evaluation, 1525
 Netilmicin
 pyelonephritis
 5 mg/kg once daily versus 3 mg/kg
 thrice daily, 1499
 Neutrophils
 pentoxifylline
 modulation of activation, 408
 Nifedipine
 cefixime
 bioavailability, effect on, 2462
 Nikkomycin Z
 C. albicans
 chitin biosynthesis, inhibition of, 1909
 Nikkomycins
 combinations
 azoles, 1284
 C. albicans, 1284
 synergy
 azoles, 1284
 C. albicans, 1284
 Nonnucleoside reverse transcriptase inhibi-
 tors
 human immunodeficiency virus resis-
 tance
 suppression of resistance to 3'-azido-
 3'-deoxythymidine, 2664
 Nonoxonyl 9
 C. trachomatis
 infected HeLa 229 cells, 1478
 infected primary monkey cervical epi-
 thelial cells, 1478
 HeLa cells
 toxicity to, 1478
 primary monkey cervical epithelial cells
 toxicity to, 1478
 Norfloxacin
 absorption
 inhibition by dairy products, 489
 E. coli
 SOS-response and cell-division mu-
 tants, 819
 E. coli colonization
 porcine gut models, 401
 P. aeruginosa resistance
 nfxB type mutation, 2562
 pharmacokinetics
 effect of dairy products, 489
 Ofloxacin
 anaerobic bacteria
 comparative evaluation, 1158
 B. melitensis, 973
 brucellosis, 973
 C. burnetii, 2529
 C. pneumoniae, 682
 C. trachomatis
 cervical infection, 1144
 comparative evaluation, 1144
 comparative evaluation
 ciprofloxacin, fleroxacin, temafloxacin,
 sparfloxacin, 682
 pharmacokinetics
 multiple intravenous doses in healthy
 volunteers, 308
 penetration into heart valves, myocar-
 dium, mediastinal fat, and bone
 marrow, 2493
 R. conorii, 2529
 R. rickettsii, 2529
 safety
 multiple intravenous doses, 308
 traveler's diarrhea
 three versus five days of therapy, 87
 L-Ofloxacin
 C. pneumoniae, 1573
 Oligonucleotides
 5-mercapto substituted
 human immunodeficiency virus type 1,
 108
 Omeprazole
 H. pylori, 1133
 OPC-17116
 comparative evaluation
 ofloxacin, enoxacin, ciprofloxacin, and
 tosufloxacin, 573
 Enterobacteriaceae
 assay conditions, effect on activity,
 1310
 comparative evaluation, 1310
 gram-positive organisms
 comparative evaluation, 2185
 in vitro activity
 assay conditions, effect of, 1310
 comparative evaluation, 1310
 Orthovirus
 5-ethyl-1- β -D-ribofuranosylimidazole-4-
 carboxamide, 435
 6'-(*R*)-6'-C-methylneplanocin A, 435
 ribavirin, 435
 Osteomyelitis
 staphylococcal
 azithromycin, 2693
 azithromycin-rifampin, 2693
 Oxytetracycline
 bacteria pathogenic to fish
 temperature-dependent activity, 1738
 Panipenem-betamipron
 pharmacokinetics
 prediction from animal data, 1810
 Pasteurella multocida
 penicillin G
 cell surface characteristics, effect of
 sub-MICs on, 2093
 virulence, effect of sub-MICs on, 2093
 tetracycline
 cell surface characteristics, effect of
 sub-MICs on, 2093
 virulence, effect of sub-MICs on, 2093
 trimethoprim-sulfamethoxazole
 cell surface characteristics, effect of
 sub-MICs on, 2093
 virulence, effect of sub-MICs on, 2093
 PD 127,391
 C. burnetii, 2529
 gram-positive organisms
 comparative evaluation, 1329
 R. conorii, 2529
 R. rickettsii, 2529
 PD 131,628
 C. burnetii, 2529
 R. conorii, 2529
 R. rickettsii, 2529
 S. pneumoniae
 comparative evaluation, 856
 PD127,391
 gram-positive organisms
 blood isolates, 1570
 comparative evaluation, 1570
 Pefloxacin
 B. melitensis, 973
 brucellosis, 973
 C. burnetii, 2529
 P. carinii
 mice, 470
 pneumonia
 mice, 470
 R. conorii, 2529
 R. rickettsii, 2529
 S. aureus
 transport across cytoplasmic mem-
 brane, 2506
 Penciclovir
 herpes simplex virus
 mechanism of action, 2747
 MRC-5 cells, 2747
 type 1, 2037
 type 2, 2037
 varicella-zoster virus
 mechanism of action, 2747
 MRC-5 cells, 2747
 Penems
 [¹⁴C]FCE 22891
 pharmacokinetics, 1958
 Penicillin
 Corynebacterium CDC group 11, 1325
 endocarditis, 1325
 synergy with gentamicin, 1325
 E. faecalis
 susceptibility changes following vari-
 ous exposure regimens, 121
 E. faecium resistance
 mechanisms of, 783
 endocarditis, 1325
 N. meningitidis susceptibility
 discrimination between moderately
 and fully susceptible isolates,
 1028
 S. pneumoniae resistance
 increased occurrence in a children's
 hospital, 1703
 susceptibilities, in vitro, 1703
 synergy
 endocarditis, 2403
 S. adjacens, 2403
 tobramycin, optimal dosing regimen,
 2403
 Penicillin G
 Enterococcus resistance
 ramoplanin, 2342
 P. multocida
 cell surface characteristics, effect of
 sub-MICs on, 2093
 virulence, effect of sub-MICs on, 2093

- Penicillin-binding proteins
E. faecium
 analysis of, 783
M. fortuitum
 β -lactam resistance, 1068
S. aureus
 characterization, 656
 polymerase chain reaction, 6
S. aureus, methicillin resistant
 PBP 2a, construction of a water-soluble form, 533
S. pneumoniae
 multiply antimicrobial resistant, 2176
- Pentamidine
 pharmacokinetics
 metabolism in rats, primary and secondary, 1825
- Pentoxifylline
 human neutrophils
 modulation of activation by amphotericin B, 408
- Peptides
C. albicans
 effect on adherence, 132
- Peptidoglycan precursors
Enterococcus spp.
 vancomycin resistant, 1487
- Peptostreptococcus* spp.
 lincosamide resistance
 inducible and constitutive phenotypes, 662
 macrolide resistance
 inducible and constitutive phenotypes, 662
- Peritonitis
 complication of continuous ambulatory peritoneal dialysis
 susceptibility testing of isolated bacteria, 1097
- Pharmacokinetics
 acyclovir
 distribution over blood-brain barrier, 339
 rats, 339
 amikacin
 cefepime, lack of interaction with, 1382
 amoxicillin
 enzyme-linked immunosorbent assay, use to assess, 1545
 penetration into lung secretions, 1545
 amphotericin B
 colloidal dispersion, 299
 relationship to safety, 299
 ampicillin
 2085P, after oral administration of, 1002
 ampicillin-sulbactam
 serum and blister fluid, 2233
 antipyrine
 rifampin, 2- and 4-day regimens, effect of, 1553
 3'-azido-3'-deoxythymidine, 808
 2',3'-dideoxyinosine, lack of interaction with, 665
 azithromycin
 AIDS patients, 1013
 lung, 1412
 uptake by phagocytes, 1412
 azoles, oral
 effect of cyclodextrin, 477
 β -lactams
 continuous infusion, minireview, 2577
- BRL 42715
 rats, 1427
- brobactam
 2085P, after oral administration of, 1002
- cefazolin
 rats, 1427
- cefepime
 age and gender, effects of, 1181
 amikacin, lack of interaction with, 1382
 patients on continuous ambulatory peritoneal dialysis, 1387
 serum and blister fluid, 453
 single and multiple intravenous administrations, 552
 subjects with renal impairment, 2676
- cefixime
 bioavailability, effect of nifedipine on, 2462
- cefmenoxime
 concentrations in sera and peritoneal tissue, 1483
 patients undergoing gastrointestinal surgery, 1483
- cefonicid
 angiotensin II, effect of, 616
- cefoperazone
 serum and blister fluid, 453
 tissue penetration model, 295
- cefotetan
 patients undergoing colorectal surgery, 1115
 serum and blister fluid, 2233
 single dose, 1115
- cefoxitin
 serum and blister fluid, 2233
- cefpime, 2085
- cefpodoxime proxetil, 796
 effect of antacid and H_2 -receptor antagonist on absorption, 796
 healthy volunteers, 126
 patients with impaired renal function, 126
 penetration into lung parenchyma and epithelial lining fluid, 2099
- cefprozil
 antacid, effect of, 962
 beagles, 687
 excretion in human breast milk, 938
 multiple dosing, 144
- ceftazidime, 2085
 patients with pneumonia, 1404
 serum and blister fluid, 453
- ceftizoxime
 serum and blister fluid, 2233
- ceftriaxone, 2085
 1,000 mg intravenously, 2804
 diclofenac, effects on, 2331
 prophylaxis in thoracic surgery, 2804
 tissue penetration, 2804
 transudative and exudative pleural effusion, penetration, 2774
- cephalosporin
 rats, rabbits, dogs, and monkeys, 966
- ciprofloxacin, 2085
 aluminum hydroxide, effect on bioavailability, 830
 bioavailability in cystic fibrosis patients, 2512
 calcium carbonate, effect on bioavailability, 830
 infants and small children, 1086
- penetration into blister fluid, 651
 single 750-mg dose, 677
 single intravenous and oral doses, 993
- clarithromycin
 infants and children, 2478
 metabolite, 14-(R) hydroxylated, 2478
 oral administration in humans, 1147
 single ascending oral doses, 2447
- CP-72,588, 2080
- CP-74,667
 laboratory animals, 1671
- daptomycin
 healthy volunteers, 318
 intravenous drug abusers, 1109
- didanosine
 influence of hemodialysis, 1519
 patients with normal and impaired renal function, 1519
 ranitidine, interaction with, 2075
 2',3'-dideoxy-5-fluoro-3'-thiacytidine
 racemic, 2432
 rhesus monkeys, 2432
 2',3'-dideoxyinosine
 3'-azido-3'-deoxythymidine, lack of interaction with, 665
 bioavailability, impact on maximal tolerated dose, 1280
- 6-dimethylaminopurine arabinoside, 353
- DQ-2556
 rats, rabbits, dogs, and monkeys, 966
- DR-3355
 antacids, effect of, 2270
 ferrous sulfate, effect of, 2270
 ranitidine, effect of, 2270
- epithelial cells
 intestinal transport of antimicrobial agents, use as a model for, 1374
- [14 C]FCE 22891
 healthy volunteers, 1958
- floxacin
 aqueous and vitreous humors, 32
 guinea pigs, 2387
 patients with liver cirrhosis, 632
 penetration into blister fluid, 651
 positron emission tomography, 2286
 rabbits with *E. coli* infections, 2286
 sucralate, effect of, 2758
- 3'-fluoro-3'-deoxythymidine, 808
 penetration into brains, muscle tissue, and veins of monkeys, 2418
 relation to antiviral action, 2418
- 2'-fluoro-5-ethyl-1- β -D-arabinofuranosyluracil
 mice and rats, 1472
 preclinical pharmacology, 1472
- foscarnet
 AIDS patients, 1821
 twice-daily administrations, 1821
- foscarnet-zidovudine, 1773
- gentamicin
 patients with end-stage renal disease, 1832
 patients with pleural effusions and hyponatremia, 679
 piperacillin, effect on gentamicin disposition, 1832
 tobramycin, comparative evaluation, 679
- 6-halo-dideoxypurine nucleosides, 2156
 central nervous system uptake, 2156
 (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine
 distribution over blood-brain barrier,

- 339
rats, 339
ICI 213,689
 healthy subjects, 2794
 renal impairment, patients with, 2794
 young and elderly healthy men, 1437
imipenem, 2085
 serum and skin window fluid of
 healthy adults, 1400
 transplacental passage, 2652
imipenem-cilastatin
 effect of biliary obstruction on hepatic
 excretion, 2057
isepamicin
 patients with end-stage renal disease,
 1832
 piperacillin, effect on isepamicin dis-
 position, 1832
L-671,329
 rhesus monkeys and DBA/2 mice, 607
lomefloxacin
 absorption, effect of antacid on, 1219
 sputum penetration, 2458
 steady state, 2458
 transudative and exudative pleural ef-
 fusion, penetration, 2774
loracarbef
 patients receiving 200 versus 400 mg,
 521
meropenem
 healthy subjects, 2794
 metabolite, 1437
 renal impairment, patients with, 2794
 renal impairment, subjects with, 1532
 young and elderly healthy men, 1437
norfloxacin
 effect of dairy products, 489
ofloxacin
 multiple intravenous doses in healthy
 volunteers, 308
 penetration into heart valves, myocar-
 dium, mediastinal fat, and bone
 marrow, 2493
panipenem-betamipron
 prediction from animal data, 1810
pentamidine
 metabolism in rats, primary and sec-
 ondary, 1825
piperacillin
 patients undergoing colorectal surgery,
 1997
 rats, 1427
pivalic acid
 S-1108, after administration of, 757
 polymorphonuclear leukocytes
 delivery and transport of drugs, 2584
pulmonary disposition of antimicrobial
 agents
 minireviews, 1171, 1176
pyrimethamine
 infants with congenital toxoplasmosis,
 1040
R 82913
 AIDS patients, 2661
 intravenous versus oral administra-
 tion, 2661
ranitidine
 didanosine, interaction with, 2075
rifampin
 intraocular penetration, 1575
RP 59500
 fibrin clots, penetration into, 2211
 rifloxacin
 multiple dose, in healthy volunteers,
 1296
S-1108, 762
 carnitine body stores, 762
 healthy volunteers, 762
SCE-2787
 comparative evaluation, 2481
SCH-39304
 human immunodeficiency virus-in-
 fected patients, 2790
sparfloxacin, 2444
 human polymorphonuclear leukocytes,
 1053
 inflammatory fluid penetration, 2444
sucralfate
 floxacin, effect on, 2758
systemic antibiotics, perioperative
 liver transplant patients, 2125
tazobactam
 patients undergoing colorectal surgery,
 1997
teicoplanin
 healthy male volunteers, 115
 metabolism in humans, 1744
temafloxacin
 multiple oral doses, 378
ticarcillin-clavulanate
 serum and blister fluid, 2233
tobramycin
 patients with pleural effusions and hy-
 poalbuminemia, 679
 proximal tubular cells, subcellular lo-
 calization in, 2204
 tobramycin, comparative evaluation,
 679
vancomycin
 intravenous drug abusers, 1109
 proximal tubular cells, subcellular lo-
 calization in, 2204
 sternal bone, penetration into, 2539
zidovudine
 intravenous and oral, 2245
 penetration into brains, muscle tissue,
 and veins of monkeys, 2418
 relation to antiviral action, 2418
Phospholipids
 amphotericin B
 influence of phospholipid/amphotericin
 B ratio on renal cell toxicity and
 fungicidal activity, 262
 influence of type on renal cell toxicity
 and fungicidal activity, 262
Piperacillin
 B. fragilis group, 2051
 combinations
 amikacin, 2808
 BRL 42715, 1427
 comparative evaluation, 2766, 2808
 E. coli, 1427
 febrile neutropenic patients with can-
 cer, 2808
 gentamicin, 1883
 intra-abdominal infections, 2766
 K. pneumoniae, 1883
 S. marcescens, 1427
 tazobactam, 1883, 2766
 tazobactam-gentamicin, 1883
gentamicin
 effect on gentamicin disposition, 1832
isepamicin
 effect on isepamicin disposition, 1832
K. pneumoniae, 1883
P. aeruginosa
 biofilms, dynamic interactions, 1208
P. aeruginosa resistance
 biofilm, barrier to diffusion, 2054
 pharmacokinetics
 patients undergoing colorectal surgery,
 1997
 rats, 1427
Pirodavin
 comparative evaluation
 R 61837, 100
 enterovirus, 100
 rhinovirus, 100
 experimental infection, 727
 safety and efficacy, 727
Plasmids
 aphA-7 kanamycin resistance determi-
 nant
 C. jejuni, 712
 characterization, 712
 kanamycin resistance
 transfer from *E. faecalis* to *E. coli*,
 502
 tetracycline resistance
 S. hyicus, *tet* (L) sequence, 580
 trimethoprim resistance
 E. coli, 1720
Plasmodium falciparum
 acridines
 anticancer, 1644
 chloroquine resistant
 fluoxetine hydrochloride, enhancement
 of susceptibility, 2761
 chloroquine-chlorpromazine, 209
 chloroquine-prochlorperazine, 209
 cinchona alkaloids
 stereochemical evaluation, 1538
 cinnamic acid derivatives, 1102
 permeability of infected cells, effect
 on, 1102
 ethanolamine, radioactive
 incorporation into phospholipids, 50
 microdilution technique, semiauto-
 mated, 50
 5-fluoroorotate
 molecular targets, 704
Platelet-activating factor antagonists
 CL 184,005
 animal models, evaluation in, 1971
 sepsis, bacterial, 1971
Plumbagin
 topoisomerase II
 DNA cleavage, induction of, 2589
Pneumocystis carinii
 antifolate agents
 rat model, 1935
 antimicrobial agents
 classification, new system for, 1943
 antiviral agents
 rat model, 1935
 benzimidazoles
 antimicrotubule activity, 779
 fluoroquinolones
 mice, 470
 L-693,989
 rats, 1964
 pefloxacillin
 mice, 470
 trimethoprim-sulfamethoxazole
 pneumonia, 2328
 trimethoprim-sulfamethoxazole-zidovu-
 dine
 pneumonia, 2328

- Pneumocystosis**
antimicrobial agents
classification, new system for, 1943
- Pneumonia**
amoxicillin
comparative evaluation, 833
efficacy and safety, 833
antifolate agents
rat model, 1935
antiviral agents
rat model, 1935
fluoroquinolones
mice, 470
P. carinii
antiviral and antifolate agents, 1935
pefloxacillin
mice, 470
sparfloxacin
lipopolysaccharide-specific monoclonal antibodies, combination with, 1352
temafloxacin
comparative evaluation, 833
efficacy and safety, 833
trimethoprim-sulfamethoxazole, 2328
trimethoprim-sulfamethoxazole-zidovudine, 2328
- pol**
human immunodeficiency virus type 1, mutations in
2',3'-dideoxycytidine, decreased susceptibility, 153
- Polyspartic acid**
toxicity
protection from, duration of, 2556
- Polyethers**
human immunodeficiency virus type 1
inhibition of replication, 492
- Polymerase chain reaction**
S. aureus
comparison with conventional microbiologic method of detection, 6
methicillin resistant, 6
penicillin-binding protein gene, 6
- Polymyxin B**
P. aeruginosa resistance
OprH, role in, 2566
- Polymorphonuclear leukocytes**
drug delivery and transport, 2584
- Polynucleotides**
5-mercapto substituted
human immunodeficiency virus type 1, 108
- [Tyr-5,12, Lys-7]polyphemusin II
human immunodeficiency virus type 1, 1249
- Polyphemusins**
mechanisms of antibacterial action, 1460
- Positron emission tomography**
pharmacokinetics
fleroxacin, 2286
- Postantibiotic effect**
E. coli
macromolecular biosynthesis, analysis of, 2118
quinolones, 2118
platelet microbicidal protein
S. aureus, 1665
- Pristinamycin**
M. genitalum, 870
M. pneumoniae, 870
- Prochlorperazine**
combinations
chloroquine, 209
P. falciparum, 209
- Protease inhibitors**
human immunodeficiency virus, 982
human immunodeficiency virus type 1
 C_2 symmetry based, 926
inhibition of replication, 926
- myxoviruses**
effects on replication, 1432
- Proteus mirabilis***
ceftazidime, 1580
E1040, 1580
outer membrane mutants
tosufloxacin, 2030
tosufloxacin uptake, 2030
tosufloxacin
outer membrane mutants, 2030
uptake, 2030
urinary tract infections
ceftazidime, 1580
E1040, 1580
- Pseudomembranous colitis**
C. difficile
effects of antibiotics on toxin production, 1332
- teicoplanin**
comparative evaluation, 2192
oral, 2192
vancomycin
comparative evaluation, 2192
oral, 2192
- Pseudomonas aeruginosa***
amikacin
postantibiotic sub-MIC effects, 1852
amikacin-aztreonam, 2741
amikacin-cefepime, 2741
amikacin-ceftazidime, 2741
bacteremia
erythromycin, 1198
rifampin-beta-lactam-aminoglycoside therapy, 620
beta-lactamase
activity in sputum samples from cystic fibrosis patients, 71
biofilms
piperacillin, barrier to diffusion, 2054
piperacillin, dynamic interactions with, 1208
tobramycin, dynamic interactions with, 1208
ceftazidime, 1580
clindamycin
proinflammatory interactions, inhibition of, 1236
E1040, 1580
E1077
morphological changes, 1894
enoxacin resistance
mechanism of resistance, 1057
pleiotropic, posttherapy mutant, 1057
erythromycin, 1198
proinflammatory interactions, inhibition of, 1236
virulence, effect on, 1922
fluoroquinolone supersusceptibility
OprH overexpression, 2365
gentamicin resistance
adaptive, 1951
dynamic in vitro model, 1951
OprH, role in, 2566
imipenem resistance
protein D2, nucleotide sequence, 1791
imipenem resistant
beta-lactamase and impermeability, association of, 2046
E1040, 684
L-627
comparative evaluation, 1928
meropenem, cephem, and quinolone cross-resistance
outer membrane protein overproduction, association with, 1847
monoclonal antibodies, antiflagellar, 1290
antibiotic combinations, 1290
nfxB
norfloxacin resistance, 2562
norfloxacin resistant
nfxB type mutation, 2562
piperacillin resistance
biofilm as a diffusion barrier, 2054
polymyxin resistance
OprH, role in, 2566
protein D2
nucleotide sequence, 1791
quinolone accumulation
fluorometric assay, 1601
rifampin-beta-lactam-aminoglycoside therapy, 620
Ro 23-9424
cancer patients, isolates from, 879
roxithromycin
proinflammatory interactions, inhibition of, 1236
sparfloxacin
lipopolysaccharide-specific monoclonal antibodies, combination with, 1352
sparfloxacin resistance, 255
ciprofloxacin, emergence of cross-resistance, 255
urinary tract infections
ceftazidime, 1580
E1040, 1580
- Pseudomonas cepacia***
resistance
pore-forming outer membrane protein, association with absence of, 2280
salicylate inducible, 2280
- Pseudomonas* spp.**
imipenem resistant
mureidomycins, 1024
mureidomycins, 1024
ofloxacin resistant
mureidomycins, 1024
- Pulse oximetry**
influenza virus
measurement of antiviral activity in mice, 473
- Pyelonephritis**
netilmicin
5 mg/kg once daily versus 3 mg/kg thrice daily, 1499
- Pyrazinamide**
combinations
antagonism with isoniazid, 548
comparative activity, 548
M. tuberculosis, 548
rifampin, 548
- Pyrimethamine**
pharmacokinetics
infants with congenital toxoplasmosis, 1040

- Q-35
in vitro activity, comparative evaluation, 1708
photostability and biological activity after UV irradiation, 1715
- Quinolones
AM-1155
in vitro and in vivo activities, 2108
CP-74,667
pharmacokinetics, 1671
cytochrome P450IA2
inhibitory potency, 942
- E. coli*
accumulation in, 1601
SOS-response and cell-division mutants, 819
- E. coli* resistance loci
genetics and regulation, 1151
nfxB, *nfxC*, and *cfxB*, 1151
- M. leprae*
comparative evaluation, 2544
- M. pneumoniae*, 1322
- OPC-17116
comparative evaluation, 573
gram-positive organisms, 2185
- P. aeruginosa*
accumulation in, 1601
- P. aeruginosa* resistance
meropenem and cephem cross-resistance, 1847
outer membrane protein overproduction, association with, 1847
- postantibiotic effect
E. coli, 2118
- S. aureus*
accumulation in, 1601
- X. maltophilia*
susceptibility, 669
- X. maltophilia* resistance
outer membrane proteins, 669
- 4-Quinolones
bacteria pathogenic to fish
temperature-dependent activity, 1738
- R 61837
human rhinovirus 9
capsid-stabilizing activity, 417
parameters of binding, 417
- R 82913
pharmacokinetics
AIDS patients, 2661
intravenous versus oral administration, 2661
- Rabies virus
ketamine
transcription, inhibition of, 1750
- Radioimmunoassays
high-pressure liquid chromatography
combined procedure for measuring intracellular zidovudine, 2473
- Ramoplanin
Enterococcus spp.
gentamicin resistant, 2342
penicillin G resistant, 2342
vancomycin resistant, 2342
gram-positive organisms
blood isolates, 1570
comparative evaluation, 1570
- Ranitidine
DR-3355
pharmacokinetics, effect on, 2270
pharmacokinetics
didanosine, interaction with, 2075
DR-3355, effect on, 2270
- Red man syndrome
teicoplanin, high dose
absence in patients treated with, 1204
vancomycin
absence in patients treated with, 1204
- Renal dehydropeptidase I
LJC 10,627
stability, 481
meropenem stability, 1577
1 β -methyl substitution, effect on stability, 1577
- Replication endpoint concentration assays
didanosine resistance
human immunodeficiency virus type 1, 920
zidovudine resistance
human immunodeficiency virus type 1, 920
- Retroviruses
antiviral agents
minireview, 509
reverse transcriptase inhibition
minireview, 245
- Rhinovirus
4',6-dicyanoflavan
mechanism of action, 95
pirodavir, 100
intranasal, 727
safety and efficacy, 727
R 61837, 100
capsid-stabilizing activity, 417
parameters of binding, 417
reverse transcriptase inhibition
minireview, 245
soluble intercellular adhesion molecule-1
in vitro activity, 1186
- Rhodococcus equi*
amikacin, 1244
ciprofloxacin, 1244
erythromycin, 1244
imipenem, 1244
minocycline, 1244
rifampin, 1244
vancomycin, 1244
- Ribavirin
influenza virus
pulse oximetry, measurement of activity in mice, 473
orthoviruses, 435
paramyxoviruses, 435
- Rickettsia conorii*
ciprofloxacin, 2529
ofloxacin, 2529
PD 127,391, 2529
PD 131,628, 2529
pefloxacin, 2529
- Rickettsia rickettsii*
ciprofloxacin, 2529
ofloxacin, 2529
PD 127,391, 2529
PD 131,628, 2529
pefloxacin, 2529
- Rifabutin
combinations
clarithromycin, 2413
M. avium complex, 2413
- Rifampin
antipyrene metabolites, formation of
2- and 4-day regimens, effect of, 1553
antipyrene pharmacokinetics
2- and 4-day regimens, effect of, 1553
- B. melitensis*, 973
bioavailability
letter to the editor, 2066
murine tuberculosis, 2066
brucellosis, 973
combinations
antagonism with isoniazid, 548
beta-lactam and aminoglycoside, 620
comparative evaluation, 548
M. tuberculosis, 548
P. aeruginosa bacteremia, 620
pyrazinamide, 548
- H. influenzae*
prophylaxis for contacts of infected patients, 545
pharmacokinetics
intraocular penetration, 1575
R. equi, 1244
- Ro 09-1227
comparative evaluation
other cephalosporins, 233
Enterobacteriaceae, 233
- Ro 23-9424
cancer patients, bacterial isolates from
comparative evaluation, 879
L. pneumophila, 2559
Legionella spp., 2559
- Ro 40-6890
Enterobacteriaceae
intestinal species, 2835
in vitro and in vivo activities
comparative evaluation, 2825
- Vibronaceae*
intestinal species, 2835
- Ro 41-3399
in vitro and in vivo activities
comparative evaluation, 2825
- Ro5-3335
human immunodeficiency virus type 1
cell type-specific activity, 2628
- Romurtide
combinations
cefmenoxime, synergy, 167
K. pneumoniae, 167
- Roxithromycin
comparative evaluation
erythromycin, azithromycin, and clarithromycin, 180
inhibitory activity in presence of human serum, 10
M. chelonae, 180
M. chelonae-like organisms, 180
M. fortuitum, 180
P. aeruginosa
proinflammatory interactions, inhibition of, 1236
- S. pneumoniae*
postantibiotic sub-MIC effects, 1852
- S. pyogenes*
postantibiotic sub-MIC effects, 1852
serum protein binding, 10
- RP 59500
gram-positive organisms
pharmacodynamic interaction, 2211
pharmacokinetics
fibrin clots, penetration into, 2211
Staphylococcus spp., 854
testing methods, evaluation of, 854
- RR 42427
C. immitis, 217
C. neoformans, 217
meningitis
cryptococcal and coccidioidal, 217

- RU-40 555
combinations
ethambutol, 2408
M. avium complex, 2408
sparfloxacin, 2408
M. avium complex, 2408
- RU 29246
in vitro activity
comparative evaluation, 2360
- RU44790
in vitro activity
comparative evaluation, 1756
- Rufloxacin
pharmacokinetics
multiple dose, in healthy volunteers, 1296
- S-1006
in vitro activity, 1336
susceptibility to hydrolysis, 1336
- S-1108
metabolic profiles of metabolites, 757
metabolism, 757
pharmacokinetics, 762
carnitine body stores, 762
healthy volunteers, 762
- Saccharomyces cerevisiae*
[*S*-methyl-³H]bleomycin A₂
lesions and preferential initial localization on cell walls, 2497
- Salmonella enteritidis*
ceftriaxone
comparative evaluation, 949
imipenem
comparative evaluation, 949
meningitis
ceftriaxone, 949
imipenem, 949
- Salmonella typhimurium*
3'-azido-3'-deoxythymidine
intracellular activity, 1081
outer membrane mutants
tosuflloxacin, 2030
tosuflloxacin uptake, 2030
tosuflloxacin
outer membrane mutants, 2030
uptake, 2030
zidovudine
intracellular activity, 1081
- Salmonellae
ampicillin resistant
amoxicillin-clavulanic acid, 1794
aztreonam, 1794
cefotaxime, 1794
ceftriaxone, 1794
chloramphenicol, 1794
ciprofloxacin, 1794
co-trimoxazole, 1794
gentamicin, 1794
nalidixic acid, 1794
tetracycline, 1794
- Saperconazole
A. fumigatus
comparative evaluation, 2681
oral and intravenous, 2681
aspergillosis
comparative evaluation, 2681
oral and intravenous, 2681
- SCE-2787
comparative evaluation, 1358
in vitro and in vivo activities, 1358
pharmacokinetics
comparative evaluation, 2481
- SCH 39304
C. albicans, 64
C. immitis, 217
C. neoformans, 217
comparative evaluation
fluconazole and ketoconazole, 64
meningitis
cryptococcal and coccidioidal, 217
pharmacokinetics
human immunodeficiency virus-infected patients, 2790
systemic fungal infections, 64
- SCH 42427
antifungal activity, 498
C. albicans, 498
in vitro and in vivo activity, 498
- SDZ 87-469
C. albicans
squalene epoxidase inhibition, 1799
- Seminal plasma
13-residue peptide from
increased antibacterial activity without
increased hemolytic activity, 2468
- Sepsis
CL 184,005
animal models, evaluation in, 1971
platelet-activating factor antagonist
animal models, evaluation in, 1971
- Serratia marcescens*
aac(6')-Ic
characterization of, 1447
aac(3)-Vb
cloning and sequence analysis, 2222
aminoglycoside resistance
aac(6')-Ic, characterization of, 1447
aac(3)-Vb, cloning and sequence analysis, 2222
aminoglycosides
factors affecting in vivo activity, 744
BRL-42715-cefazolin, 1427
BRL-42715-piperacillin, 1427
- Shigella sonnei*
fluoroquinolones
newer, 2346
- Shikonin
topoisomerase II
DNA cleavage, induction of, 2589
- Siderophores
β-lactams
E. coli, mechanism of action, 2166
E. coli
β-lactam hypersusceptible, 840
growth promotion studies, 840
- Simian immunodeficiency virus
3'-azido-3'-deoxythymidine
rhesus macaques, 2381
3'-azidothymidine
long-term tolerance and efficacy, 1770
3'-fluorothymidine
long-term tolerance and efficacy, 1770
- Skin infections
cefadroxil suspension, 1614
cefuroxime axetil suspension, 1614
- Soluble intercellular adhesion molecule-1
rhinovirus
in vitro activity, 1186
- Sparfloxacin
anaerobic organisms, 239
comparative evaluation, 1158
C. pneumoniae, 682
C. trachomatis, 188
combinations
ethambutol, 2408
lipopolysaccharide-specific monoclonal antibodies, 1352
M. avium complex, 2408
P. aeruginosa, 1352
RU-40 555, 2408
comparative evaluation
ciprofloxacin, ofloxacin, fleroxacin, temafloxacin, 682
other quinolone derivatives, 255
other quinolones, 558
other quinolones and tetracyclines, 188
E. coli, 505
gram-negative organisms
comparative evaluation, 558
gram-positive organisms
comparative evaluation, 558
human polymorphonuclear leukocytes
uptake and intracellular activity, 1053
invasive isolates from pediatric patients, 255
M. avium complex, 2408
P. aeruginosa resistance, 255
ciprofloxacin, emergence of cross-resistance, 255
pharmacokinetics, 2444
human polymorphonuclear leukocytes, 1053
inflammatory fluid penetration, 2444
renal infection
mice, 505
S. aureus, 505
S. aureus resistance, 255
ciprofloxacin, emergence of cross-resistance, 255
S. pneumoniae
comparative evaluation, 856
penicillin susceptible and resistant, 2698
postantibiotic sub-MIC effects, 1852
S. pyogenes
postantibiotic sub-MIC effects, 1852
- SS 42426
C. immitis, 217
C. neoformans, 217
meningitis
cryptococcal and coccidioidal, 217
- Staphylococcus aureus*
β-lactamase repressor
homology with enterococci, 2265
sequence analysis, 2265
β-lactamases
characterization, 440
cefadroxil suspension, 1614
cefuroxime axetil suspension, 1614
cephalexin
interaction of biofilm cells in a chemostat system, 890
cephem antibiotics
effect of serum protein binding on efficacy, 17
CI-960, 1192
ciprofloxacin resistant
CI-960, 1192
daptomycin, 318
daptomycin early killing
in vitro pharmacodynamic model, investigation by, 2334
E1077
morphological changes, 1894
endocarditis
ticarcillin-clavulanic acid, 458

- erythromycin resistant
impetigo, 287
- KB-5246 accumulation
carbonyl cyanide *m*-chlorophenylhydrazone, lack of effect on, 883
- MDL 62,873, 446
- methicillin resistance
chromosomal factors, mapping and characterization of, 1367
letter to the editor, 1585
polymerase chain reaction, detection by, 1585
- methicillin resistant
autolytic properties, 566
gyrA mutations associated with ciprofloxacin resistance, 1166
mecA, *mecR1-mecI*, and *femA-femB*, 2617
polymerase chain reaction, 6
- methicillin susceptible
autolytic properties, 566
- NorA
B. subtilis Bmr, structural and functional homolog, 484
- pefloxacin
transport across cytoplasmic membrane, 2506
- penicillin-binding protein 2
characterization, 656
- penicillin-binding proteins
construction of a water-soluble form, 533
- postantibiotic effect
platelet microbicidal protein, enhancement of, 1665
- quinolone accumulation
fluorometric assay, 1601
- quinolone susceptible
pefloxacin, transport across cytoplasmic membrane, 2506
- skin infections
cefadroxil suspension, 1614
cefuroxime axetil suspension, 1614
- sparfloxacin
renal infection in mice, 505
sparfloxacin resistance, 255
ciprofloxacin, emergence of cross-resistance, 255
- ticarcillin-clavulanic acid
dosing ratio, 1585
endocarditis in rats, 458
letter to the editor, 1585
- tobramycin
interaction of biofilm cells in a chemostat system, 890
- toxic shock syndrome toxin 1
glycerol monolaurate, effect on production, 626
- WIN 57273
 β -lactamase- and transpeptidase-inhibitory activities, 894
- Staphylococcus hyicus*
pSTE1
tet (L) sequence, 580
tetracycline resistance, 580
- Staphylococcus* spp.
 β -lactamase-encoding fragments
comparison with those from *Enterococcus* spp., 273
- CI-960
comparative evaluation, 851
mecA transcription
methicillin resistance, correlation with, 25
- methicillin resistance
mecA transcription, correlation with, 25
- methicillin resistant
mecA distribution, 429
- Ro 23-9424
cancer patients, isolates from, 879
- RP 59500, 854
testing methods, evaluation of, 854
- time-kill studies
concentration and pharmacodynamic response, relationship, 1766
- vancomycin, 1766
- vancomycin
concentration and pharmacodynamic response, relationship, 1766
time-kill studies, 1766
- WIN 57273
comparative evaluation, 851
- Streptococcus adjacens*
penicillin-tobramycin
optimal tobramycin dosing regimen, 2403
synergy, 2403
- temafloxacin
endocarditis, 2216
- Streptococcus agalactiae*
gentamicin resistance
structural gene, identical to those of *E. faecalis* and *E. faecium*, 1215
- Streptococcus pneumoniae*
cefalor
kill and growth rates, 46
- cefidinir
kill and growth rates, 46
- cefotaxime and ceftriaxone resistance, high level
characterization of isolate, 886
- ciprofloxacin
comparative evaluation, 856
- erythromycin
comparative evaluation, 856
- MDL 62,873, 446
- multiply antimicrobial resistant
multilocus enzyme electrophoresis profiles, 2176
- penicillin-binding proteins, 2176
- ribotypes, 2176
- ofloxacin
comparative evaluation, 856
- PD 131628
comparative evaluation, 856
- penicillin resistant
increased occurrence in a children's hospital, 1703
susceptibilities, in vitro, 1703
- penicillin susceptible and resistant
sparfloxacin, 2698
- roxithromycin
postantibiotic sub-MIC effects, 1852
- RP 59500
comparative evaluation, 856
- sparfloxacin
comparative evaluation, 856
postantibiotic sub-MIC effects, 1852
- temafloxacin
comparative evaluation, 856
- vancomycin
comparative evaluation, 856
postantibiotic sub-MIC effects, 1852
- Win 57273
comparative evaluation, 856
- Streptococcus pyogenes*
cefadroxil suspension, 1614
cefuroxime axetil suspension, 1614
MDL 62,873, 446
- roxithromycin
postantibiotic sub-MIC effects, 1852
- skin infections
cefadroxil suspension, 1614
cefuroxime axetil suspension, 1614
- sparfloxacin
postantibiotic sub-MIC effects, 1852
- vancomycin
postantibiotic sub-MIC effects, 1852
- Streptococcus* spp.
endocarditis, native valve
teicoplanin, 723
- Ro 23-9424
cancer patients, isolates from, 879
- teicoplanin
4-week treatment, 723
endocarditis, native valve, 723
- tetracycline resistant
occurrence of structures with homology to Tn916, 59
- Streptogramins
RP 59500
Staphylococcus spp., 854
- Streptomyces lividans*
MGT enzyme
specificity of action, 348
substrate profile, 348
- tetracycline resistance gene
protein with similarities to translation elongation factors, Tet(M), and Tet(O), 1119
- Streptomycin
B. melitensis, 973
brucellosis, 973
- E. corrodens*
resistance gene, 740
- K. rhinoscleromatis*, 1785
- M. avium-M. intracellulare* complex
human peripheral blood monocyte/macrophages, 2816
- liposome encapsulated, 2816
- Sucralfate
floxacin
pharmacokinetics, effect on, 2758
- Subactam
combinations
ampicillin, 2014, 2233
major head and neck surgery in cancer patients, prophylaxis for, 2014
pharmacokinetics, 2233
- Sulfones
 β -lactamases
CO₂ and pH, effect on inhibition, 1870
- Susceptibility patterns
B. fragilis group
Canada, 343
- Susceptibility testing
antimycobacterial agents
stability in, 2398
- B. wadsworthia*
endpoint determination, triphenyltetrazolium chloride, 1658
- bacteria from patients with peritonitis
complicating continuous ambulatory peritoneal dialysis, 1097
- Candida* spp.
relative growth measurement, 1727
- correlation with clinical outcome
B. fragilis group infections treated

- with cefoxitin, 540
 endpoint determination system
 yeasts, 1619
 fluconazole
 standardization, 1805
Methylobacterium spp., 1635
N. gonorrhoeae
 isolates from the Philippines, 277
 yeasts
 endpoint determination system, 1619
- Synergy**
 clarithromycin-minocycline
T. gondii, 2852
 minireview
 animal models, contribution of, 907
- Syphilis**
 cefetamet pivoxil
 rabbits, 598
- T22**
 human immunodeficiency virus type 1,
 1249
- T-3761**
 in vitro activity
 comparative evaluation, 2293
- TA**
 genes required for production
 expression of, *Tn5lac*, use to study,
 2322
 mutation and mapping of, 2316
- Tachyplexins**
 mechanisms of antibacterial action, 1460
- Tazobactam**
 combinations
 comparative evaluation, 2766
 gentamicin, 1883
 intra-abdominal infections, 2766
K. pneumoniae, 1883
 piperacillin, 1883, 2766
 piperacillin-gentamicin, 1883
K. pneumoniae, 1883
 pharmacokinetics
 patients undergoing colorectal surgery,
 1997
- Teicoplanin**
C. difficile
 comparative evaluation, 2192
 diarrhea, 2192
 diarrhea
C. difficile, 2192
 comparative evaluation, 2192
E. faecalis
 endocarditis, 1276
E. faecium
 glycopeptide resistant, 2611
 high versus low dose, 2611
 endocarditis, 1276
 high versus low dose, 2611
 endocarditis, native valve
 4-week treatment, 723
 streptococcal, 723
 gram-positive organisms
 blood isolates, 1570
 comparative evaluation, 1570
 pharmacokinetics
 healthy male volunteers, 115
 metabolism in humans, 1744
 pseudomembranous colitis
 comparative evaluation, 2192
 red man syndrome
 absence in patients treated with high
 doses, 1204
Streptococcus spp.
 endocarditis, 723
- TEM-1**
 sulfones
 CO₂ and pH, effect on inhibition, 1870
- TEM-12**
K. oxytoca
 transposition of gene encoding, 1981
- Temafloracin**
 anaerobic organisms, 239
 comparative evaluation, 1158
 autoradiographic diffusion pattern
 cardiac vegetations, 2216
C. pneumoniae, 682
 comparative evaluation
 ciprofloxacin, ofloxacin, fleroxacin,
 sparfloxacin, 682
 penicillin, tetracycline, ceftriaxone,
 ciprofloxacin, and ofloxacin, 1131
 endocarditis, 2216
 gram-negative organisms, 1140
N. gonorrhoeae, 1131
 pharmacokinetics
 multiple oral doses, 378
 pneumonia
 community acquired, 833
 comparative evaluation, 833
 efficacy and safety, 833
S. adjacens, 2216
S. pneumoniae
 comparative evaluation, 856
- Terbinafine**
C. albicans
 squalene epoxidase inhibition, 1799
- Tet determinants**
 tetracycline resistance
 evidence for division of tetracyclines
 into 2 classes, 876
- tet(M)**
Tn916
 mechanism of regulation, 769
 nucleotide sequence analysis, 769
 regulation by transcription attenua-
 tion, 769
- Tetracycline**
 analogs whose primary target is not the
 ribosome
E. coli lysis, 913
 mechanisms of action, 913
 anticollagenase action
 relevance to anti-inflammatory poten-
 tial, 227
Bacteroides resistance
 ribosome protection gene, 1005
C. pneumoniae, 291
C. trachomatis, 291
Enterococcus resistance
 occurrence of structures with homol-
 ogy to *Tn916*, 59
K. rhinoscleromatis, 1785
L. monocytogenes resistance
 genetic basis, 463
M. genitalum, 870
M. pneumoniae, 870, 1322
P. multocida
 cell surface characteristics, effect of
 sub-MICs on, 2093
 virulence, effect of sub-MICs on, 2093
S. hyicus resistance
 pSTE1, *tet* (L) sequence, 560
S. lividans resistance gene
 protein with similarities to translation
 elongation factors, *Tet*(M), and
Tet(O), 1119
 salmonellae
 ampicillin resistant, 1794
Streptococcus resistance
 occurrence of structures with homol-
 ogy to *Tn916*, 59
 Tet determinants
 evidence for division of tetracyclines
 into 2 classes, 876
tet(M)
 determinant of *Tn916*, characterization
 of, 769
 regulation by transcription attenua-
 tion, 769
V. salmonicida resistance determinant
 identification and cloning, 611
- Tetrahydroechinocandin B**
 antifungal activity, 1648
 1,3- β -D-glucan synthesis inhibition, 1648
- Ticarcillin**
B. fragilis group, 2051
 combinations
B. fragilis group, 2051
 clavulanate, 2233
 clavulanic acid, 137, 458, 2051, 2352
 letter to the editor, 2352
 pharmacokinetics, 2233
S. aureus endocarditis, 458
 susceptibility tests, error rates, 137
 zone size criteria, 2352
 susceptibility tests
Enterobacteriaceae, 137
 error rates, 137
- Ticarcillin-clavulanic acid**
S. aureus
 dosing ratio, 1585
 letter to the editor, 1585
 susceptibility testing
 interpretive criteria, 1343
 letter to the editor, 1343
- Time-kill studies**
Staphylococcus spp.
 concentration and pharmacodynamic
 response, relationship, 1766
 vancomycin, 1766
 vancomycin
 concentration and pharmacodynamic
 response, relationship, 1766
Staphylococcus spp., 1766
- Tinea pedis**
 butenafine
 relapse rate reduction in guinea pigs,
 2523
- Tinidazole**
H. pylori, 1133
- Tn5lac**
 antibiotic TA
 expression of genes required for pro-
 duction, 2322
- Tn21**
 gram-negative organisms
 Tn21-specific structures, 1915
- Tobramycin**
P. aeruginosa
 biofilms, dynamic interactions, 1208
 pharmacokinetics
 gentamicin, comparative evaluation,
 679
 patients with pleural effusions and hy-
 poalbuminemia, 679
 proximal tubular cells, subcellular lo-
 calization in, 2204

- S. aureus* biofilm cells
interaction in a chemostat system, 890
synergy
endocarditis, 2403
optimal dosing regimen, 2403
penicillin, 2403
S. adjacens, 2403
- Tolciclate
C. albicans
squalene epoxidase inhibition, 1799
- Tolnaftate
C. albicans
squalene epoxidase inhibition, 1799
- Topoisomerase II
plumbagin
induction of DNA cleavage, 2589
shikonin
induction of DNA cleavage, 2589
- Topoisomerase II inhibitors
Leishmania spp.
cytotoxicity for promastigotes, 495
- Topoisomerases
A. niger
targets for discovery of antifungal agents, 2778
C. albicans
drug discovery, target for, 2131
targets for discovery of antifungal agents, 2778
fluoroquinolones
effects of catalytic activities, 751
influence of C-8 fluorine group, 751
isothiazoloquinolones
DNA breakage, induction of, 81
- Tosufloxacin
E. coli
outer membrane mutants, 2030
uptake, 2030
P. mirabilis
outer membrane mutants, 2030
uptake, 2030
S. typhimurium
outer membrane mutants, 2030
uptake, 2030
- Toxic shock syndrome
S. aureus toxin 1
glycerol monolaurate, effect on production, 626
- Toxicity
amphotericin B
aggregation and solvent, effects on, 2518
effect of infusion rates, 172
flucytosine, effects of, 2670
influence of phospholipid type, 262
influence of phospholipid/amphotericin B ratio, 262
infusion rates, effect of, 2573
letter to the editor, 2573
ventricular dysrhythmias with 1-hour infusion, 2542
antifungal agents
in vitro models, 1799
minireview, 1799
cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-) and (+) enantiomers, 2686
gentamicin
polyaspartic acid, protection from, duration, 2556
MS-8209, 2722
zidovudine
fetal toxicity in pregnant mice, amelioration of, 2370
- Toxicology
ISIS 1082
in vitro, 527
- Toxoplasma gondii*
566C80
cysts, 326
azithromycin, 997
pyrimethamine, synergy with, 997
sulfadiazine, synergy with, 997
clarithromycin
murine model, 2454
clarithromycin-minocycline
synergy, 2852
clarithromycin-pyrimethamine
murine model, 2454
clarithromycin-sulfadiazine
murine model, 2454
clindamycin
infected human fibroblasts, 1091
resistant mutant, selection of, 1091
hydroxynaphthoquinones
566C80, 326
cysts, 326
- Toxoplasmosis
azithromycin, 997
pyrimethamine, synergy with, 997
sulfadiazine, synergy with, 997
clarithromycin
murine model, 2454
clarithromycin-minocycline
synergy, 2852
clarithromycin-pyrimethamine
murine model, 2454
clarithromycin-sulfadiazine
murine model, 2454
pyrimethamine
levels in cerebrospinal and ventricular fluids and sera of infants, 1040
- Transpeptidases
S. aureus
WIN 57273, inhibitory activity, 894
- Traveler's diarrhea
trimethoprim-sulfamethoxazole-loperamide, T426
- Treponema pallidum*
cefetamet pivoxil, 598
- Trimethoprim
E. coli resistance
identification of new gene, 1720
resistance gene *dhfrIX*
spread among human and porcine pathogens, 2704
- Trimethoprim-sulfamethoxazole
combinations
loperamide, 2821
P. carinii, 2328
pneumonia, 2328
traveler's diarrhea, 2821
zidovudine, 2328
K. rhinoscleromatis, 1785
Mediterranean spotted fever
letter to the editor, 1342
P. carinii
pneumonia, 2328
P. multocida
cell surface characteristics, effect of sub-MICs on, 2093
virulence, effect of sub-MICs on, 2093
pneumonia, 2328
- Trypanosoma brucei rhodesiense*
MDL 73811
S-adenosylmethionine decarboxylase inhibitor, 2736
- Trypanosoma lewisi*
acridines
anticancer, 1644
- TSAO derivatives
purine and pyrimidine
human immunodeficiency virus inhibitors, 1073
- Tumor necrosis factor alpha
combinations
interleukin-6, 68
L. monocytogenes, 68
minireview, 1
nonspecific resistance to infection, 1
- Urethritis
cefpodoxime proxetil, 1764
N. gonorrhoeae
cefpodoxime proxetil, 1764
- Urinary tract infections
ceftazidime, 1580
E1040, 1580
P. aeruginosa
ceftazidime, 1580
E1040, 1580
P. mirabilis
ceftazidime, 1580
E1040, 1580
- Vaccines
U.S. FDA approvals, 1584
- vanC*
E. gallinarum
species specificity, 2005
vancomycin resistance, 2005
vancomycin resistance
E. gallinarum, species specificity, 2005
- Vancomycin
bacteremia, 1109
C. difficile
comparative evaluation, 2192
diarrhea, 2192
carboxypeptidase activity
induction in *Enterococcus* spp., 77
combinations
ampicillin and gentamicin, 1563
Corynebacterium CDC group II, 1325
E. faecium, vancomycin and ampicillin resistant, 1563
gentamicin, 1325
Corynebacterium CDC group II, 1325
diarrhea
C. difficile, 2192
comparative evaluation, 2192
E. faecalis
endocarditis, 1276
E. faecium resistance
VanY, characterization of, 1514
E. gallinarum resistance, 1392
penicillin-binding protein 6, possible role in, 1392
vanC, species specificity, 2005
endocarditis, 1276, 1325
comparative evaluation, 1854
enterococci, penicillin resistant, 1864
endocarditis, gram positive, 1109
Enterococcus resistance
carboxypeptidase activity, 77
effects of amino acids on expression, 902
D-lactate, incorporation into pepti-

- doglycan precursors, 867
 peptidoglycan precursors, analysis of, 1487
 ramoplanin, 2342
Enterococcus spp.
 comparative evaluation, 1864
 endocarditis, 1864
 penicillin resistant, 1864
Enterococcus spp., highly vancomycin resistant
 ampicillin, absence of synergy, 2201
Enterococcus susceptibility
 gentamicin resistance, high level, and beta-hemolysis, influence on, 2526
 febrile neutropenic patients receiving ceftazidime
 initial treatment, not necessary for, 1062
 gram-positive organisms
 blood isolates, 1570
 comparative evaluation, 1570
 hemodialysis
 serum, removal from by high-flux hemodialysis membranes, 1424
 pharmacokinetics
 intravenous drug abusers, 1109
 proximal tubular cells, subcellular localization in, 2204
 sternal bone, penetration into, 2539
 pseudomembranous colitis
 comparative evaluation, 2192
R. equi, 1244
 red man syndrome
 absence in patients treated with, 1204
S. pneumoniae
 postantibiotic sub-MIC effects, 1852
S. pyogenes
 postantibiotic sub-MIC effects, 1852
 serum bactericidal activity
 concentration, pH, and growth phase, effects on, 2709
Staphylococcus spp.
 concentration and pharmacodynamic response, relationship, 1766
 time-kill studies
 concentration and pharmacodynamic response, relationship, 1766
Staphylococcus spp., 1766
- Varicella-zoster virus
 penciclovir
 mechanism of action, 2747
 MRC-5 cells, 2747
Vibrio anguillarum
 oxytetracycline
 temperature-dependent activity, 1738
 4-quinolones
 temperature-dependent activity, 1738
Vibrio cholerae
 β -lactam resistance, 788
 β -lactams
 interaction, novel features of, 788
Vibrio salmonicida
 oxytetracycline
 temperature-dependent activity, 1738
 4-quinolones
 temperature-dependent activity, 1738
 tetracycline resistance determinant
 identification and cloning, 611
Vibrionaceae
 Ro 40-6890
 intestinal species, 2835
- WIN 54954
 coxsackievirus
 mice, 425
 myocarditis
 mice, 425
 WIN 57273
 anaerobic bacteria
 comparative evaluation, 1158
 anaerobic organisms, 239
 M. avium complex
 human macrophages, 2104
 S. aureus
 β -lactamase- and transpeptidase-inhibitory activities, 894
 S. pneumoniae
 comparative evaluation, 856
 Staphylococcus spp.
 comparative evaluation, 851
- Xanthomonas maltophilia*
 quinolone resistant
 outer membrane proteins, 669
 quinolone susceptibility, 669
- Yeasts
 susceptibility testing
 endpoint determination system, 1619
Yersinia enterocolitica
 ampC-ampR
 nucleotide sequence, 1049
 β -lactamases
 nucleotide sequence of structural gene, 1049
Yersinia ruckeri
 oxytetracycline
 temperature-dependent activity, 1738
 4-quinolones
 temperature-dependent activity, 1738
- Zidovudine
 azithromycin
 effect on disposition in AIDS patients, 1013
 coagulation effects
 human immunodeficiency virus-infected hemophiliacs, 2245
 combinations
 2',3'-dideoxycytidine, 1559
 foscarnet, 1773
 human immunodeficiency virus type 1, 1559
 P. carinii, 2328
 pharmacokinetics, 1773
 pneumonia, 2328
 trimethoprim-sulfamethoxazole, 2328
 human immunodeficiency virus type 1
 ganciclovir antagonism, 1127
 human immunodeficiency virus type 1
 resistance
 replication endpoint concentration assay, 920
 pharmacokinetics
 human immunodeficiency virus-infected hemophiliacs, 2245
 intravenous and oral, 2245
 penetration into brains, muscle tissue, and veins of monkeys, 2418
 relation to antiviral action, 2418
S. typhimurium
 intracellular activity, 1081
 toxicity
 fetal, amelioration in pregnant mice, 2370